# ESC Guidelines: Acute Coronary Syndromes (2023)

**Source**: `2023_Acute_Coronary_Syndromes.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 107

---

## Table of Contents

- [2023 ESC Guidelines for the management of acute coronary syndromes](#2023-esc-guidelines-for-the-management-of-acute-co) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. Definitions | Acute coronary syndromes and myocardial infarction](#21-definitions-|-acute-coronary-syndromes-and-myoc) *(p. 11)*
    - [2.2. Epidemiology of acute coronary syndromes](#22-epidemiology-of-acute-coronary-syndromes) *(p. 13)*
    - [2.3. Number and breakdown of classes of recommendations](#23-number-and-breakdown-of-classes-of-recommendati) *(p. 13)*
    - [2.4. What is new](#24-what-is-new) *(p. 14)*
  - [3. Triage and diagnosis](#3-triage-and-diagnosis) *(p. 16)*
    - [3.1. Clinical presentation and physical examination](#31-clinical-presentation-and-physical-examination) *(p. 16)*
      - [3.1.1. Clinical presentation](#311-clinical-presentation) *(p. 16)*
      - [3.1.2. History taking and physical examination](#312-history-taking-and-physical-examination) *(p. 18)*
    - [3.2. Diagnostic tools | Electrocardiogram](#32-diagnostic-tools-|-electrocardiogram) *(p. 18)*
      - [3.2.1. Acute coronary syndrome with persistent ST-segment elevation (suspected ST-elevation myocardial infarction)](#321-acute-coronary-syndrome-with-persistent-st-seg) *(p. 19)*
      - [3.2.2. Acute coronary syndrome without persistent ST-segment elevation (non-ST elevation acute coronary syndrome)](#322-acute-coronary-syndrome-without-persistent-st-) *(p. 19)*
    - [3.3. Diagnostic tools | Biomarkers](#33-diagnostic-tools-|-biomarkers) *(p. 20)*
      - [3.3.1. High-sensitivity cardiac troponins](#331-high-sensitivity-cardiac-troponins) *(p. 20)*
      - [3.3.2. Central laboratory vs. point of care](#332-central-laboratory-vs-point-of-care) *(p. 20)*
      - [3.3.3. Confounders of cardiac troponin concentration](#333-confounders-of-cardiac-troponin-concentration) *(p. 20)*
      - [3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms](#334-rapid-‘rule-in’-and-‘rule-out’-algorithms) *(p. 20)*
        - [3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h algorithms](#3341-european-society-of-cardiology-0-h/1-h-and-0-) *(p. 21)*
          - [3.3.4.1.1. Rule-out](#33411-rule-out) *(p. 21)*
          - [3.3.4.1.2. Rule-in](#33412-rule-in) *(p. 21)*
          - [3.3.4.1.3. Observe](#33413-observe) *(p. 21)*
        - [3.3.4.2. Practical guidance on how to implement the European Society of Cardiology 0 h/1 h algorithm](#3342-practical-guidance-on-how-to-implement-the-eu) *(p. 23)*
      - [3.3.5. Other biomarkers](#335-other-biomarkers) *(p. 23)*
    - [3.4. Diagnostic tools | Non-invasive imaging](#34-diagnostic-tools-|-non-invasive-imaging) *(p. 23)*
      - [3.4.1. Echocardiography](#341-echocardiography) *(p. 23)*
      - [3.4.2. Computed tomography](#342-computed-tomography) *(p. 23)*
      - [3.4.3. Cardiac magnetic resonance imaging with or without stress testing](#343-cardiac-magnetic-resonance-imaging-with-or-wit) *(p. 23)*
    - [3.5. Differential diagnosis for acute chest pain](#35-differential-diagnosis-for-acute-chest-pain) *(p. 24)*
  - [4. Initial measures for patients presenting with suspected acute coronary syndrome | Initial treatment](#4-initial-measures-for-patients-presenting-with-su) *(p. 24)*
    - [4.1. Pre-hospital logistics of care](#41-pre-hospital-logistics-of-care) *(p. 24)*
      - [4.1.1. Time to treatment](#411-time-to-treatment) *(p. 24)*
      - [4.1.2. Healthcare systems and system delays](#412-healthcare-systems-and-system-delays) *(p. 24)*
      - [4.1.3. Emergency medical services](#413-emergency-medical-services) *(p. 24)*
      - [4.1.4. General practitioners](#414-general-practitioners) *(p. 25)*
      - [4.1.5. Organization of ST-elevation myocardial infarction treatment in networks](#415-organization-of-st-elevation-myocardial-infarc) *(p. 25)*
    - [4.2. Emergency care](#42-emergency-care) *(p. 25)*
      - [4.2.1. Initial diagnosis and monitoring](#421-initial-diagnosis-and-monitoring) *(p. 25)*
      - [4.2.2. Acute pharmacotherapy](#422-acute-pharmacotherapy) *(p. 25)*
        - [4.2.2.1. Oxygen](#4221-oxygen) *(p. 25)*
        - [4.2.2.2. Nitrates](#4222-nitrates) *(p. 25)*
        - [4.2.2.3. Pain relief](#4223-pain-relief) *(p. 25)*
        - [4.2.2.4. Intravenous beta-blockers](#4224-intravenous-beta-blockers) *(p. 25)*
  - [5. Acute-phase management of patients with acute coronary syndrome](#5-acute-phase-management-of-patients-with-acute-co) *(p. 26)*
    - [5.1. Selection of invasive strategy and reperfusion therapy](#51-selection-of-invasive-strategy-and-reperfusion-) *(p. 26)*
    - [5.2. Acute coronary syndrome managed with invasive strategy](#52-acute-coronary-syndrome-managed-with-invasive-s) *(p. 26)*
      - [5.2.1. Primary percutaneous coronary intervention strategy for ST-elevation myocardial infarction](#521-primary-percutaneous-coronary-intervention-str) *(p. 26)*
        - [5.2.1.1. Invasive strategy in ST-elevation myocardial infarction late presenters](#5211-invasive-strategy-in-st-elevation-myocardial-) *(p. 28)*
      - [5.2.2. Immediate invasive strategy for non-ST elevation acute coronary syndrome](#522-immediate-invasive-strategy-for-non-st-elevati) *(p. 28)*
      - [5.2.3. Routine vs. selective invasive strategy](#523-routine-vs-selective-invasive-strategy) *(p. 28)*
        - [5.2.3.1. Early vs. delayed invasive strategy for non-ST elevation acute coronary syndrome](#5231-early-vs-delayed-invasive-strategy-for-non-st) *(p. 28)*
      - [5.2.4. Summary of invasive strategies for patients with non-ST elevation acute coronary syndrome](#524-summary-of-invasive-strategies-for-patients-wi) *(p. 28)*
    - [5.3. Fibrinolysis and pharmaco-invasive strategy in patients with ST-elevation myocardial infarction](#53-fibrinolysis-and-pharmaco-invasive-strategy-in-) *(p. 30)*
      - [5.3.1. Benefit and indication of fibrinolysis](#531-benefit-and-indication-of-fibrinolysis) *(p. 30)*
        - [5.3.1.1. Pre-hospital fibrinolysis](#5311-pre-hospital-fibrinolysis) *(p. 30)*
        - [5.3.1.2. Angiography and percutaneous coronary intervention after fibrinolysis (pharmaco-invasive strategy)](#5312-angiography-and-percutaneous-coronary-interve) *(p. 30)*
          - [5.3.1.2.1. Comparison of fibrinolytic agents](#53121-comparison-of-fibrinolytic-agents) *(p. 30)*
          - [5.3.1.2.2. Hazards of fibrinolysis and contraindications](#53122-hazards-of-fibrinolysis-and-contraindication) *(p. 30)*
    - [5.4. Patients not undergoing reperfusion](#54-patients-not-undergoing-reperfusion) *(p. 30)*
      - [5.4.1. Patients who are not candidates for invasive coronary angiography](#541-patients-who-are-not-candidates-for-invasive-c) *(p. 30)*
      - [5.4.2. Patients with coronary artery disease not amenable to revascularization](#542-patients-with-coronary-artery-disease-not-amen) *(p. 30)*
  - [6. Antithrombotic therapy](#6-antithrombotic-therapy) *(p. 31)*
    - [6.1. Antiplatelet therapy in the acute phase](#61-antiplatelet-therapy-in-the-acute-phase) *(p. 33)*
      - [6.1.1. Oral antiplatelet therapy](#611-oral-antiplatelet-therapy) *(p. 33)*
      - [6.1.2. Timing of loading dose of oral antiplatelet therapy](#612-timing-of-loading-dose-of-oral-antiplatelet-th) *(p. 34)*
        - [6.1.2.1. Pre-treatment in patients with suspected ST-elevation myocardial infarction](#6121-pre-treatment-in-patients-with-suspected-st-e) *(p. 34)*
        - [6.1.2.2. Pre-treatment in patients with non-ST-elevation acute coronary syndrome](#6122-pre-treatment-in-patients-with-non-st-elevati) *(p. 34)*
        - [6.1.2.3. Summary of pre-treatment strategies](#6123-summary-of-pre-treatment-strategies) *(p. 34)*
      - [6.1.3. Intravenous antiplatelet drugs](#613-intravenous-antiplatelet-drugs) *(p. 34)*
    - [6.2. Anticoagulant treatment in the acute phase](#62-anticoagulant-treatment-in-the-acute-phase) *(p. 35)*
      - [6.2.1. Anticoagulation in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention](#621-anticoagulation-in-patients-with-st-elevation-) *(p. 35)*
      - [6.2.2. Anticoagulation in patients with non-ST-elevation acute coronary syndrome undergoing angiography and percutaneous coronary intervention if indicated](#622-anticoagulation-in-patients-with-non-st-elevat) *(p. 35)*
    - [6.3. Maintenance antithrombotic therapy after revascularization](#63-maintenance-antithrombotic-therapy-after-revasc) *(p. 36)*
      - [6.3.1. Shortening dual antiplatelet therapy](#631-shortening-dual-antiplatelet-therapy) *(p. 37)*
      - [6.3.2. De-escalation from potent P2Y12 inhibitor to clopidogrel](#632-de-escalation-from-potent-p2y12-inhibitor-to-c) *(p. 37)*
      - [6.3.3. Summary of alternative antiplatelet strategies to reduce bleeding risk in the first 12 months after acute coronary syndrome](#633-summary-of-alternative-antiplatelet-strategies) *(p. 38)*
    - [6.4. Long-term treatment](#64-long-term-treatment) *(p. 40)*
      - [6.4.1. Prolonging antithrombotic therapy beyond 12 months](#641-prolonging-antithrombotic-therapy-beyond-12-mo) *(p. 40)*
    - [6.5. Antiplatelet therapy in patients requiring oral anticoagulation](#65-antiplatelet-therapy-in-patients-requiring-oral) *(p. 41)*
      - [6.5.1. Acute coronary syndrome patients requiring anticoagulation](#651-acute-coronary-syndrome-patients-requiring-ant) *(p. 41)*
      - [6.5.2. Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery](#652-patients-requiring-vitamin-k-antagonists-or-un) *(p. 43)*
    - [6.6. Antithrombotic therapy as an adjunct to fibrinolysis](#66-antithrombotic-therapy-as-an-adjunct-to-fibrino) *(p. 43)*
    - [6.7. Antithrombotic therapy in patients not undergoing reperfusion](#67-antithrombotic-therapy-in-patients-not-undergoi) *(p. 43)*
  - [7. Acute coronary syndrome with unstable presentation](#7-acute-coronary-syndrome-with-unstable-presentati) *(p. 43)*
    - [7.1. Out-of-hospital cardiac arrest in acute coronary syndrome](#71-out-of-hospital-cardiac-arrest-in-acute-coronar) *(p. 44)*
      - [7.1.1. Systems of care](#711-systems-of-care) *(p. 44)*
    - [7.2. Cardiogenic shock complicating acute coronary syndrome](#72-cardiogenic-shock-complicating-acute-coronary-s) *(p. 44)*
  - [8. Management of acute coronary syndrome during hospitalization](#8-management-of-acute-coronary-syndrome-during-hos) *(p. 45)*
    - [8.1. Coronary care unit/intensive cardiac care unit](#81-coronary-care-unit/intensive-cardiac-care-unit) *(p. 45)*
      - [8.1.1. Monitoring](#811-monitoring) *(p. 45)*
      - [8.1.2. Ambulation](#812-ambulation) *(p. 45)*
      - [8.1.3. Length of stay in the intensive cardiac care unit](#813-length-of-stay-in-the-intensive-cardiac-care-u) *(p. 46)*
    - [8.2. In-hospital care](#82-in-hospital-care) *(p. 46)*
      - [8.2.1. Length of hospital stay](#821-length-of-hospital-stay) *(p. 46)*
      - [8.2.2. Risk assessment](#822-risk-assessment) *(p. 46)*
        - [8.2.2.1. Clinical risk assessment](#8221-clinical-risk-assessment) *(p. 46)*
        - [8.2.2.2. Imaging risk assessment](#8222-imaging-risk-assessment) *(p. 46)*
        - [8.2.2.3. Biomarkers for risk assessment](#8223-biomarkers-for-risk-assessment) *(p. 46)*
        - [8.2.2.4. Bleeding risk assessment](#8224-bleeding-risk-assessment) *(p. 46)*
        - [8.2.2.5. Integrating ischaemic and bleeding risks](#8225-integrating-ischaemic-and-bleeding-risks) *(p. 46)*
  - [9. Technical aspects of invasive strategies](#9-technical-aspects-of-invasive-strategies) *(p. 47)*
    - [9.1. Percutaneous coronary intervention](#91-percutaneous-coronary-intervention) *(p. 47)*
      - [9.1.1. Vascular access](#911-vascular-access) *(p. 47)*
      - [9.1.2. Intravascular imaging/physiology of the infarct-related artery](#912-intravascular-imaging/physiology-of-the-infarc) *(p. 47)*
        - [9.1.2.1. Intravascular imaging](#9121-intravascular-imaging) *(p. 47)*
        - [9.1.2.2. Intravascular physiology](#9122-intravascular-physiology) *(p. 48)*
      - [9.1.3. Timing of revascularization with percutaneous coronary intervention](#913-timing-of-revascularization-with-percutaneous-) *(p. 48)*
      - [9.1.4. Balloons and stents](#914-balloons-and-stents) *(p. 49)*
      - [9.1.5. Embolic protection and microvascular salvage strategies](#915-embolic-protection-and-microvascular-salvage-s) *(p. 49)*
        - [9.1.5.1. Thrombus aspiration](#9151-thrombus-aspiration) *(p. 49)*
        - [9.1.5.2. Interventions to protect the microcirculation](#9152-interventions-to-protect-the-microcirculation) *(p. 49)*
    - [9.2. Coronary artery bypass grafting](#92-coronary-artery-bypass-grafting) *(p. 49)*
      - [9.2.1. Indication and timing of coronary artery bypass grafting in acute coronary syndrome patients](#921-indication-and-timing-of-coronary-artery-bypas) *(p. 49)*
      - [9.2.2. Technical considerations specific to acute coronary syndrome patients](#922-technical-considerations-specific-to-acute-cor) *(p. 49)*
    - [9.3. Spontaneous coronary artery dissection](#93-spontaneous-coronary-artery-dissection) *(p. 49)*
      - [9.3.1. Intravascular imaging](#931-intravascular-imaging) *(p. 50)*
      - [9.3.2. Revascularization](#932-revascularization) *(p. 50)*
  - [10. Management of patients with multivessel disease](#10-management-of-patients-with-multivessel-disease) *(p. 50)*
    - [10.1. Management of multivessel disease in acute coronary syndrome complicated by cardiogenic shock](#101-management-of-multivessel-disease-in-acute-cor) *(p. 50)*
    - [10.2. Patients with multivessel coronary artery disease undergoing primary percutaneous coronary intervention](#102-patients-with-multivessel-coronary-artery-dise) *(p. 51)*
    - [10.3. Timing of non-infarct-related artery revascularization in acute coronary syndrome](#103-timing-of-non-infarct-related-artery-revascula) *(p. 52)*
      - [10.3.1. Patients presenting with ST-elevation myocardial infarction and multivessel coronary artery disease](#1031-patients-presenting-with-st-elevation-myocard) *(p. 52)*
      - [10.3.2. Patients presenting with non-ST-elevation acute coronary syndrome and multivessel coronary artery disease](#1032-patients-presenting-with-non-st-elevation-acu) *(p. 52)*
    - [10.4. Evaluation of non-infarct-related artery stenosis severity (angiography vs. physiology)](#104-evaluation-of-non-infarct-related-artery-steno) *(p. 52)*
    - [10.5. Hybrid revascularization](#105-hybrid-revascularization) *(p. 53)*
  - [11. Myocardial infarction with non-obstructive coronary arteries](#11-myocardial-infarction-with-non-obstructive-coro) *(p. 53)*
  - [12. Special situations](#12-special-situations) *(p. 56)*
    - [12.1. Type 2 myocardial infarction and acute myocardial injury](#121-type-2-myocardial-infarction-and-acute-myocard) *(p. 56)*
    - [12.2. Complications](#122-complications) *(p. 56)*
      - [12.2.1. Heart failure](#1221-heart-failure) *(p. 56)*
      - [12.2.2. Mechanical complications](#1222-mechanical-complications) *(p. 57)*
      - [12.2.3. Left ventricular thrombus](#1223-left-ventricular-thrombus) *(p. 57)*
      - [12.2.4. Post-acute coronary syndrome pericarditis](#1224-post-acute-coronary-syndrome-pericarditis) *(p. 57)*
      - [12.2.5. Arrhythmias](#1225-arrhythmias) *(p. 57)*
        - [12.2.5.1. Atrial fibrillation](#12251-atrial-fibrillation) *(p. 57)*
        - [12.2.5.2. Ventricular arrhythmias](#12252-ventricular-arrhythmias) *(p. 58)*
      - [12.2.6. Bleeding](#1226-bleeding) *(p. 58)*
        - [12.2.6.1. Management of bleeding](#12261-management-of-bleeding) *(p. 58)*
    - [12.3. Comorbid conditions](#123-comorbid-conditions) *(p. 59)*
      - [12.3.1. Patients at high bleeding risk and with blood disorders (anaemia and thrombocytopaenia)](#1231-patients-at-high-bleeding-risk-and-with-blood) *(p. 59)*
      - [12.3.2. Chronic kidney disease](#1232-chronic-kidney-disease) *(p. 60)*
      - [12.3.3. Diabetes mellitus](#1233-diabetes-mellitus) *(p. 60)*
      - [12.3.4. Older adults with frailty and multimorbidity](#1234-older-adults-with-frailty-and-multimorbidity) *(p. 60)*
        - [12.3.4.1. The older person](#12341-the-older-person) *(p. 60)*
        - [12.3.4.2. Frailty and multimorbidity](#12342-frailty-and-multimorbidity) *(p. 60)*
      - [12.3.5. Pregnancy](#1235-pregnancy) *(p. 61)*
      - [12.3.6. Drug abuse](#1236-drug-abuse) *(p. 61)*
      - [12.3.7. Patients with cancer](#1237-patients-with-cancer) *(p. 61)*
      - [12.3.8. Coronavirus disease (COVID-19)](#1238-coronavirus-disease-(covid-19)) *(p. 61)*
  - [13. Long-term treatment](#13-long-term-treatment) *(p. 62)*
    - [13.1. Cardiac rehabilitation](#131-cardiac-rehabilitation) *(p. 64)*
      - [13.1.1. Comprehensive cardiac rehabilitation](#1311-comprehensive-cardiac-rehabilitation) *(p. 64)*
      - [13.1.2. Digital health](#1312-digital-health) *(p. 64)*
      - [13.1.3. Adherence and persistence](#1313-adherence-and-persistence) *(p. 64)*
    - [13.2. Lifestyle management](#132-lifestyle-management) *(p. 64)*
      - [13.2.1. Tobacco](#1321-tobacco) *(p. 64)*
      - [13.2.2. Nutrition and alcohol](#1322-nutrition-and-alcohol) *(p. 64)*
      - [13.2.3. Physical activity and exercise](#1323-physical-activity-and-exercise) *(p. 65)*
      - [13.2.4. Psychological considerations](#1324-psychological-considerations) *(p. 65)*
      - [13.2.5. Resumption of activities](#1325-resumption-of-activities) *(p. 65)*
    - [13.3. Pharmacological treatment](#133-pharmacological-treatment) *(p. 65)*
      - [13.3.1. Antithrombotic therapy](#1331-antithrombotic-therapy) *(p. 65)*
      - [13.3.2. Lipid-lowering therapy](#1332-lipid-lowering-therapy) *(p. 65)*
      - [13.3.3. Beta-blockers](#1333-beta-blockers) *(p. 66)*
      - [13.3.4. Nitrates and calcium channel blockers](#1334-nitrates-and-calcium-channel-blockers) *(p. 67)*
      - [13.3.5. Renin–angiotensin–aldosterone system inhibitors](#1335-renin–angiotensin–aldosterone-system-inhibito) *(p. 67)*
      - [13.3.6. Medications for diabetes](#1336-medications-for-diabetes) *(p. 67)*
        - [13.3.6.1. Sodium–glucose co-transporter 2 inhibitors](#13361-sodium–glucose-co-transporter-2-inhibitors) *(p. 67)*
        - [13.3.6.2. Glucagon-like peptide-1 receptor agonists](#13362-glucagon-like-peptide-1-receptor-agonists) *(p. 68)*
      - [13.3.7. Proton pump inhibitors](#1337-proton-pump-inhibitors) *(p. 68)*
      - [13.3.8. Vaccination](#1338-vaccination) *(p. 68)*
      - [13.3.9. Anti-inflammatory drugs](#1339-anti-inflammatory-drugs) *(p. 68)*
      - [13.3.10. Hormone replacement therapy](#13310-hormone-replacement-therapy) *(p. 68)*
  - [14. Patient perspectives](#14-patient-perspectives) *(p. 69)*
    - [14.1. Patient-centred care](#141-patient-centred-care) *(p. 69)*
    - [14.2. Shared decision-making](#142-shared-decision-making) *(p. 70)*
    - [14.3. Informed consent](#143-informed-consent) *(p. 70)*
    - [14.4. Research participation and consent in the acute setting](#144-research-participation-and-consent-in-the-acut) *(p. 71)*
    - [14.5. Patient satisfaction and expectations](#145-patient-satisfaction-and-expectations) *(p. 71)*
    - [14.6. Patient-reported outcome measures and patient-reported experience measures](#146-patient-reported-outcome-measures-and-patient-) *(p. 72)*
    - [14.7. Preparation for discharge](#147-preparation-for-discharge) *(p. 72)*
  - [15. Key messages](#15-key-messages) *(p. 72)*
  - [16. Gaps in evidence](#16-gaps-in-evidence) *(p. 74)*
  - [17. Sex differences](#17-sex-differences) *(p. 76)*
  - [18. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#18-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 77)*
  - [19. Quality indicators](#19-quality-indicators) *(p. 82)*
  - [20. Supplementary data](#20-supplementary-data) *(p. 82)*
  - [21. Data availability statement](#21-data-availability-statement) *(p. 82)*
  - [22. Author information](#22-author-information) *(p. 82)*
  - [Appendix](#appendix) *(p. 82)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of acute coronary syndromes
Developed by the task force on the management of acute coronary 
syndromes of the European Society of Cardiology (ESC)
Authors/Task Force Members: Robert A. Byrne  *†, (Chairperson) (Ireland), 
Xavier Rossello  
‡, (Task Force Co-ordinator) (Spain), J.J. Coughlan  
‡, 
(Task Force Co-ordinator) (Ireland), Emanuele Barbato  
(Italy), Colin Berry  
(United Kingdom), Alaide Chieffo  
(Italy), Marc J. Claeys  
(Belgium), 
Gheorghe-Andrei Dan  
(Romania), Marc R. Dweck  
(United Kingdom), 
Mary Galbraith  
(United Kingdom), Martine Gilard (France), 
Lynne Hinterbuchner  
(Austria), Ewa A. Jankowska  
(Poland), Peter Jüni 
(United Kingdom), Takeshi Kimura (Japan), Vijay Kunadian  
(United Kingdom), 
Margret Leosdottir  
(Sweden), Roberto Lorusso  
(Netherlands), 
Roberto F.E. Pedretti  
(Italy), Angelos G. Rigopoulos  
(Greece), 
Maria Rubini Gimenez  
(Germany), Holger Thiele (Germany),  
Pascal Vranckx (Belgium), Sven Wassmann (Germany), Nanette Kass Wenger 
(United States of America), Borja Ibanez  *†, (Chairperson) (Spain), and ESC 
Scientific Document Group
* Corresponding authors: Robert A. Byrne, Department of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland, and School of Pharmacy 
and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Tel: +353-1-2483190, E-mail: robertabyrne@rcsi.ie; and Borja Ibanez, Clinical Research 
Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, and Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, 
Spain, CIBERCV, ISCIII, Madrid, Spain. Tel: +3491 4531200, E-mail: bibanez@cnic.es
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, E-Cardiology, Myocardial and Pericardial Diseases, Thrombosis.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
This article is co-published with permission in European Heart Journal and European Heart Journal - Acute Cardiovascular Care. All rights reserved. © The European Society of Cardiology 
2023. The articles are identical except for stylistic differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions, please e-mail: 
journals.permissions@oup.com
https://doi.org/10.1093/eurheartj/ehad191
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Sigrun Halvorsen, (Clinical Practice Guidelines Review Co-ordinator) (Norway), 
Stefan James, (Clinical Practice Guidelines Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt), 
Victor Aboyans (France), Nina Ajmone Marsan (Netherlands), Sotiris Antoniou (United Kingdom), 
Riccardo Asteggiano (Italy), Maria Bäck (Sweden), Davide Capodanno (Italy), Ruben Casado-Arroyo (Belgium), 
Salvatore Cassese (Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), 
Gregory Ducrocq (France), Volkmar Falk (Germany), Laurent Fauchier (France), Tobias Geisler (Germany), Diana 
A. Gorog (United Kingdom), Lene Holmvang (Denmark), Tiny Jaarsma (Sweden), Hywel Wynne Jones (United 
Kingdom), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), 
Konstantin A. Krychtiuk (Austria), Ulf Landmesser (Germany), George Lazaros (Greece), Basil S. Lewis (Israel), 
Bertil Lindahl (Sweden), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Mamas A. Mamas (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Christian Mueller (Switzerland), Lis Neubeck (United Kingdom), Josef Niebauer (Austria), Jens 
Cosedis Nielsen (Denmark), Alexander Niessner (Austria), Valeria Paradies (Netherlands), Agnes A. Pasquet 
(Belgium), Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Bianca Rocca (Italy), Giuseppe M.C. Rosano (Italy), Leyla Elif Sade (United States of America / Türkiye), 
François Schiele (France), Jolanta M. Siller-Matula (Austria), Christian Sticherling (Switzerland), Robert F. Storey 
(United Kingdom), Matthias Thielmann (Germany), Christiaan Vrints (Belgium), Stephan Windecker 
(Switzerland), Rune Wiseth (Norway), and Adam Witkowski (Poland)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Acute cardiac care • Acute coronary syndrome • Antithrombotic therapy • Fibrinolysis • High- 
sensitivity troponin • Invasive strategy • MINOCA • Myocardial infarction • Non-ST-elevation myocardial infarction 
• Patient-centred care • Percutaneous coronary intervention • Recommendations • Reperfusion therapy • 
Revascularization • Secondary prevention • ST-segment elevation myocardial infarction • Unstable angina
Table of contents
1. Preamble .............................................................................................................. 3727
2. Introduction ....................................................................................................... 3728
2.1. Definitions | Acute coronary syndromes and myocardial 
infarction .............................................................................................................
3730
2.2. Epidemiology of acute coronary syndromes ..............................
3732
2.3. Number and breakdown of classes of recommendations ...
3732
2.4. What is new .............................................................................................
3733
3. Triage and diagnosis ........................................................................................ 3735
3.1. Clinical presentation and physical examination .........................
3735
3.1.1. Clinical presentation ...................................................................... 3735
3.1.2. History taking and physical examination .............................. 3737
3.2. Diagnostic tools | Electrocardiogram ............................................
3737
3.2.1. Acute coronary syndrome with persistent ST-segment 
elevation (suspected ST-elevation myocardial infarction) ......... 3738
3.2.2. Acute coronary syndrome without persistent ST- 
segment elevation (non-ST elevation acute coronary 
syndrome) ...................................................................................................... 3738
3.3. Diagnostic tools | Biomarkers ...........................................................
3739
3.3.1. High-sensitivity cardiac troponins ............................................ 3739
3.3.2. Central laboratory vs. point of care ....................................... 3739
3.3.3. Confounders of cardiac troponin concentration ............. 3739
3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms ................................ 3739
3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h 
algorithms ..................................................................................................
3740
3.3.4.1.1. Rule-out .............................................................................
3740
3.3.4.1.2. Rule-in ................................................................................
3740
3.3.4.1.3. Observe .............................................................................
3740
3.3.4.2. Practical guidance on how to implement the 
European Society of Cardiology 0 h/1 h algorithm .................
3742
3.3.5. Other biomarkers .......................................................................... 3742
3.4. Diagnostic tools | Non-invasive imaging .......................................
3742
3.4.1. Echocardiography ........................................................................... 3742
3.4.2. Computed tomography ............................................................... 3742
3.4.3. Cardiac magnetic resonance imaging with or without 
stress testing ................................................................................................. 3742
3.5. Differential diagnosis for acute chest pain ..................................
3743
4. Initial measures for patients presenting with suspected acute 
coronary syndrome | Initial treatment ........................................................ 3743
4.1. Pre-hospital logistics of care ..............................................................
3743
4.1.1. Time to treatment ......................................................................... 3743
ESC Guidelines                                                                                                                                                                                          3721


<!-- PAGE 3 -->

### Page 3

4.1.2. Healthcare systems and system delays .................................. 3743
4.1.3. Emergency medical services ....................................................... 3743
4.1.4. General practitioners .................................................................... 3744
4.1.5. Organization of ST-elevation myocardial infarction 
treatment in networks .............................................................................. 3744
4.2. Emergency care .......................................................................................
3744
4.2.1. Initial diagnosis and monitoring ................................................ 3744
4.2.2. Acute pharmacotherapy .............................................................. 3744
4.2.2.1. Oxygen .......................................................................................
3744
4.2.2.2. Nitrates ......................................................................................
3744
4.2.2.3. Pain relief ...................................................................................
3744
4.2.2.4. Intravenous beta-blockers ..................................................
3744
5. Acute-phase management of patients with acute coronary 
syndrome .................................................................................................................. 3745
5.1. Selection of invasive strategy and reperfusion therapy .........
3745
5.2. Acute coronary syndrome managed with invasive strategy
3745
5.2.1. Primary percutaneous coronary intervention strategy for 
ST-elevation myocardial infarction ...................................................... 3745
5.2.1.1. Invasive strategy in ST-elevation myocardial infarction 
late presenters .........................................................................................
3747
5.2.2. Immediate invasive strategy for non-ST elevation acute 
coronary syndrome .................................................................................... 3747
5.2.3. Routine vs. selective invasive strategy .................................... 3747
5.2.3.1. Early vs. delayed invasive strategy for non-ST 
elevation acute coronary syndrome ..............................................
3747
5.2.4. Summary of invasive strategies for patients with non-ST 
elevation acute coronary syndrome ................................................... 3747
5.3. Fibrinolysis and pharmaco-invasive strategy in patients with 
ST-elevation myocardial infarction ..........................................................
3749
5.3.1. Benefit and indication of fibrinolysis ....................................... 3749
5.3.1.1. Pre-hospital fibrinolysis ........................................................
3749
5.3.1.2. Angiography and percutaneous coronary 
intervention after fibrinolysis (pharmaco-invasive strategy)
3749
5.3.1.2.1. Comparison of fibrinolytic agents ..........................
3749
5.3.1.2.2. Hazards of fibrinolysis and contraindications ....
3749
5.4. Patients not undergoing reperfusion .............................................
3749
5.4.1. Patients who are not candidates for invasive coronary 
angiography .................................................................................................... 3749
5.4.2. Patients with coronary artery disease not amenable to 
revascularization .......................................................................................... 3749
6. Antithrombotic therapy ................................................................................ 3750
6.1. Antiplatelet therapy in the acute phase .......................................
3752
6.1.1. Oral antiplatelet therapy ............................................................. 3752
6.1.2. Timing of loading dose of oral antiplatelet therapy ......... 3753
6.1.2.1. Pre-treatment in patients with suspected ST- 
elevation myocardial infarction ........................................................
3753
6.1.2.2. Pre-treatment in patients with non-ST-elevation 
acute coronary syndrome ..................................................................
3753
6.1.2.3. Summary of pre-treatment strategies ...........................
3753
6.1.3. Intravenous antiplatelet drugs ................................................... 3753
6.2. Anticoagulant treatment in the acute phase ..............................
3754
6.2.1. Anticoagulation in patients with ST-elevation myocardial 
infarction undergoing primary percutaneous coronary 
intervention ................................................................................................... 3754
6.2.2. Anticoagulation in patients with non-ST-elevation acute 
coronary syndrome undergoing angiography and percutaneous 
coronary intervention if indicated ....................................................... 3754
6.3. Maintenance antithrombotic therapy after revascularization
3755
6.3.1. Shortening dual antiplatelet therapy ....................................... 3756
6.3.2. De-escalation from potent P2Y12 inhibitor to 
clopidogrel ..................................................................................................... 3756
6.3.3. Summary of alternative antiplatelet strategies to reduce 
bleeding risk in the first 12 months after acute coronary 
syndrome ........................................................................................................ 3757
6.4. Long-term treatment ............................................................................
3759
6.4.1. Prolonging antithrombotic therapy beyond 12 months
3759
6.5. Antiplatelet therapy in patients requiring oral 
anticoagulation .................................................................................................
3760
6.5.1. Acute coronary syndrome patients requiring 
anticoagulation ............................................................................................. 3760
6.5.2. Patients requiring vitamin K antagonists or undergoing 
coronary artery bypass surgery ............................................................ 3762
6.6. Antithrombotic therapy as an adjunct to fibrinolysis .............
3762
6.7. Antithrombotic therapy in patients not undergoing 
reperfusion .........................................................................................................
3762
7. Acute coronary syndrome with unstable presentation .................. 3762
7.1. Out-of-hospital cardiac arrest in acute coronary syndrome
3763
7.1.1. Systems of care ................................................................................ 3763
7.2. Cardiogenic shock complicating acute coronary syndrome
3763
8. Management of acute coronary syndrome during hospitalization
3764
8.1. Coronary care unit/intensive cardiac care unit .........................
3764
8.1.1. Monitoring ......................................................................................... 3764
8.1.2. Ambulation ........................................................................................ 3764
8.1.3. Length of stay in the intensive cardiac care unit ............... 3765
8.2. In-hospital care ........................................................................................
3765
8.2.1. Length of hospital stay ................................................................. 3765
8.2.2. Risk assessment ............................................................................... 3765
8.2.2.1. Clinical risk assessment ........................................................
3765
8.2.2.2. Imaging risk assessment .......................................................
3765
8.2.2.3. Biomarkers for risk assessment .......................................
3765
8.2.2.4. Bleeding risk assessment .....................................................
3765
8.2.2.5. Integrating ischaemic and bleeding risks .......................
3765
9. Technical aspects of invasive strategies .................................................. 3766
9.1. Percutaneous coronary intervention .............................................
3766
9.1.1. Vascular access ................................................................................ 3766
9.1.2. Intravascular imaging/physiology of the infarct-related 
artery ................................................................................................................ 3766
9.1.2.1. Intravascular imaging .............................................................
3766
9.1.2.2. Intravascular physiology .......................................................
3767
9.1.3. Timing of revascularization with percutaneous coronary 
intervention ................................................................................................... 3767
9.1.4. Balloons and stents ........................................................................ 3768
9.1.5. Embolic protection and microvascular salvage strategies
3768
9.1.5.1. Thrombus aspiration ............................................................
3768
9.1.5.2. Interventions to protect the microcirculation ..........
3768
9.2. Coronary artery bypass grafting ......................................................
3768
9.2.1. Indication and timing of coronary artery bypass grafting in 
acute coronary syndrome patients ..................................................... 3768
9.2.2. Technical considerations specific to acute coronary 
syndrome patients ...................................................................................... 3768
9.3. Spontaneous coronary artery dissection .....................................
3768
9.3.1. Intravascular imaging ..................................................................... 3769
9.3.2. Revascularization ............................................................................. 3769
10. Management of patients with multivessel disease ........................... 3769
10.1. Management of multivessel disease in acute coronary 
syndrome complicated by cardiogenic shock .....................................
3769


<!-- PAGE 4 -->

### Page 4

10.2. Patients with multivessel coronary artery disease 
undergoing primary percutaneous coronary intervention ............
3770
10.3. Timing of non-infarct-related artery revascularization in 
acute coronary syndrome ...........................................................................
3771
10.3.1. Patients presenting with ST-elevation myocardial 
infarction and multivessel coronary artery disease ...................... 3771
10.3.2. Patients presenting with non-ST-elevation acute 
coronary syndrome and multivessel coronary artery disease . 3771
10.4. Evaluation of non-infarct-related artery stenosis severity 
(angiography vs. physiology) .......................................................................
3771
10.5. Hybrid revascularization ...................................................................
3772
11. Myocardial infarction with non-obstructive coronary arteries . 3772
12. Special situations ............................................................................................ 3775
12.1. Type 2 myocardial infarction and acute myocardial injury
3775
12.2. Complications .......................................................................................
3775
12.2.1. Heart failure ................................................................................... 3775
12.2.2. Mechanical complications ......................................................... 3776
12.2.3. Left ventricular thrombus ......................................................... 3776
12.2.4. Post-acute coronary syndrome pericarditis ..................... 3776
12.2.5. Arrhythmias .................................................................................... 3776
12.2.5.1. Atrial fibrillation ....................................................................
3776
12.2.5.2. Ventricular arrhythmias ....................................................
3777
12.2.6. Bleeding ............................................................................................ 3777
12.2.6.1. Management of bleeding ..................................................
3777
12.3. Comorbid conditions .........................................................................
3778
12.3.1. Patients at high bleeding risk and with blood disorders 
(anaemia and thrombocytopaenia) ..................................................... 3778
12.3.2. Chronic kidney disease .............................................................. 3779
12.3.3. Diabetes mellitus .......................................................................... 3779
12.3.4. Older adults with frailty and multimorbidity ................... 3779
12.3.4.1. The older person .................................................................
3779
12.3.4.2. Frailty and multimorbidity ................................................
3779
12.3.5. Pregnancy ........................................................................................ 3780
12.3.6. Drug abuse ...................................................................................... 3780
12.3.7. Patients with cancer .................................................................... 3780
12.3.8. Coronavirus disease (COVID-19) ........................................ 3780
13. Long-term treatment ................................................................................... 3781
13.1. Cardiac rehabilitation .........................................................................
3783
13.1.1. Comprehensive cardiac rehabilitation ................................. 3783
13.1.2. Digital health .................................................................................. 3783
13.1.3. Adherence and persistence ..................................................... 3783
13.2. Lifestyle management .........................................................................
3783
13.2.1. Tobacco ........................................................................................... 3783
13.2.2. Nutrition and alcohol ................................................................. 3783
13.2.3. Physical activity and exercise .................................................. 3784
13.2.4. Psychological considerations ................................................... 3784
13.2.5. Resumption of activities ............................................................ 3784
13.3. Pharmacological treatment ..............................................................
3784
13.3.1. Antithrombotic therapy ............................................................ 3784
13.3.2. Lipid-lowering therapy ............................................................... 3784
13.3.3. Beta-blockers ................................................................................. 3785
13.3.4. Nitrates and calcium channel blockers ............................... 3786
13.3.5. Renin–angiotensin–aldosterone system inhibitors ......... 3786
13.3.6. Medications for diabetes ........................................................... 3786
13.3.6.1. Sodium–glucose co-transporter 2 inhibitors ...........
3786
13.3.6.2. Glucagon-like peptide-1 receptor agonists ..............
3787
13.3.7. Proton pump inhibitors ............................................................. 3787
13.3.8. Vaccination ...................................................................................... 3787
13.3.9. Anti-inflammatory drugs ........................................................... 3787
13.3.10. Hormone replacement therapy .......................................... 3787
14. Patient perspectives ..................................................................................... 3788
14.1. Patient-centred care ...........................................................................
3788
14.2. Shared decision-making .....................................................................
3789
14.3. Informed consent ................................................................................
3789
14.4. Research participation and consent in the acute setting ....
3790
14.5. Patient satisfaction and expectations ..........................................
3790
14.6. Patient-reported outcome measures and patient-reported 
experience measures .....................................................................................
3791
14.7. Preparation for discharge .................................................................
3791
15. Key messages .................................................................................................. 3791
16. Gaps in evidence ............................................................................................ 3793
17. Sex differences ............................................................................................... 3795
18. ‘What to do’ and ‘What not to do’ messages from the 
Guidelines ................................................................................................................. 3796
19. Quality indicators .......................................................................................... 3801
20. Supplementary data ...................................................................................... 3801
21. Data availability statement ......................................................................... 3801
22. Author information ...................................................................................... 3801
23. Appendix ........................................................................................................... 3801
Tables of Recommendations
Recommendation Table 1 — Recommendations for clinical and 
diagnostic tools for patients with suspected acute coronary 
syndrome .................................................................................................................. 3738
Recommendation Table 2 — Recommendations for non-invasive 
imaging in the initial assessment of patients with suspected acute 
coronary syndrome .............................................................................................. 3742
Recommendation Table 3 — Recommendations for the initial 
management of patients with acute coronary syndrome ................... 3745
Recommendation Table 4 — Recommendations for reperfusion 
therapy and timing of invasive strategy ....................................................... 3750
Recommendation Table 5 — Recommendations for antiplatelet and 
anticoagulant therapy in acute coronary syndrome .............................. 3758
Recommendation Table 6 — Recommendations for  
alternative antithrombotic therapy regimens ........................................... 3759
Recommendation Table 7 — Recommendations for fibrinolytic 
therapy ....................................................................................................................... 3762
Recommendation Table 8 — Recommendations for cardiac arrest 
and out-of-hospital cardiac arrest ................................................................. 3763
Recommendation Table 9 — Recommendations for cardiogenic 
shock .......................................................................................................................... 3764
Recommendation Table 10 — Recommendations for in-hospital 
management ............................................................................................................ 3766
Recommendation Table 11 — Recommendations for technical 
aspects of invasive strategies ............................................................................ 3769
Recommendation Table 12 — Recommendations for management 
of patients with multivessel disease .............................................................. 3772
Recommendation Table 13 — Recommendations for myocardial 
infarction with non-obstructive coronary arteries ................................. 3775
Recommendation Table 14 — Recommendations for acute 
coronary syndrome complications ................................................................ 3777
Recommendation Table 15 — Recommendations for acute 
coronary syndrome comorbid conditions ................................................. 3781
ESC Guidelines                                                                                                                                                                                          3723


<!-- PAGE 5 -->

### Page 5

Recommendation Table 16 — Recommendations for long-term 
management ............................................................................................................ 3787
Recommendation Table 17 — Recommendations for patient 
perspectives in acute coronary syndrome care ....................................... 3791
List of tables
Table 1 Classes of recommendations .......................................................... 3728
Table 2 Levels of evidence ................................................................................ 3728
Table 3 Definitions of terms related to invasive strategy and 
reperfusion therapy commonly used in this document ....................... 3731
Table 4 New recommendations .................................................................... 3733
Table 5 Revised recommendations ............................................................... 3734
Table 6 Dose regimen of antiplatelet and anticoagulant drugs in 
acute coronary syndrome patients ............................................................... 3751
Table 7 Suggested strategies to reduce bleeding risk related to 
percutaneous coronary intervention ............................................................ 3760
Table 8 Gaps in evidence .................................................................................. 3793
Table 9 ‘What to do’ and ‘What not to do’ ............................................. 3796
List of figures
Figure 1 Central illustration .............................................................................. 3729
Figure 2 The spectrum of clinical presentations, electrocardiographic 
findings, and high-sensitivity cardiac troponin levels in patients with 
acute coronary syndrome ................................................................................. 3730
Figure 3 Classification of patients presenting with suspected acute 
coronary syndrome: from a working to a final diagnosis .................... 3732
Figure 4 An overview of the initial triage, management and 
investigation of patients who present with signs and symptoms 
potentially consistent with acute coronary syndrome ......................... 3736
Figure 5 The A.C.S. assessment for the initial evaluation of patients 
with suspected acute coronary syndrome ................................................. 3737
Figure 6 The 0 h/1 h or 0 h/2 h rule-out and rule-in algorithms using 
high-sensitivity cardiac troponin assays in patients presenting to the 
emergency department with suspected NSTEMI and without an 
indication for immediate invasive angiography ......................................... 3741
Figure 7 Modes of presentation and pathways to invasive 
management and myocardial revascularization in patients presenting 
with STEMI .............................................................................................................. 3746
Figure 8 Selection of invasive strategy and reperfusion therapy in 
patients presenting with NSTE-ACS ............................................................ 3748
Figure 9 Antithrombotic treatments in acute coronary syndrome: 
pharmacological targets ...................................................................................... 3752
Figure 10 Recommended default antithrombotic therapy regimens 
in acute coronary syndrome patients without an indication for oral 
anticoagulation ....................................................................................................... 3755
Figure 11 Alternative antiplatelet strategies to reduce bleeding risk in 
the first 12 months after an ACS .................................................................. 3757
Figure 12 Antithrombotic regimens in patients with acute coronary 
syndrome and an indication for oral anticoagulation ................................
3761
Figure 13 A practical algorithm to guide intravascular imaging in 
acute coronary syndrome patients ............................................................... 3767
Figure 14 Algorithm for the management of acute coronary 
syndrome patients with multivessel coronary artery disease ............ 3770
Figure 15 Underlying causes for patients with a working diagnosis of 
myocardial infarction with non-obstructive coronary arteries ......... 3773
Figure 16 Evaluation of patients with a working diagnosis of 
MINOCA .................................................................................................................. 3774
Figure 17 Long-term management after acute coronary syndrome
3782
Figure 18 Lipid-lowering therapy in ACS patients .................................. 3785
Figure 19 A person-centred approach to the ACS journey .............. 3789
Figure 20 Acute coronary syndrome patient expectations ................ 3790
Abbreviations and acronyms
AβYSS
Beta Blocker Interruption After 
Uncomplicated Myocardial Infarction
ACCOAST
A Comparison of Prasugrel at the Time of 
Percutaneous Coronary Intervention or as 
Pretreatment at the Time of Diagnosis in 
Patients with Non-ST Elevation Myocardial 
Infarction
ACE
Angiotensin-converting enzyme
ACS
Acute coronary syndrome
AF
Atrial fibrillation
AFIRE
Atrial Fibrillation and Ischemic Events With 
Rivaroxaban in Patients With Stable Coronary 
Artery Disease
AMI
Acute myocardial infarction
ARB
Angiotensin receptor blocker
ARC-HBR
Academic Research Consortium for High 
Bleeding Risk
ARNI
Angiotensin receptor/neprilysin inhibitor
ASCVD
Atherosclerotic cardiovascular disease
ASSENT 3
ASsessment of the Safety and Efficacy of a New 
Thrombolytic 3
ATLANTIC
Administration of Ticagrelor in the Cath Lab or 
in the Ambulance for New ST Elevation 
Myocardial Infarction to Open the Coronary 
Artery
AUGUSTUS
An Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety 
of Apixaban Versus Vitamin K Antagonist and 
Aspirin Versus Aspirin Placebo in Patients With 
Atrial Fibrillation and Acute Coronary 
Syndrome or Percutaneous Coronary 
Intervention
AV
Atrioventricular
BARC
Bleeding Academic Research Consortium b.i.d.
Bis in die (twice a day)
BBB
Bundle branch block
BEACON
Better Evaluation of Acute Chest Pain with 
Coronary Computed Tomography Angiography
BETAMI
BEtablocker Treatment After Acute 
Myocardial Infarction in Patients Without 
Reduced Left Ventricular Systolic Function
BMS
Bare metal stent
BNP
Brain natriuretic peptide
CABG
Coronary artery bypass grafting
CAD
Coronary artery disease
CAPITAL-RCT
Carvedilol Post-Intervention Long-Term 
Administration in Large-scale Randomized 
Controlled Trial
CAPRICORN
CArvedilol Post-infaRct survIval COntRolled 
evaluatioN
CCS
Chronic coronary syndrome


<!-- PAGE 6 -->

### Page 6

CCTA
Coronary computed tomography angiography
CCU
Coronary care unit
CHA2DS2-VASc
Congestive heart failure, Hypertension, Age, 
Diabetes, Stroke or TIA-Vascular disease
CHAMPION PCI
Cangrelor versus Standard Therapy to 
Achieve Optimal Management of Platelet 
Inhibition
CHAMPION 
PHOENIX
A Clinical Trial Comparing Cangrelor to 
Clopidogrel Standard Therapy in Subjects 
Who Require Percutaneous Coronary 
Intervention
CHAMPION 
PLATFORM
Cangrelor Versus Standard Therapy to 
Achieve Optimal Management of Platelet 
Inhibition
CKD
Chronic kidney disease
CMR
Cardiac magnetic resonance
CI
Confidence interval
COACT
Coronary Angiography after Cardiac Arrest
COLCOT
Colchicine Cardiovascular Outcomes Trial
COMFORTABLE- 
AMI
Comparison of Biolimus Eluted From an Erodible 
Stent Coating With Bare Metal Stents in Acute 
ST-Elevation Myocardial Infarction
COMPARE-ACUTE
Comparison Between FFR Guided 
Revascularization Versus Conventional 
Strategy in Acute STEMI Patients With MVD
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COMPLETE
Complete vs. Culprit-only Revascularization to 
Treat Multivessel Disease After Early PCI for 
STEMI
COVID-19
Coronavirus disease 2019
CR
Cardiac rehabilitation
CRT
Cardiac resynchronization therapy— 
defibrillator/pacemaker
CS
Cardiogenic shock
CT
Computed tomography
CV
Cardiovascular
CVD
Cardiovascular disease
CvLPRIT
Complete versus Lesion-only Primary PCI Trial cTn
Cardiac troponin
CULPRIT-SHOCK
Culprit Lesion Only PCI versus Multivessel PCI 
in Cardiogenic Shock
DANAMI-3– 
PRIMULTI
Third Danish Study of Optimal Acute 
Treatment of Patients with ST-Segment 
Elevation Myocardial Infarction—Primary PCI 
in Multivessel Disease
DANBLOCK
Danish Trial of Beta Blocker Treatment After 
Myocardial Infarction Without Reduced 
Ejection Fraction
DAPT
Dual antiplatelet therapy
DAT
Dual antithrombotic therapy
DCB
Drug-coated balloon
DES
Drug-eluting stent(s)
DM
Diabetes mellitus
ECG
Electrocardiography/gram
ECMO
Extracorporeal membrane oxygenation eGFR
Estimated glomerular filtration rate
ED
Emergency department
EMS
Emergency medical service(s)
EPHESUS
Eplerenone Post-AMI Heart failure Efficacy and 
SUrvival Study
ESC
European Society of Cardiology
EXAMINATION
Everolimus-Eluting Stents Versus Bare-Metal 
Stents in ST Segment Elevation Myocardial 
Infarction
ExTRACT-TIMI 25
Enoxaparin and Thrombolysis Reperfusion for 
Acute myocardial infarction Treatment 
Thrombolysis In Myocardial Infarction—Study 25
FAME
Fractional Flow Reserve versus Angiography 
for Multivessel Evaluation
FAMOUS-NSTEMI
Fractional flow reserve (FFR) versus 
angiography in guiding management to 
optimise outcomes in non-ST segment 
elevation myocardial infarction
FAST-MI
French Registry of Acute ST-elevation and 
non-ST-elevation Myocardial Infarction
FFR
Fractional flow reserve
FLOWER-MI
Flow Evaluation to Guide Revascularization in 
Multivessel ST-Elevation Myocardial Infarction
FMC
First medical contact
GLP-1RA
Glucagon-like peptide-1 receptor agonist
GP
Glycoprotein
GRACE
Global Registry of Acute Coronary Events
HBR
High bleeding risk
HCR
Hybrid coronary revascularization
HF
Heart failure
HFrEF
Heart failure with reduced ejection fraction
HOST-REDUCE-P­
OLYTECH-ACS
Harmonizing Optimal Strategy for Treatment 
of Coronary Artery Diseases Trial— 
Comparison of REDUCTION of PrasugrEl 
Dose & POLYmer TECHnology in ACS 
Patients
HR
Hazard ratio
HR-QoL
Health-related quality of life hs-cTn
High-sensitivity cardiac troponin
IABP
Intra-aortic balloon counter pulsation/pumping
IABP-SHOCK II
Intraaortic Balloon Pump in Cardiogenic Shock II
ICA
Invasive coronary angiography
ICCU
Intensive cardiac care unit
ICD
Implantable cardioverter defibrillator
ICU
Intensive care unit
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial
INR
International normalized ratio
IRA
Infarct-related artery
ISAR-REACT 5
Intracoronary stenting and Antithrombotic 
regimen Rapid Early Action for Coronary 
Treatment
ISIS-4
Fourth International Study of Infarct Survival i.v.
Intravenous
IVUS
Intravascular ultrasound
LAD
Left anterior descending
LBBB
Left bundle branch block
LD
Loading dose
LDL-C
Low-density lipoprotein-cholesterol
LIMA
Left internal mammary artery
LMWH
Low-molecular-weight heparin
LoDoCo2
Low-dose Colchicine trial-2
LV
Left ventricular(cle)
LVAD
Left ventricular assist device
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
ESC Guidelines                                                                                                                                                                                          3725


<!-- PAGE 7 -->

### Page 7

MASTER DAPT
Management of High Bleeding Risk Patients 
Post Bioresorbable Polymer Coated Stent 
Implantation With an Abbreviated Versus 
Prolonged DAPT Regimen
MATRIX
Minimizing Adverse Haemorrhagic Events by 
Transradial Access Site and Systemic 
Implementation of angioX
MCS
Mechanical circulatory support
MD
Maintenance dose
MI
Myocardial infarction
MINOCA
Myocardial infarction with non-obstructive 
coronary arteries
MRA
Mineralocorticoid receptor antagonist
MVD
Multivessel disease
MVO
Microvascular obstruction
NOAC
Non-vitamin K antagonist oral anticoagulant
NORSTENT
Norwegian Coronary Stent Trial
NPV
Negative predictive value
NRT
Nicotine replacement therapy
NSTE
Non-ST elevation
NSTE-ACS
Non-ST elevation acute coronary syndrome
NSTEMI
Non-ST-elevation myocardial infarction
NT-pro BNP
N-terminal pro B-type natriuretic peptide
NYHA
New York Heart Association o.d.
Once a day
OAC
Oral anticoagulant/ation
OASIS-5
Fifth Organization to Assess Strategies in Acute 
Ischemic Syndromes
OASIS-6
The Safety and Efficacy of Fondaparinux Versus 
Control Therapy in Patients With ST Segment 
Elevation Acute Myocardial Infarction
OAT
Occluded Artery Trial
OCT
Optical coherence tomography
ODYSSEY 
OUTCOMES
Evaluation of Cardiovascular Outcomes After 
an Acute Coronary Syndrome During 
Treatment With Alirocumab
OHCA
Out-of-hospital cardiac arrest
OR
Odds ratio
PARADISE-MI
Prospective ARNI vs ACE Inhibitor Trial to 
Determine Superiority in Reducing Heart 
Failure Events After MI
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
PE
Pulmonary embolism
PEGASUS-TIMI 54
PrEvention with TicaGrelor of SecondAry 
Thrombotic Events in High-RiSk Patients with 
Prior AcUte Coronary Syndrome— 
Thrombolysis In Myocardial Infarction
PEPCAD NSTEMI
Bare Metal Stent Versus Drug Coated Balloon 
With Provisional Stenting in Non-ST-Elevation 
Myocardial Infarction
PLATO
PLATelet inhibition and patient Outcomes
POC
Point of care
POPular Genetics
Cost-effectiveness of CYP2C19 Genotype 
Guided Treatment With Antiplatelet Drugs in 
Patients With ST-segment-elevation Myocardial 
Infarction Undergoing Immediate PCI With 
Stent Implantation: Optimization of Treatment
PPCI
Primary percutaneous coronary intervention
PPI
Proton pump inhibitor
PPV
Positive predictive value
PRAMI
Preventive Angioplasty in Myocardial Infarction
PREM
Patient-reported experience measure
PROM
Patient-reported outcome measure
QI
Quality indicator
RAAS
Renin–angiotensin–aldosterone system
RAPID-CTCA
Rapid Assessment of Potential Ischaemic heart 
Disease with CTCA
RCT
Randomized controlled trial
REALITY
Restrictive and Liberal Transfusion  
Strategies in Patients With Acute Myocardial 
Infarction
REBOOT-CNIC
TREatment With Beta-blockers After 
myOcardial Infarction withOut Reduced 
Ejection fracTion
REDUCE-SWEDE­
HEART
Evaluation of Decreased Usage of Betablockers 
After Myocardial Infarction in the 
SWEDEHEART Registry
REMINDER
Double-Blind, Randomized, 
Placebo-Controlled Trial Evaluating The Safety 
And Efficacy Of Early Treatment With 
Eplerenone In Patients With Acute Myocardial 
Infarction
REVELATION
REVascularization With PaclitaxEL-Coated 
Balloon Angioplasty Versus Drug-Eluting 
Stenting in Acute Myocardial InfarcTION
RIVAL
RadIal Vs femorAL access for coronary 
intervention
ROMICAT II
Multicenter Study to Rule Out Myocardial 
Infarction by Cardiac Computed Tomography
ROSC
Return of spontaneous circulation
RR
Relative risk
RV
Right ventricular
SAPT
Single antiplatelet therapy
SBP
Systolic blood pressure s.c.
Subcutaneous
SCAD
Spontaneous coronary artery dissection
SHOCK
Should We Emergently Revascularize 
Occluded Coronaries for Cardiogenic Shock
SGLT2
Sodium–glucose co-transporter 2
SMART-DECISION
Long-term Beta-blocker Therapy After Acute 
Myocardial Infarction
SPECT
Single-photon emission computerized 
tomography
STE
ST elevation
STEMI
ST-elevation myocardial infarction
STOPDAPT-2-ACS
ShorT and OPtimal Duration of Dual 
AntiPlatelet Therapy-2 Study for the Patients 
With ACS
STREAM
Strategic Reperfusion Early After Myocardial 
Infarction
SWEDEHEART
Swedish Web-System for Enhancement and 
Development of Evidence-Based Care in Heart 
Disease Evaluated According to 
Recommended Therapies
TALOS-AMI
TicAgrelor Versus CLOpidogrel in Stabilized 
Patients With Acute Myocardial Infarction
TAT
Triple antithrombotic therapy


<!-- PAGE 8 -->

### Page 8

TICO
Ticagrelor Monotherapy After 3 Months in the 
Patients Treated With New Generation 
Sirolimus Stent for Acute Coronary Syndrome
TIMI
Thrombolysis In Myocardial Infarction
TLR
Target lesion revascularization
TOMAHAWK
Immediate Unselected Coronary Angiography 
Versus Delayed Triage in Survivors of 
Out-of-hospital Cardiac Arrest Without 
ST-segment Elevation
TOPIC
Timing of Platelet Inhibition After Acute 
Coronary Syndrome
TOTAL
Trial of routine aspiration ThrOmbecTomy 
with PCI vs. PCI ALone in patients with STEMI
TRITON-TIMI 38
TRial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet InhibitioN 
with Prasugrel Thrombolysis In Myocardial 
Infarction 38
TROPICAL-ACS
Testing Responsiveness to Platelet Inhibition 
on Chronic Antiplatelet Treatment For Acute 
Coronary Syndromes
TTE
Transthoracic echocardiography
TWILIGHT
Ticagrelor With Aspirin or Alone in High-Risk 
Patients After Coronary Intervention
UA
Unstable angina
UFH
Unfractionated heparin
VA-ECMO
Veno-arterial extracorporeal membrane 
oxygenation
VALIANT
VALsartan In Acute myocardial iNfarcTion
VF
Ventricular fibrillation
VKA
Vitamin K antagonist
VT
Ventricular tachycardia
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to 
represent professionals involved with the medical care of patients 
with this pathology. The selection procedure aimed to include 
members from across the whole of the ESC region and from rele­
vant ESC Subspecialty Communities. Consideration was given to 
diversity and inclusion, notably with respect to gender and country 
of origin. The Task Force performed a critical evaluation of diag­
nostic and therapeutic approaches, including assessment of the 
risk-benefit ratio. The strength of every recommendation and the 
level of evidence supporting them were weighed and scored ac­
cording to predefined scales as outlined below. The Task Force fol­
lowed ESC voting procedures, and all approved recommendations 
were subject to a vote and achieved at least 75% agreement among 
voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
Guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its en­
tire financial support from the ESC without any involvement from the 
healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. ESC Guidelines undergo extensive review 
by the CPG Committee and external experts, including members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities and National Cardiac Societies. After appro­
priate revisions, the guidelines are signed off by all the experts involved 
in the Task Force. The finalized document is signed off by the CPG 
Committee for publication in the European Heart Journal. The guidelines 
were developed after careful consideration of the scientific and medical 
knowledge and the evidence available at the time of their writing. Tables 
of evidence summarizing the findings of studies informing development 
of the guidelines are included. The ESC warns readers that the technical 
language may be misinterpreted and declines any responsibility in this 
respect.
Off-label use of medication may be presented in this guideline if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
ESC Guidelines                                                                                                                                                                                          3727


<!-- PAGE 9 -->

### Page 9

### 2 Introduction

The major aspects of the management of patients with acute coronary 
syndromes described in this European Society of Cardiology (ESC) 
Guideline are summarized in Figure 1.
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023


<!-- PAGE 10 -->

### Page 10

Aim for complete 
revascularization
2
3
4
1
5
ACS encompasses a spectrum
Think secondary prevention
Abnormal
ECG?
Clinical context?
Stable patient?
Think ‘A.C.S.’ at initial assessment
Think antithrombotic therapy
Primary PCI
Fibrinolysis
(If timely primary PCI not feasible)
Immediate angiography ± PCI
AND
OR
OR
OR
Early (<24 h) angiography should be considered
Aspirin
UFH
LMWH
Bivalirudin
Fondaparinux
P2Y12 inhibitor
STEMI
OR
Very high-risk NSTE-ACS
High-risk NSTE-ACS
Antiplatelet therapy
+
Anticoagulant therapy
PCI
Antithrombotic 
therapy
Lipid lowering 
therapy
Smoking 
cessation
Cardiac 
rehabilitation
Risk factor management
Psychosocial considerations
CABG
Based on clinical status, co-morbidities,
and disease complexity
OR
Consider adjunctive tests to guide revascularization
Think invasive management
Think revascularization
Intravascular imaging
Intravascular physiology
Unstable angina
NSTEMI
STEMI
Figure 1 Central illustration. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ECG, electrocardiogram; LMWH, low molecular- 
weight heparin; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction; UFH, unfractionated heparin. Patients with acute coronary syndrome (ACS) can initially present with 
a wide variety of clinical signs and symptoms and it is important that there is a high degree of awareness of this amongst both the general public and healthcare 
providers. If ACS is suspected, think ‘A.C.S.’ for the initial triage and assessment. This involves performing an electrocardiogram (ECG) to assess for 
Abnormalities or evidence of ischaemia, taking a targeted clinical history to assess the clinical Context of the presentation, and carrying out a targeted clinical 
examination to assess for clinical and haemodynamic Stability. Based on the initial assessment, the healthcare provider can decide whether immediate invasive 
management is required. Patients with ST-elevation myocardial infarction (STEMI) require primary percutaneous coronary intervention (PPCI) (or fibrinoly­
sis if PPCI within 120 min is not feasible); patients with non-ST-elevation ACS (NSTE-ACS) with very high-risk features require immediate angiography ± PCI 
if indicated; patients with NSTE-ACS and high-risk features should undergo inpatient angiography (angiography within 24 h should be considered). A com­
bination of antiplatelet and anticoagulant therapy is indicated acutely for patients with ACS. The majority of patients with ACS will eventually undergo re­
vascularization, most commonly with PCI. Once the final diagnosis of ACS has been established, it is important to implement measures to prevent recurrent 
events and to optimize cardiovascular risk. This consists of medical therapy, lifestyle changes and cardiac rehabilitation, as well as consideration of psycho­
social factors.
ESC Guidelines                                                                                                                                                                                          3729


<!-- PAGE 11 -->

### Page 11

2.1. Definitions | Acute coronary 
syndromes and myocardial infarction
Acute coronary syndromes (ACS) encompass a spectrum of condi­
tions that include patients presenting with recent changes in clinical 
symptoms or signs, with or without changes on 12-lead electrocardio­
gram (ECG) and with or without acute elevations in cardiac tropo­
nin (cTn) concentrations (Figure 2). Patients presenting with 
suspected ACS may eventually receive a diagnosis of acute myocar­
dial infarction (AMI) or unstable angina (UA). The diagnosis of 
myocardial infarction (MI) is associated with cTn release and is 
made based on the fourth universal definition of MI.1 UA is defined 
as myocardial ischaemia at rest or on minimal exertion in the ab­
sence of acute cardiomyocyte injury/necrosis. It is characterized by 
specific clinical findings of prolonged (>20 min) angina at rest; new 
onset of severe angina; angina that is increasing in frequency, longer 
in duration, or lower in threshold; or angina that occurs after a re­
cent episode of MI. ACS are associated with a broad range of clinical 
presentations, from patients who are symptom free at presentation 
to patients with ongoing chest discomfort/symptoms and patients
Increasing chest pain/symptoms
Oligo/
asymptomatic 
Persistent chest pain/symptoms
Cardiogenic shock/
acute heart failure 
Cardiac arrest
Normal 
ST segment depression 
ST segment elevation
Malignant arrhythmia
Clinical presentation
ECG
findings hs-cTn levels
The ACS spectrum
Final diagnosis
Working diagnosis
Non-elevated
Unstable angina 
NSTE-ACS
NSTEMI
Rise and fall 
STEMI
STEMI
Figure 2 The spectrum of clinical presentations, electrocardiographic findings, and high-sensitivity cardiac troponin levels in patients with acute coronary 
syndrome. ACS, acute coronary syndrome; ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; NSTE-ACS, non-ST-elevation acute coronary 
syndrome; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.


<!-- PAGE 12 -->

### Page 12

with cardiac arrest, electrical/haemodynamic instability, or cardio­
genic shock (CS) (Figure 2).
Patients presenting with suspected ACS are typically classified based 
on ECG at presentation for the purposes of initial management. After 
this, patients can be further classified based on the presence or absence 
of cardiac troponin elevation (once these results are available), as de­
monstrated in Figures 2 and 3. These features (ECG changes and cardiac 
troponin elevation) are important in the initial triage and diagnosis of 
patients with ACS, helping to risk stratify patients and guide the initial 
management strategy. However, after the acute management and sta­
bilization phase, most aspects of the subsequent management strategy 
are common to all patients with ACS (regardless of the initial ECG 
pattern or the presence/absence of cardiac troponin elevation at 
presentation) and can therefore be considered under a common 
pathway. A glossary of the terms related to invasive strategies and 
reperfusion therapy commonly used in this document, and their 
associated definitions, is provided in Table 3.
While they are closely related, it is important to recognize that ACS 
is not the same as MI.1 AMI is defined as cardiomyocyte necrosis in the 
clinical setting of acute myocardial ischaemia. This includes MI due to 
atherothrombotic events (Type 1 MI) and also other potential causes 
of myocardial ischaemia and myocyte necrosis (Type 2–5 MI) 
(Supplementary data online, Table S1). Myocardial injury is another 
distinct entity, used to describe troponin release due to mechanisms 
other than myocardial ischaemia and not meeting the criteria for MI 
outlined in Supplementary data online, Table S1. Myocardial injury 
can be acute or chronic depending on whether there is evidence of 
dynamic change in the elevated troponins on serial testing. Some 
causes of myocardial injury include myocarditis, sepsis, takotsubo car­
diomyopathy, heart valve disease, cardiac arrhythmias, and heart fail­
ure (HF).
The focus of this guideline is largely centred on the management of 
patients who will eventually receive a diagnosis of Type 1 MI. 
However, at every stage of the management of patients presenting 
with ACS, physicians must carefully consider other differential diag­
noses in their clinical assessment because they are common, asso­
ciated with different underlying pathological mechanisms, have 
different prognoses, and frequently require different treatment ap­
proaches. More information is provided in the Supplementary 
data online. In general, detailed information regarding the results 
of individual trials will not be provided in the main guideline. 
However, where appropriate, this information is provided in the 
Supplementary data online evidence tables.
Table 3 Definitions of terms related to invasive strat­
egy and reperfusion therapy commonly used in this 
document
Term
Definition
First medical contact (FMC)
The time point when the patient is initially 
assessed by a physician, paramedic, nurse, 
or other trained emergency medical 
services worker who can obtain and 
interpret the ECG and deliver initial 
interventions (e.g. defibrillation). FMC can 
be either in the pre-hospital setting or 
upon patient arrival at the hospital (e.g. 
the emergency department)
STEMI diagnosis
The time at which a patient with ischaemic 
symptoms is interpreted as presenting 
with ACS and ST-segment elevation (or 
ST-segment elevation equivalent)
Primary PCIa
Emergent PCI with balloon, stent, or 
other approved device, performed on the 
IRA without previous fibrinolytic 
treatment
Primary PCI strategya
Emergency coronary angiography and PCI 
of the IRA if indicated
Rescue PCIa
Emergency PCI performed as soon as 
possible in cases of failed fibrinolytic 
treatment
Routine early PCI strategy 
after fibrinolysisa
Coronary angiography, with PCI of the 
IRA if indicated, performed between 2 h 
and 24 h after successful fibrinolysis
Pharmaco-invasive strategya
Fibrinolysis combined with rescue PCI (in 
cases of failed fibrinolysis) or routine early 
PCI strategy (in cases of successful 
fibrinolysis)
Immediate invasive strategy
Emergency coronary angiography (i.e. as 
soon as possible) and PCI/CABG of the 
IRA if indicated
Early invasive strategy
Early coronary angiography (<24 h from 
diagnosis of ACS) and PCI/CABG of the 
IRA if indicated
Selective invasive strategy
Coronary angiography ± PCI/CABG 
based on clinical assessment and/or 
non-invasive testing
© ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ECG, 
electrocardiogram; IRA, infarct-related artery; PCI, percutaneous coronary intervention; 
STE-ACS, ST-segment-elevation acute coronary syndrome. 
aCABG may also be indicated instead of PCI in certain circumstances.
ESC Guidelines                                                                                                                                                                                          3731


<!-- PAGE 13 -->

### Page 13

2.2. Epidemiology of acute coronary 
syndromes
Cardiovascular disease (CVD) is the most common cause of mortality 
and morbidity worldwide, with a substantial portion of this burden 
borne by low- and middle-income countries.2,3 ACS is often the first 
clinical manifestation of CVD. In 2019, there were an estimated 5.8 mil­
lion new cases of ischaemic heart disease in the 57 ESC member coun­
tries.3 The median age-standardized incidence estimate per 100 000 
people was 293.3 (interquartile ratio 195.8–529.5). CVD remains the 
most common cause of death within ESC member countries, account­
ing for just under 2.2 million deaths in females and just over 1.9 million 
deaths in males in the most recent year of available data. Ischaemic 
heart disease is the most common cause of CVD death, accounting 
for 38% of all CVD deaths in females and 44% in males.3
2.3. Number and breakdown of classes of 
recommendations
The total number of recommendations in this guideline is 193. A sum­
mary of the recommendations according to Class of Recommendation 
and Level of Evidence (LoE) is also provided. As per Class of 
Recommendation, there were 106 Class I, 70 Class II, and 17 Class III 
recommendations. As per LoE, there were 56 LoE A, 64 LoE B, and 
73 LoE C recommendations.
STEMI
NSTE-ACS
STEMI
NSTEMI
Unstable angina 
Non-ACS diagnosis hs-cTn levels
± Angiography
± Imaging
Final diagnosisb
Working diagnosisa
Further investigations
Clinical presentation
If a patient has signs/symptoms suggestive of ACS,
perform an ECG
within 10 min of FMC
ECG
Figure 3 Classification of patients presenting with suspected acute coronary syndrome: from a working to a final diagnosis. ACS, acute coronary syndrome; 
ECG, electrocardiogram; FMC, first medical contact; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction: STEMI, ST-elevation myocardial infarction. aThe working ACS diagnosis can be clas­
sified as STEMI or NSTE-ACS on the basis of available clinical information and ECG findings. This allows for initial triage and assessment. bThe final diagnosis is 
based on symptoms, ECG and troponin for the diagnosis of MI as well as the results of other tests (i.e. imaging and/or angiography) to facilitate understanding 
of the mechanism and subclassification of the type of MI. Patients initially assigned a working diagnosis of STEMI or NSTE-ACS may eventually receive a final 
non-ACS diagnosis.


<!-- PAGE 14 -->

### Page 14

2.4. What is new
Table 4 New recommendations
Recommendations
Classa
Levelb
Recommendations for antiplatelet and anticoagulant therapy in acute coronary syndrome
If patients presenting with ACS stop DAPT to undergo coronary artery bypass grafting, it is recommended they resume DAPT after surgery 
for at least 12 months.
I
C
In older ACS patients, especially if HBR, clopidogrel as the P2Y12 receptor inhibitor may be considered.
IIb
B
Recommendations for alternative antithrombotic therapy regimens
In patients who are event-free after 3–6 months of DAPT and who are not high ischaemic risk, single antiplatelet therapy (preferably with a 
P2Y12 receptor inhibitor) should be considered.
IIa
A
P2Y12 inhibitor monotherapy may be considered as an alternative to aspirin monotherapy for long-term treatment.
IIb
A
In HBR patients, aspirin or P2Y12 receptor inhibitor monotherapy after 1 month of DAPT may be considered.
IIb
B
In patients requiring OAC, withdrawing antiplatelet therapy at 6 months while continuing OAC may be considered.
IIb
B
De-escalation of antiplatelet therapy in the first 30 days after an ACS event is not recommended.
III
B
Recommendations for cardiac arrest and out-of-hospital cardiac arrest
Evaluation of neurological prognosis (no earlier than 72 h after admission) is recommended in all comatose survivors after cardiac arrest.
I
C
Transport of patients with out-of-hospital cardiac arrest to a cardiac arrest centre according to local protocol should be considered.
IIa
C
Recommendations for technical aspects of invasive strategies
In patients with spontaneous coronary artery dissection, PCI is recommended only for patients with symptoms and signs of ongoing 
myocardial ischaemia, a large area of myocardium in jeopardy, and reduced antegrade flow. 
I
C
Intravascular imaging should be considered to guide PCI.
IIa
A
Intravascular imaging (preferably optical coherence tomography) may be considered in patients with ambiguous culprit lesions.
IIb
C
Recommendations for multivessel disease in ACS patients presenting in cardiogenic shock
Staged PCI of non-IRA should be considered.
IIa
C
Recommendations for multivessel disease in haemodynamically stable STEMI patients undergoing primary PCI
It is recommended that PCI of the non-IRA is based on angiographic severity.
I
B
Invasive epicardial functional assessment of non-culprit segments of the IRA is not recommended during the index procedure.
III
C
Recommendations for acute coronary syndrome complications
Implantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 
days after MI.
I
C
Cardiac magnetic resonance imaging should be considered in patients with equivocal echocardiographic images or in cases of high clinical 
suspicion of LV thrombus.
IIa
C
Following an acute anterior MI, a contrast echocardiogram may be considered for the detection of LV thrombus if the apex is not well 
visualized on echocardiography.
IIb
C
In selected patients with high-degree AV block in the context of an anterior wall MI and acute heart failure, early device implantation (cardiac 
resynchronization therapy—defibrillator/pacemaker) may be considered.
IIb
C
In patients with recurrent life-threatening ventricular arrhythmias, sedation or general anaesthesia to reduce sympathetic drive may be 
considered.
IIb
C
Recommendations for acute coronary syndrome comorbid conditions
It is recommended to base the choice of long-term glucose-lowering treatment on the presence of comorbidities, including heart failure, 
chronic kidney disease, and obesity.
I
A
For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological 
treatments after careful evaluation of the risks and benefits.
I
B
An invasive strategy is recommended in cancer patients presenting with high-risk ACS with expected survival ≥6 months.
I
B
A temporary interruption of cancer therapy is recommended in patients in whom the cancer therapy is suspected to be a contributing cause 
of ACS.
I
C
A conservative non-invasive strategy should be considered in ACS patients with poor cancer prognosis (i.e. with expected life survival <6 
months) and/or very high bleeding risk.
IIa
C
Aspirin is not recommended in cancer patients with a platelet count <10 000/μL.
III
C
Continued
ESC Guidelines                                                                                                                                                                                          3733


<!-- PAGE 15 -->

### Page 15

Clopidogrel is not recommended in cancer patients with a platelet count <30 000/μL.
III
C
In ACS patients with cancer and <50 000/μL platelet count, prasugrel or ticagrelor are not recommended.
III
C
Recommendations for long-term management
It is recommended to intensify lipid-lowering therapy during the index ACS hospitalization for patients who were on lipid-lowering therapy 
before admission.
I
C
Low-dose colchicine (0.5 mg once a day) may be considered, particularly if other risk factors are insufficiently controlled or if recurrent 
cardiovascular disease events occur under optimal therapy.
IIb
A
Combination therapy with a high-dose statin plus ezetimibe may be considered during index hospitalization.
IIb
B
Recommendations for patient perspectives in acute coronary syndrome care
Patient-centred care is recommended by assessing and adhering to individual patient preferences, needs and beliefs, ensuring that patient 
values are used to inform all clinical decisions.
I
B
It is recommended to include ACS patients in decision-making (as much as their condition allows) and to inform them about the risk of 
adverse events, radiation exposure, and alternative options. Decision aids should be used to facilitate the discussion.
I
B
It is recommended to assess symptoms using methods that help patients to describe their experience.
I
C
Use of the ‘teach back’ technique for decision support during the securing of informed consent should be considered.
IIa
B
Patient discharge information should be provided in both written and verbal formats prior to discharge. Adequate preparation and 
education for patient discharge using the teach back technique and/or motivational interviewing, giving information in chunks, and checking 
for understanding, should be considered.
IIa
B
Assessment of mental well-being using a validated tool and onward psychological referral when appropriate should be considered.
IIa
B
© ESC 2023
ACS, acute coronary syndrome; AV, atrioventricular; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; IRA, infarct-related artery; LV, left ventricular(cle); MI, myocardial infarction; 
OAC, oral anticoagulant/ation; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.
Table 5 Revised recommendations
Recommendations in 2017 and 2020 versions
Classa
LoEb
Recommendations in 2023 version
Classa
LoEb
Recommendations for imaging for patients with suspected NSTE-ACS
In patients with no recurrence of chest pain, normal ECG 
findings, and normal levels of cardiac troponin (preferably 
high sensitivity), but still with suspected ACS, a 
non-invasive stress test (preferably with imaging) for 
inducible ischaemia or CCTA is recommended before 
deciding on an invasive approach.
I
B
In patients with suspected ACS, non-elevated (or 
uncertain) hs-cTn, no ECG changes and no recurrence of 
pain, incorporating CCTA or a non-invasive stress 
imaging test as part of the initial workup should be 
considered.
IIa
A
Recommendations for timing of invasive strategy in NSTE-ACS
An early invasive strategy within 24 h is recommended in 
patients with any of the following high-risk criteria: 
• Diagnosis of NSTEMI suggested by the diagnostic 
algorithm recommended in Section 3
• Dynamic or presumably new contiguous ST/T-segment 
changes suggesting ongoing ischaemia
• Transient ST-segment elevation
• GRACE risk score >140.
I
A
An early invasive strategy within 24 h should be 
considered in patients with at least one of the following 
high-risk criteria: 
• Confirmed diagnosis of NSTEMI based on current 
recommended ESC hs-cTn algorithms
• Dynamic ST-segment or T wave changes
• Transient ST-segment elevation
• GRACE risk score >140.
IIa
A
Recommendations for antiplatelet and anticoagulant therapy in STEMI
A potent P2Y12 inhibitor (prasugrel or ticagrelor), or 
clopidogrel if these are not available or are contraindicated, 
is recommended before (or at latest at the time of) PCI, and 
maintained over 12 months, unless there are 
contraindications such as excessive risk of bleeding.
I
A
Pre-treatment with a P2Y12 receptor inhibitor may be 
considered in patients undergoing a primary PCI strategy.
IIb
B
Recommendations for long-term antithrombotic therapy
After stent implantation in patients undergoing a strategy 
of DAPT, stopping aspirin after 3–6 months should be 
considered, depending on the balance between the 
ischaemic and bleeding risks.
IIa
A
In patients who are event-free after 3–6 months of DAPT 
and who are not high ischaemic risk, SAPT (preferably 
with a P2Y12 receptor inhibitor) should be considered.
IIa
A
Continued


<!-- PAGE 16 -->

### Page 16

New/revised concepts 
• ACS should be considered a spectrum, which encompasses both 
non-ST-elevation (NSTE)-ACS and ST-elevation MI (STEMI).
• A section on the management of ACS in patients with cancer is 
provided.
• A section on patient perspectives is provided.
3. Triage and diagnosis
3.1. Clinical presentation and physical 
examination
3.1.1. Clinical presentation
Acute chest discomfort—which may be described as pain, pressure, 
tightness, heaviness, or burning—is the leading presenting symptom 
prompting consideration of the clinical diagnosis of ACS and the initi­
ation of testing aligned with specific diagnostic algorithms (Figure 4).
Chest pain descriptors should be classified as cardiac, possibly car­
diac, and likely non-cardiac. Further information on the suggested use 
of these terms is provided in the Supplementary data online. The use 
of the descriptor ‘atypical’ should be avoided. Chest pain-equivalent 
symptoms include dyspnoea, epigastric pain, and pain in the left or right 
arm or neck/jaw.
Misdiagnosis or delayed diagnosis is sometimes due to an incomplete 
history or difficulty in eliciting symptoms from the patient. In order to 
understand the complexity of ACS-related symptomatology, careful 
history taking and comprehensive interaction with the patient are 
crucial and may help to facilitate an early and accurate diagnosis. 
Further information is provided in the Supplementary data online, in­
cluding Figure S1, which outlines some of the most common symptoms 
of ACS in women and men.
Recommendations for cardiac arrest and out-of-hospital cardiac arrest
Delayed as opposed to immediate angiography should be 
considered among haemodynamically stable patients 
without ST-segment elevation successfully resuscitated 
after out-of-hospital cardiac arrest.
IIa
B
Routine immediate angiography after resuscitated cardiac 
arrest is not recommended in haemodynamically stable 
patients without persistent ST-segment elevation (or 
equivalents).
III
A
Targeted temperature management (also called 
therapeutic hypothermia), aiming for a constant 
temperature between 32 and 36 C for at least 24 h, is 
indicated in patients who remain unconscious after 
resuscitation from cardiac arrest (of presumed cardiac 
cause).
I
B
Temperature control (i.e. continuous monitoring of core 
temperature and active prevention of fever [i.e. >37.7°C]) 
is recommended after either out-of-hospital or in-hospital 
cardiac arrest for adults who remain unresponsive after 
return of spontaneous circulation.
I
B
Recommendations for in-hospital management
When echocardiography is suboptimal/inconclusive, an 
alternative imaging method (CMR preferably) should be 
considered.
IIa
C
When echocardiography is suboptimal/inconclusive, 
CMR imaging may be considered.
IIb
C
Recommendations for management of multivessel disease in haemodynamically stable STEMI patients undergoing primary PCI
Routine revascularization of non-IRA lesions should be 
considered in STEMI patients with multivessel disease 
before hospital discharge.
IIa
A
Complete revascularization is recommended either 
during the index PCI procedure or within 45 days.
I
A
Recommendations for acute coronary syndrome comorbid conditions
Glucose-lowering therapy should be considered in ACS 
patients with blood glucose >10 mmol/L (>180 mg/dL), 
with the target adapted to comorbidities, while episodes 
of hypoglycaemia should be avoided.
IIa
B
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, while 
episodes of hypoglycaemia should be avoided.
IIa
C
© ESC 2023
ACS, acute coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; DAPT, dual antiplatelet therapy; ECG, electrocardiography/gram; 
ESC European Society of Cardiology; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; IRA, infarct-related artery; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, ST-elevation myocardial 
infarction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3735


<!-- PAGE 17 -->

### Page 17

It is important that awareness of the symptoms associated with 
ACS is high among the general population, in particular red flag 
symptoms such as prolonged chest pain (>15 min) and/or recurrent 
pain within 1 h, which should prompt patients or other members of 
the public to seek urgent medical help. Continuous education, pro­
motion, and advocacy efforts are important to make sure that this 
information is as widely available as possible to the general 
population.
ACS
presentation
Initial A.C.S.
assessment
ECG
Physical examination
Clinical history
Vital signs hs-cTna levels
Non-immediate angiography
Echo
Intravascular imaging hs-cTna levels
Non-invasive imaging
ECG
monitoring
PCI
CABG
Long-term medical therapy
Lifestyle measures
Smoking cessation
STEMI
NSTE-ACS
with very high-risk featuresb
NSTE-ACS
without very high-risk featuresb
Immediate angiography ± 
PPCI or fibrinolysis if timely
PPCI not feasible
PPCI
ATT
Fibrinolysis
Immediate angiography 
± PCI
Consider angiography within 24 h for NSTE-ACS
with high risk features
Working diagnosis
Early invasive angiography according to patient risk
Further management
Further investigations
PCI
ATT
PCI
ATT
Figure 4 An overview of the initial triage, management and investigation of patients who present with signs and symptoms potentially consistent with acute 
coronary syndrome. ACS, acute coronary syndrome; ATT, antithrombotic therapy; CABG, coronary artery bypass grafting; ECG, electrocardiogram; hs-cTn, 
high-sensitivity cardiac troponin; NSTE-ACS, non-ST-elevation acute coronary syndrome; PPCI, primary percutaneous coronary intervention; STEMI, 
ST-elevation myocardial infarction. The ‘A.C.S.’ assessment is detailed in Figure 5. aResults of hs-cTn measurements are not required for the initial stratifi­
cation of ACS and the initial emergency management (i.e. for patients with a working diagnosis of STEMI or very high-risk NSTE-ACS) should not be delayed 
based on this. bFor patients with NSTE-ACS with very high-risk features, immediate angiography is recommended. For patients with NSTE-ACS with high- 
risk features, early invasive angiography (i.e. <24 h) should be considered and inpatient invasive angiography is recommended. See Recommendation Table 4 
for details.


<!-- PAGE 18 -->

### Page 18

3.1.2. History taking and physical examination
Patients with suspected ACS present in a broad range of clinical scen­
arios, including in the community, at the emergency department (ED), 
or in the inpatient setting. It is crucial to take a focused medical history 
and accurately characterize the presenting symptoms in order to 
manage the patient via the appropriate care pathway as soon as 
possible.
Prompt assessment of vital signs is recommended at first medical 
contact (FMC), at the same time as acquisition of an initial ECG 
(Figure 5). In patients presenting with suspected ACS, physical examin­
ation is recommended and is useful both to eliminate differential diag­
noses and to identify very high-risk and high-risk ACS features. This may 
be particularly relevant for patients presenting with cardiac arrest, signs 
of CS, and/or haemodynamic or electrical instability.4 Focused physical 
examination should include checking for the presence of all major 
pulses, measurement of blood pressure in both arms, auscultation of 
the heart and lungs, and assessing for signs of HF or circulatory 
compromise.
3.2. Diagnostic tools | Electrocardiogram
The resting 12-lead ECG is the first-line diagnostic tool in the assess­
ment of patients with suspected ACS. It is recommended that an 
ECG is obtained immediately upon FMC and interpreted by a qualified 
emergency medical technician or physician within 10 min.4,5 It should 
be repeated as necessary, especially if symptoms have waned at FMC. 
Based on the initial ECG, patients with suspected ACS can be differen­
tiated into two working diagnoses: 
• Patients with acute chest pain (or chest pain-equivalent 
signs/symptoms) and persistent ST-segment elevation 
(or ST-segment elevation equivalents) on ECG (working 
diagnosis: ST-segment elevation MI: STEMI). The vast major­
ity of these patients will sustain myocardial necrosis and troponin ele­
vation, fulfilling the criteria for an MI, but MI will not be the final 
diagnosis in all patients with a working diagnosis of STEMI.
• Patients with acute chest pain (or chest pain-equivalent 
signs/symptoms) but without persistent ST-segment 
A
C
S
Abnormal
ECG?
Clinical context?
Stable patient?
Perform an ECG to assess 
for evidence of ischaemia  
or other abnormalities
Consider the clinical 
context and available 
investigations
Perform an exam to assess 
if the patient is clinically 
and vitally stable
Figure 5 The A.C.S. assessment for the initial evaluation of patients with suspected acute coronary syndrome. ECG, electrocardiogram. This figure sum­
marizes the initial ‘A.C.S. assessment’ that can be performed for a patient presenting with suspected ACS. ‘A’ stands for ‘Abnormal ECG?’: an ECG should be 
performed within 10 min of FMC and assessed for evidence of abnormalities or ischaemia. ‘C’ stands for ‘Clinical Context?’: it is important to consider the 
clinical context of the patient’s presentation and the results of any investigations that are available. This should also include a targeted history with the aim of 
determining the patient’s symptoms and elucidating any other relevant background information. ‘S’ stands for ‘Stable Patient?’: the patient should be quickly 
assessed to determine if they are clinically stable—this should include assessment of the clinical vital signs, including heart rate, blood pressure, and oxygen 
saturations, if possible, as well as checking for potential signs of CS.
ESC Guidelines                                                                                                                                                                                          3737


<!-- PAGE 19 -->

### Page 19

elevation (or ST-segment elevation equivalents) on ECG 
(working diagnosis: non-ST-elevation [NSTE]-ACS). 
These patients may exhibit other ECG alterations, including transient 
ST-segment elevation, persistent or transient ST-segment depres­
sion, and T wave abnormalities, including hyperacute T waves, T 
wave inversion, biphasic T waves, flat T waves, and pseudo- 
normalization of T waves. Alternatively, the ECG may be normal. 
The majority of patients in this category who subsequently display 
a typical rise and fall in cardiac troponin levels (i.e. fulfilling MI criteria 
as per the fourth universal definition of MI) will receive a final diagno­
sis of non-ST-elevation MI (NSTEMI). In other patients, the troponin 
level will remain below the 99th centile and they will receive a final 
diagnosis of UA, although with high-sensitivity troponin assays this 
diagnosis has become less common. It is also important to recognize 
that NSTEMI or UA will not be the final diagnosis in all patients with 
an initial working diagnosis of NSTE-ACS.
3.2.1. Acute coronary syndrome with persistent 
ST-segment elevation (suspected ST-elevation 
myocardial infarction)
The priority for these patients is the implementation of reperfusion ther­
apy as soon as possible (see Section 5). In the appropriate clinical context, 
ST-segment elevation (measured at the J-point) is considered suggestive 
of ongoing coronary artery acute occlusion in the following cases:
New ST elevation at the J-point in at least two contiguous leads: 
• ≥2.5 mm in men <40 years, ≥2 mm in men ≥40 years, or ≥1.5 mm 
in women regardless of age in leads V2–V3
• and/or ≥1 mm in the other leads (in the absence of left ventricular 
[LV] hypertrophy or left bundle branch block [LBBB]).
In patients with suspected inferior STEMI, it is recommended to re­
cord right precordial leads (V3R and V4R) in order to assess for 
ST-segment elevation.6 Posterior leads (V7–V9) can also be recorded 
to investigate for posterior STEMI, particularly in patients with ongoing 
symptoms and an inconclusive standard 12-lead ECG.
The diagnosis of ongoing acute coronary artery occlusion on ECG 
can sometimes be challenging, and some cases may warrant prompt 
management and triage for immediate reperfusion therapy despite 
the absence of ST-segment elevation. It is also important to recognize 
that while the most sensitive sign for ongoing acute coronary 
artery occlusion is ST-segment elevation, there are other ECG find­
ings that can be suggestive of ongoing coronary artery occlusion (or 
severe ischaemia). If these findings are present, prompt triage for 
immediate reperfusion therapy is indicated (see Supplementary data 
online, Figure S2).
ST-segment depression in leads V1–V3 (especially when the terminal 
T wave is positive) and/or ST-segment elevation in V7–V9 are highly 
suggestive of posterior coronary artery occlusion (often the left cir­
cumflex artery).1,7 ST-segment elevation in V3R and V4R is highly sug­
gestive of ongoing RV ischaemia.8 ST depression ≥1 mm in ≥6 surface 
leads (inferolateral ST depression), coupled with ST-segment elevation 
in aVR and/or V1, suggests multivessel ischaemia or left main coronary 
artery obstruction, particularly if the patient presents with haemo­
dynamic compromise.9–11
Bundle branch block (BBB). In patients with a high clinical sus­
picion of ongoing myocardial ischaemia, the presence of LBBB, right 
bundle branch block (RBBB), or a paced rhythm precludes an accurate 
assessment of the presence or absence of ST-segment elevation. 
Therefore, patients presenting with these ECG patterns in combination 
with signs/symptoms that are highly suspicious for ongoing myocardial 
ischaemia should be managed similarly to those with clear ST-segment 
elevation, regardless of whether the BBB is previously known (see 
Supplementary data online).4
3.2.2. Acute coronary syndrome without persistent 
ST-segment elevation (non-ST elevation acute 
coronary syndrome)
While the ECG in the setting of NSTE-ACS may be normal in more 
than one-third of patients, characteristic ECG abnormalities are fre­
quently present and increase the diagnostic probability of ACS.12–16
These ECG abnormalities include ST depression and T wave changes 
(especially biphasic T waves or prominent negative T waves 
[Wellens’ sign, related to severe proximal left anterior descending ar­
tery stenosis]), (see Supplementary data online, Figure S3).
Recommendation Table 1 — Recommendations for 
clinical and diagnostic tools for patients with suspected 
acute coronary syndrome
Recommendations
Classa
Levelb
It is recommended to base the diagnosis and initial 
short-term risk stratification of ACS on a 
combination of clinical history, symptoms, vital signs, 
other physical findings, ECG, and hs-cTn.1,17,18
I
B
ECG
Twelve-lead ECG recording and interpretation is 
recommended as soon as possible at the point of 
FMC, with a target of <10 min.5,19
I
B
Continuous ECG monitoring and the availability of 
defibrillator capacity is recommended as soon as 
possible in all patients with suspected STEMI, in 
suspected ACS with other ECG changes or ongoing 
chest pain, and once the diagnosis of MI is made.20,21
I
B
The use of additional ECG leads (V3R, V4R, and V7– 
V9) is recommended in cases of inferior STEMI or if 
total vessel occlusion is suspected and standard leads 
are inconclusive.22–24
I
B
An additional 12-lead ECG is recommended in cases 
with recurrent symptoms or diagnostic uncertainty.
I
C
Continued


<!-- PAGE 20 -->

### Page 20

3.3. Diagnostic tools | Biomarkers
3.3.1. High-sensitivity cardiac troponins
After excluding clinical and ECG signs suggestive of STEMI or very high- 
risk NSTE-ACS, biomarkers play a complementary role in the diagnosis, 
risk stratification, and management of patients with suspected ACS. 
Measurement of a biomarker of cardiomyocyte injury, preferably high- 
sensitivity cardiac troponin (hs-cTn), is recommended in all patients 
with suspected ACS.15,17,25–27,53,54 If the clinical presentation is com­
patible with myocardial ischaemia, then a rise and/or fall in cTn above 
the 99th percentile of healthy individuals points to a diagnosis of MI 
as per the criteria in the fourth universal definition of MI.1 In patients 
with MI, levels of cTn rise rapidly (i.e. usually within 1 h if using high- 
sensitivity assays) after symptom onset and remain elevated for a vari­
able period of time (usually several days).1,15,26,53,55–58
Advances in technology have led to a refinement in cTn assays and 
have improved their accuracy in detecting and quantifying cardiomyo­
cyte injury.1,12–15,18,26,34,35,53,55–60 Data from large multicentre studies 
have consistently shown that hs-cTn assays increase diagnostic accuracy 
for MI at the time of presentation in comparison to conventional assays, 
especially in patients presenting early after chest pain onset, enabling 
more rapid ‘rule-in’ and ‘rule-out’ of MI.1,12–15,26,34,35,53,55–58 Overall, 
hs-cTn T and hs-cTn I subunit assays appear to provide comparable 
diagnostic accuracy in the early diagnosis of MI.28,32,61,62 The use of 
the terms ‘normal’ and ‘abnormal’ to describe hs-cTn levels should 
be avoided; instead, the terms ‘non-elevated’ and ‘elevated’ should be 
used to refer to hs-cTn levels below and above the 99th percentile. 
Some of the clinical implications of hs-cTn assays are detailed in 
Supplementary data online, Table S2.
It is also important to consider that there are other clinical conditions 
apart from Type 1 MI in which elevations in cTn can be observed (see 
Supplementary data online, Section 3.3.1 and Table S3).
3.3.2. Central laboratory vs. point of care
The vast majority of cTn assays that run on automated platforms in the 
central laboratory are sensitive (i.e. allow for the detection of cTn in 
∼20–50% of healthy individuals) or high-sensitivity (i.e. allow for the de­
tection of cTn in ∼50–95% of healthy individuals) assays. 
High-sensitivity assays are recommended over lower-sensitivity assays, 
as they provide higher diagnostic accuracy at an identical low 
cost.1,12,15,25–27,57,63
The majority of currently used point-of-care (POC) tests cannot be 
considered high-sensitivity assays.64 The advantage of POC tests is a 
shorter turnaround time. However, this is counterbalanced by lower 
sensitivity, lower diagnostic accuracy, and lower negative predictive va­
lue (NPV). A randomized trial in low-risk chest pain patients with sus­
pected NSTE-ACS and onset of symptoms ≥2 h before ambulance 
presentation reported that the use of a pre-hospital rule-out strategy 
(with a single POC conventional troponin T test) resulted in a signifi­
cant reduction of 30-day healthcare costs and a comparable major ad­
verse cardiovascular event (MACE) rate in comparison to an ED 
rule-out strategy (with evaluation as per standard local practice).65
Overall, automated assays have been more thoroughly evaluated 
than POC tests and are currently preferred.1,12–15,26,34,35,53,55–58
However, this is a rapidly developing field and it will be important to 
re-evaluate this preference when more extensively validated high- 
sensitivity POC tests are clinically available.66–68
3.3.3. Confounders of cardiac troponin concentration
In patients presenting with suspected NSTE-ACS, four clinical variables 
affect hs-cTn concentrations beyond the presence or absence of MI. 
These variables are: age (concentrations in healthy very young vs. 
‘healthy’ very old individuals differ by up to 300%); renal dysfunction 
(differences between otherwise healthy patients with very high vs. 
very low estimated glomerular filtration rate [eGFR] of up to 300%); 
time from chest pain onset (>300%); and, to a lesser extent, sex 
(≈40%).28,34,35,69–76 Despite the potential baseline differences in 
hs-cTn values based on these four variables, absolute changes in 
hs-cTn levels are still of diagnostic and prognostic value. Current data 
on the use of sex-specific hs-cTn values in the diagnosis of MI have 
been controversial and failed to demonstrate a clear clinical bene­
fit.74,75,77–80 Therefore, until automated tools (i.e. risk assessment cal­
culators) incorporating the effect of all four clinical variables (age, 
eGFR, time from chest pain onset, and sex) are available, the use of uni­
form cut-off concentrations should remain the standard of care for the 
early diagnosis of MI.28,30,31,34,35,73,81,82
3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms
Due to their higher sensitivity and diagnostic accuracy for the detection 
of MI at presentation, the time interval to the second cTn assessment 
can be shortened with the use of hs-cTn assays. This substantially re­
duces the delay to diagnosis, translating into shorter stays in the ED, 
lower costs, and less diagnostic uncertainty for patients.15,83–88 It is re­
commended to use the 0 h/1 h algorithm (best option) or the 0 h/2 h 
Blood sampling
It is recommended to measure cardiac troponins 
with high-sensitivity assays immediately after 
presentation and to obtain the results within 60 min 
of blood sampling.15,25–27
I
B
It is recommended to use an ESC algorithmic 
approach with serial hs-cTn measurements (0 h/1 h 
or 0 h/2 h) to rule in and rule out NSTEMI.28–44
I
B
Additional testing after 3 h is recommended if the 
first two hs-cTn measurements of the 0 h/1 h 
algorithm are inconclusive and no alternative 
diagnoses explaining the condition have been 
made.45,46
I
B
The use of established risk scores (e.g. GRACE risk 
score) for prognosis estimation should be 
considered.47–49
IIa
B
Triage for emergency reperfusion strategy
It is recommended that patients with suspected 
STEMI are immediately triaged for an emergency 
reperfusion strategy.50–52
I
A
© ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; ESC, European Society of 
Cardiology; FMC, first medical contact; GRACE, Global Registry of Acute Coronary 
Events; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTEMI, 
non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3739


<!-- PAGE 21 -->

### Page 21

algorithm (second-best option) (Figure 6). These algorithms have been 
derived and validated in large multicentre diagnostic studies using cen­
tral adjudication of the final diagnosis for all currently available hs-cTn 
assays.27–39,62,70,73,82,89–93 Optimal thresholds for rule-out were se­
lected to allow a sensitivity and NPV of at least 99%. Optimal thresholds 
for rule-in were selected to allow a positive predictive value (PPV) of at 
least 70%. These algorithms were developed from large derivation co­
horts and then validated in large independent validation cohorts. The 
previous ESC 0 h/3 h algorithm was considered as an alternative,40,56
but three recent large diagnostic studies suggested that the ESC 0 h/ 
3 h algorithm appears to balance efficacy and safety less well than 
more rapid protocols using lower rule-out concentrations, including 
the ESC 0 h/1 h algorithm.41–43 The very high safety and high efficacy 
of applying the ESC 0 h/1 h algorithm was recently confirmed in three 
real-life implementation studies, including one randomized controlled 
trial (RCT).44,94,95 Therefore, the ESC 0 h/3 h algorithm is an alternative 
for cases where the ESC 0 h/1 h or 0 h/2 h algorithms are not available. 
Of note, patients assigned to the ‘rule-out’ pathway using the ESC 0 h/ 
1 h or 0 h/2 h algorithms have a very low rate of clinical events through 
to 30 days.95,96
3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h 
algorithms
The ESC 0 h/1 h and 0 h/2 h algorithms are based on two underlying 
concepts: firstly, hs-cTn is a continuous variable and the probability 
of MI increases with increasing hs-cTn values.28,30,31,34,35,73,82
Secondly, early absolute changes in the levels within 1 h or 2 h can be 
used as surrogates for absolute changes over 3 h or 6 h and provide in­
cremental diagnostic value to the single cTn assessment at presenta­
tion.27,28,30,31,34,35,73,82,97 The cut-off concentrations within the 0 h/ 
1 h and 0 h/2 h algorithms are assay specific (Supplementary data 
online, Table S4).27,28,30,31,34,35,73,82
3.3.4.1.1. Rule-out. The NPV for MI in patients assigned to the 
‘rule-out’ pathway has exceeded 99% in several large validation 
cohorts.28–30,34,35,73 Assignment to the rule-out pathway does not al­
ways equal outpatient management. However, when used in conjunc­
tion with clinical and ECG findings, the 0 h/1 h and 0 h/2 h algorithms 
will enable the identification of appropriate candidates for early dis­
charge and outpatient management. Even after the ruling out of MI, 
elective non-invasive or invasive imaging may be appropriate according 
to clinical and risk assessment, and an alternative diagnosis to MI should 
be identified.
3.3.4.1.2. Rule-in. The PPV for MI in patients meeting the ‘rule-in’ 
pathway criteria in several studies has been ∼70–75%. Most of the 
‘rule-in’ pathway patients with diagnoses other than MI still have condi­
tions that require specialist cardiology input and either coronary angi­
ography or non-invasive imaging in order to establish an accurate 
final diagnosis.28,30,31,34,35,73,82 Therefore, the vast majority of patients 
triaged towards the ‘rule-in’ pathway by these algorithms will require 
hospital admission and invasive coronary angiography (ICA).
3.3.4.1.3. Observe. Patients who do not qualify for the ‘rule-out’ or 
‘rule-in’ pathways are assigned to the ‘observe’ pathway. These patients re­
present a heterogeneous group and have been shown to have a mortality 
rate that is comparable to rule-in patients.98 Therefore, an individual as­
sessment based on the particular risk profile of the patient (i.e. risk scores) 
is of paramount importance for patients in this group. Additionally, a third 
measurement of cTn at 3 h (± echocardiography) is recommended as the 
next step in order to guide further management.45,46
Most patients in the observe zone with a high degree of clinical 
suspicion of ACS (e.g. relevant increase in cTn from presentation 
to 3 h) are candidates for ICA. Conversely, most patients with a 
low to intermediate likelihood for ACS according to clinical judg­
ment are candidates for non-invasive imaging after transfer from 
the ED to the ward. Computed tomography (CT) angiography can 
be used to aid diagnosis and, in particular, to identify patients with 
non-obstructed coronary arteries who can be discharged if other 
relevant diseases have been excluded. CT angiography can also iden­
tify patients with obstructive coronary disease in whom revascular­
ization may be considered. In the appropriate clinical context, if 
alternative conditions have been identified that explain the cTn va­
lues (i.e. rapid ventricular rate response to atrial fibrillation [AF], 
marked anaemia, or a hypertensive emergency), further diagnostic 
testing (i.e. ICA) may not be required.
The same concepts apply to the 0 h/2 h algorithm. Cut-off levels for 
both the 0 h/1 h and 0 h/2 h algorithms are also assay specific, and these 
cut-off levels are shown in Supplementary data online, Table S4.99
The ESC 0 h/1 h and 0 h/2 h algorithms should always be integrated 
with a detailed clinical assessment and a 12-lead ECG. Repeat blood 
sampling is mandatory in cases where there is ongoing or recurrent 
chest pain. Recently, artificial intelligence models that include serial 
hs-cTn measurements in conjunction with individual risk profiles have 
been proposed to be useful to facilitate a personalized diagnostic evalu­
ation of patients with suspected MI. Similarly, risk-assessment models 
combining hs-cTn values at presentation and after early or late resam­
pling have been developed to predict MI events during the first 30 days. 
These models may facilitate alternative hs-cTn cut-offs based on the 
balance between NPV and PPV best suited to individual clinical sites.27
A diagnostic approach to the use of the ESC 0 h/1 h and 0 h/2 h algo­
rithms is shown in Figure 6.


<!-- PAGE 22 -->

### Page 22

Patient presents with a suspected NSTEMI and 
without an indication for immediate invasive angiography
Appropriate management can be determined based on the hs-cTn levels and clinical situation
Take hs-cTn at 0 h and 1 h/2 h
Very low initial hs-cTna
Low initial hs-cTn and no increase in 1 h/2 h hs-cTn
Patients who do not meet the criteria for either of the other two pathways 
Observe pathway
Rule-out pathway
Rule-in pathway
High initial hs-cTn
OR
OR
Increase in 1 h/2 h hs-cTn
Figure 6 The 0 h/1 h or 0 h/2 h rule-out and rule-in algorithms using high-sensitivity cardiac troponin assays in patients presenting to the emergency de­
partment with suspected NSTEMI and without an indication for immediate invasive angiography. hs-cTn, high-sensitivity cardiac troponin; NSTEMI, 
non-ST-elevation myocardial infarction. Patients are classified into one of three pathways as per the results of their hs-cTn values at 0 h (time of initial blood 
test) and 1 h or 2 h later. Patients with a very low initial hs-cTn value or patients with a low initial value and no 1 h/2 h change in hs-cTn are assigned to the 
‘rule-out’ pathway. Patients with a high initial hs-cTn value or a 1 h/2 h change in hs-cTn are assigned to the ‘rule-in’ pathway. Patients who do not meet the 
criteria for the rule-out or rule-in strategies are assigned to the ‘observe’ pathway, and these patients should have hs-cTn levels checked at 3 h ± echocar­
diography in order to decide on further management. Cut-offs are assay specific (see Supplementary material online, Table S4) and derived to meet 
pre-defined criteria for sensitivity and specificity for NSTEMI. Potential management and testing options for each of the three strategies are provided in 
the relevant sections of the main text.12–15,26,27,53,55–58,100,101 aOnly applicable if the chest pain onset was >3 h prior to the 0 h hs-cTn measurement.
ESC Guidelines                                                                                                                                                                                          3741


<!-- PAGE 23 -->

### Page 23

3.3.4.2. Practical guidance on how to implement the European 
Society of Cardiology 0 h/1 h algorithm
In order to maximize the safety and feasibility of implementing the 0 h/ 
1 h algorithm, blood samples for hs-cTn at 0 h and 1 h should be ob­
tained irrespective of other clinical details and pending results (see ca­
veats of using rapid algorithms in Supplementary data online, Section 3.3. 
2.2). This may result in unnecessary cTn measurements in the ∼10– 
15% of patients with very low 0 h concentrations and chest pain onset 
>3 h, but substantially facilitates the process and thereby further in­
creases patient safety. Similarly, the 0 h blood sample should be ob­
tained immediately after admission to the ED.
3.3.5. Other biomarkers
The use of biomarkers other than cTn for the diagnosis of ACS is not 
recommended (unless cTn is not available). Among the multitude of 
additional biomarkers evaluated for the diagnosis of NSTEMI, only cre­
atine kinase myocardial band isoenzyme, myosin-binding protein C, and 
copeptin may have clinical relevance when used in combination with 
(standard) cTn T/I, although in most clinical situations their incremental 
value above and beyond cTn is limited.45,46,83,102–114
3.4. Diagnostic tools | Non-invasive imaging
3.4.1. Echocardiography
In emergency rooms and chest pain units, transthoracic echocardiog­
raphy (TTE) performed or interpreted by trained healthcare profes­
sionals should be routinely available. In cases of suspected ACS with 
diagnostic uncertainty, TTE can be useful to identify signs suggestive of 
ongoing ischaemia or prior MI. However, this should not result in rele­
vant delays in transfer to the cardiac catheterization laboratory if there 
is suspicion of an acute coronary artery occlusion. TTE can also be useful 
to suggest alternative aetiologies associated with chest pain (i.e. acute 
aortic disease, RV signs in pulmonary embolism [PE]). All patients pre­
senting with CS or haemodynamic instability should undergo emergency 
TTE to try to identify the underlying cause—in particular, to assess LV 
and RV function and look for evidence of mechanical complications.
3.4.2. Computed tomography
Upon clinical presentation, CT is often the diagnostic tool of choice for 
ruling out alternative potentially life-threatening differential diagnoses 
of ACS, like PE or aortic dissection (this should be an ECG-gated con­
trast CT angiogram with full coverage of the thoracic aorta and the 
proximal head and neck vessels). Generally, CT does not have a role 
in patients presenting with suspicion of ongoing acute coronary occlu­
sion, for whom emergency ICA is the priority.
Coronary CT angiography (CCTA) has been investigated in many trials 
for the assessment of patients presenting to the ED with suspected 
NSTE-ACS. However, trials investigating CCTA in the era of hs-cTn as­
says may be of greater relevance for contemporary practice. The 
BEACON (Better Evaluation of Acute Chest Pain with Coronary 
Computed Tomography Angiography) study showed no reduction of in- 
hospital duration of stay or hospital admission in the CCTA arm com­
pared with patients investigated with hs-cTn, with similar results to those 
observed in the ROMICAT II (Rule Out Myocardial Ischemia/Infarction by 
Computer Assisted Tomography) and RAPID-CTCA (Rapid Assessment 
of Potential Ischaemic Heart Disease with CTCA) trials.115–117 In the lat­
ter study, a default approach using early non-invasive CCTA in patients 
with suspected NSTE-ACS did not improve clinical outcomes at 1 year 
and was associated with a modest increase in the duration and cost of 
the hospital stay. A default approach using CCTA as the first-line imaging 
investigation in patients with suspected NSTE-ACS is therefore not 
recommended. However, CCTA may provide added value in certain clin­
ical settings (i.e. for patients in the observe zone in whom cTn and ECG 
results remain inconclusive). A normal CCTA (ruling out both obstructive 
and non-obstructive plaque) has a high NPV to exclude ACS and is asso­
ciated with excellent clinical outcomes.
The systematic use of CCTA in rule-out patients after hospital dis­
charge may identify the presence of obstructive or non-obstructive pla­
que and guide preventative medical therapies.118 CCTA can also be 
used to risk stratify selected low-risk NSTEMI patients. Such patients, 
who are found to have normal coronary arteries, non-obstructive cor­
onary disease, or distal obstructive disease, may then not require 
ICA.119–121 Of note, the utility of CCTA may be limited in patients 
with tachycardia, established coronary artery disease (CAD), previous 
stents, or extensive coronary calcification.
3.4.3. Cardiac magnetic resonance imaging with or 
without stress testing
Cardiac magnetic resonance (CMR) imaging delineates cardiac struc­
ture and function, and also has the ability to provide assessments of 
myocardial perfusion and the pattern of myocardial injury. CMR is 
the imaging test of choice when poor echocardiographic windows pre­
clude diagnostic echocardiographic evaluation. CMR allows direct visu­
alization of infarcted regions, providing information on scarring and 
viability that can be differentiated from other forms of myocardial injury 
(e.g. myocarditis). CMR is therefore of particular clinical value in estab­
lishing a diagnosis of AMI where there is diagnostic uncertainty. CMR 
can also be useful in identifying the culprit vascular territory and in con­
firming a diagnosis of myocarditis or takotsubo cardiomyopathy, 
amongst other differentials. CMR is of particular value in establishing 
a diagnosis in patients presenting with a working diagnosis of myocardial 
infarction with non-obstructive coronary arteries (MINOCA) following 
invasive angiography and is the gold standard for the assessment of LV 
thrombus.
Recommendation Table 2 — Recommendations for 
non-invasive imaging in the initial assessment of patients 
with suspected acute coronary syndrome
Recommendations
Classa
Levelb
Emergency TTE is recommended in patients with 
suspected ACS presenting with cardiogenic shock or 
suspected mechanical complications.
I
C
In patients with suspected ACS, non-elevated (or 
uncertain) hs-cTn levels, no ECG changes and no 
recurrence of pain, incorporating CCTA or a 
non-invasive stress imaging test as part of the initial 
workup should be considered.116,122–127
IIa
A
Emergency TTE should be considered at triage in 
cases of diagnostic uncertainty but this should not 
result in delays in transfer to the cardiac 
catheterization laboratory if there is suspicion of an 
acute coronary artery occlusion.
IIa
C
Routine, early CCTA in patients with suspected ACS 
is not recommended.117
III
B
© ESC 2023
ACS, acute coronary syndrome; CCTA, coronary computed tomography angiography; 
ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 24 -->

### Page 24

Cardiac magnetic resonance can also assess myocardial perfusion 
with pharmacological stress. This can be used as an alternative to 
CCTA in the assessment of patients in the observe zone following 
ECG and hs-cTn assessments, particularly in those with advanced, es­
tablished CAD, in whom assessments of myocardial perfusion and via­
bility may provide more useful information than CCTA. Some 
additional information on CMR, single-photon emission computerized 
tomography (SPECT) perfusion imaging and stress echocardiography 
is provided in the Supplementary data online.
Depending on local expertise and availability, other forms of stress 
imaging (e.g. SPECT, nuclear, stress echo) can be used to assess patients 
in the observe zone.
3.5. Differential diagnosis for acute chest 
pain
Several cardiac and non-cardiac conditions that may mimic ACS should 
be considered in the differential diagnosis of acute chest pain as part of 
the clinical assessment. More information about the differential diagno­
sis of acute chest pain is provided in the sections on MINOCA and Type 
2 MI and in the Supplementary data online, Table S5.
4. Initial measures for patients 
presenting with suspected acute 
coronary syndrome | Initial 
treatment
4.1. Pre-hospital logistics of care
Individuals experiencing acute chest pain in the community represent 
an undifferentiated population, often presenting ad hoc to first med­
ical responders in the pre-hospital setting. These patients should 
undergo immediate risk assessment and triage following local proto­
cols established within the emergency medical service (EMS) 
(Figures 7 and 8).
If the first responding medical professional suspects ACS, a 12-lead 
ECG should be acquired and analysed as soon as possible. It is recom­
mended that all medical and paramedical personnel caring for ACS pa­
tients within the EMS setting have access to defibrillation equipment 
and are trained in basic cardiac life support. Patients with suspected 
ACS are initially categorized on the basis of the 12-lead ECG and 
triaged into two initial treatment pathways: (i) one for patients with 
an ECG consistent with STEMI (persistent ST-segment elevation or 
equivalent ECG patterns) (Figure 7); and (ii) one for patients without 
ST-segment elevation or equivalent ECG patterns (suspected 
NSTE-ACS) (Figure 8). The initial ECG-guided risk stratification should 
also trigger treatment decisions in the pre-hospital setting, including the 
choice of target hospital, and serve to determine the sequence of initial 
investigations and interventions (including pharmacological), in particu­
lar, the timing of ICA.
An initial diagnosis of suspected STEMI portends a higher risk of im­
mediate, life-threatening complications (e.g. ventricular fibrillation 
[VF]). Accordingly, there is an indication for initiating an emergency re­
perfusion strategy and direct transfer to a centre with 24/7 PCI capabil­
ities. Patients who present with an ECG without ST-segment elevation 
(or equivalent ECG patterns) but have ongoing ischaemic symptoms 
should undergo pre-hospital triage in accordance with protocols for pa­
tients in the STEMI pathway, since they also face immediate risks, in­
cluding ventricular arrhythmias.
4.1.1. Time to treatment
Time to treatment is vital for the care of patients triaged to the STEMI 
pathway. Components of the total ischaemic time, contributors to delays 
in initial management, and the selection of reperfusion strategy for STEMI 
patients are shown in Figure 7. Treatment times reflect the efficiency and 
quality of care of a system taking care of patients with suspected STEMI. 
The multidisciplinary STEMI treatment pathway should be subject to 
continuous clinical audit in order to assess the treatment times for indi­
vidual patients and identify opportunities for healthcare improvement 
through quality indicators (QIs). If projected QIs are not met, interven­
tions are needed to improve the performance of the system.
Recognition of ischaemic symptoms by individuals in the community 
has pivotal importance in activation of the out-of-hospital pathway, and 
this is especially relevant to first responders without healthcare training. 
The recommended action should be to contact the EMS rather than to 
self-present to an ED or primary care clinician.
The time from symptom onset to ‘first call for help’ is associated with 
socioeconomic factors and sex.128 In order to avoid delays through fail­
ure to recognize and act on symptoms of a ‘heart attack’, community 
education initiatives should target less well-served groups (i.e. those 
from deprived communities, ethnic minority groups) and use targeted 
public health messaging (i.e. avoiding stereotyped messaging that under­
pins a negative bias based on sex, ethnicity, or social background, and 
using language and images that will resonate with those groups). 
System delays are representative of the quality of care and it is recom­
mended to measure these as QIs.
4.1.2. Healthcare systems and system delays
For patients with suspected STEMI, the system delay (the time from 
when the patient contacts the healthcare system to reperfusion) is 
amenable to improvement by organizational measures, whereas patient 
delay is multifactorial. System delay is a predictor of mortality in STEMI 
patients treated with primary PCI (PPCI).129–131 When a working diag­
nosis of STEMI is made in the pre-hospital setting (EMS), immediate ac­
tivation of the catheterization laboratory team reduces treatment 
delays and mortality.132–136
When a STEMI working diagnosis is made by the EMS in the pre- 
hospital setting and the patient is triaged for emergency invasive manage­
ment, they should bypass the ED and go straight to the catheterization 
laboratory. Bypassing the ED is associated with a significant saving in the 
time from FMC to wire crossing and may be associated with improved 
survival.137–139 For patients presenting to a non-PCI centre with a sus­
pected STEMI, the ‘door-in to door-out time’—defined as the duration 
between arrival of the patient at the hospital to discharge of the patient 
in an ambulance ‘en route’ to the PCI centre—is also an important clinical 
performance measure, and a door-in to door-out time of ≤30 min is re­
commended to expedite reperfusion therapy.140
4.1.3. Emergency medical services
At a national level, an EMS with an easily recalled and well-publicised un­
ique medical dispatching number (112 for most European Union coun­
tries) is important to speed-up system activation. Parallel circuits 
for the referral and transport of patients with suspected STEMI that by­
pass the EMS should be avoided. The ambulance system plays a critical 
role in the early management of patients with suspected STEMI, including 
immediately establishing the initial diagnosis, triage, and treatment.129,141
Ambulances in the EMS must be equipped with ECG recorders, de­
fibrillators, telemetry devices, and at least one person trained in ad­
vanced life support. The quality of the care provided depends on the 
ESC Guidelines                                                                                                                                                                                          3743


<!-- PAGE 25 -->

### Page 25

training of the staff involved. Ambulance personnel must be trained to 
recognize ischaemic symptoms, administer oxygen when appropriate, 
secure intravenous (i.v.) access, effectively relieve pain, administer fi­
brinolysis when indicated, and provide basic life support.142
Ambulance staff should record an ECG as soon as possible for diagnos­
tic purposes and either interpret the ECG or transmit it so that it can be 
reviewed by experienced staff to establish or refute a working diagnosis 
of STEMI. Regular and structured training of ambulance staff is manda­
tory for a high-quality pre-hospital service.
4.1.4. General practitioners
In some countries, primary care clinicians (general practitioners) play an 
important role in the early care of patients with suspected ACS and 
may provide the FMC. Education and training of general practitioners 
in emergency, pre-hospital care is essential for the delivery of optimal 
pre-hospital care in this setting. The responsibilities of the primary 
care clinicians may include diagnosis, activation of the EMS, risk stratifi­
cation, and initiation of pre-hospital treatment. However, in most set­
tings, consultation with a general practitioner instead of a direct call to 
the EMS will increase the pre-hospital delay. Therefore, the public 
should be educated to call the EMS directly rather than a primary 
care physician for symptoms suggestive of ACS.
4.1.5. Organization of ST-elevation myocardial 
infarction treatment in networks
It is recommended that a regional reperfusion strategy is established to 
maximize the efficiency of care for patients with a working diagnosis of 
STEMI.143 The optimal treatment of patients with a working diagnosis 
of STEMI should be based on the implementation of networks between 
hospitals with various levels of clinical service provision (the ‘hub and 
spoke’ model), linked by a prioritized and efficient ambulance service. 
A PCI centre is a multidisciplinary acute care centre that provides emer­
gency invasive management 24/7 for patients presenting with suspected 
STEMI. This centre should also provide intensive care facilities, and 
more advanced centres should offer cardio-thoracic services, advanced 
haemodynamic support, and surgery.
The goal of STEMI networks is to provide optimal care while minimizing 
delays, thereby improving clinical outcomes. Cardiologists should actively 
collaborate with all stakeholders, particularly emergency physicians, in estab­
lishing such networks. The main features of such a network are detailed in 
Supplementary data online, Table S6. It is recommended that the EMS should 
transport patients with a working diagnosis of STEMI to hospitals with a 24/7 
service for PCI, bypassing non-PCI-capable hospitals.144Further information 
on this topic is provided in the Supplementary data online.
Geographic areas where the expected transfer time to the primary 
PCI centre makes it impossible to routinely achieve the maximal allow­
able delays indicated in the recommendations should develop protocols 
for rapid fibrinolysis at the place of STEMI diagnosis, with the aim of 
treatment within 10 min of FMC, followed by immediate transfer to 
a centre with 24/7 service for PCI. Such networks increase the propor­
tion of patients receiving reperfusion with the shortest possible treat­
ment delay.145–147 The quality of care, time delays, and patient 
outcomes should be measured and reported to the healthcare profes­
sionals contributing to the EMS.
4.2. Emergency care
4.2.1. Initial diagnosis and monitoring
Management of ACS starts from the point of FMC, when a working 
diagnosis of ACS is established. The working diagnosis of ACS is usually 
based on symptoms consistent with myocardial ischaemia and the signs 
on a 12-lead ECG (see Section 3.2). It is recommended to initiate ECG 
monitoring as soon as possible in all patients with suspected ACS in or­
der to detect life-threatening arrhythmias and to allow prompt defibril­
lation if indicated.
4.2.2. Acute pharmacotherapy
4.2.2.1. Oxygen
Oxygen supplementation is recommended in ACS patients with hypox­
aemia (oxygen saturations <90%). Oxygen supplementation in patients 
who are not hypoxic (oxygen saturations >90%) is not associated with 
clinical benefits and is therefore not recommended.148,149
4.2.2.2. Nitrates
Sublingual nitrate may be helpful to relieve ischaemic symptoms. 
However, a reduction in chest pain after nitroglycerine administra­
tion can be misleading and is not recommended as a diagnostic man­
oeuvre.150 In patients with an ECG compatible with ongoing STEMI 
and symptom relief after nitroglycerine administration, it is recom­
mended to obtain another 12-lead ECG. Complete normalization 
of ST-segment elevation, along with relief of symptoms, after nitro­
glycerine administration is suggestive of coronary spasm, with or 
without associated MI. Nitrates should not be given to patients 
with hypotension, marked bradycardia or tachycardia, RV infarction, 
known severe aortic stenosis, or phosphodiesterase 5 inhibitor use 
within the previous 24–48 h.
4.2.2.3. Pain relief
Intravenous opioids (e.g. morphine 5–10 mg) should be considered for 
the relief of severe chest pain. Other forms of pain relief (e.g. nitrous 
oxide/oxygen plus i.v. acetaminophen/paracetamol) have been re­
ported to be inferior to morphine.151 However, morphine may en­
hance nausea and vomiting and slow the gastrointestinal absorption 
of oral medicines, which may delay the onset of action of orally admi­
nistered antiplatelet therapy.152,153 Evidence from small-scale trials sug­
gests that i.v. morphine may also reduce myocardial and microvascular 
damage when given to patients with ongoing acute coronary artery oc­
clusion, though co-administration with metoclopramide appears to 
negate this effect. Conversely, morphine has also been reported to re­
duce antiplatelet activity after administration of ticagrelor, though this 
effect was rescued by metoclopramide administration.154,155 The posi­
tive effects of morphine on myocardial damage may potentially be re­
lated to reduced oxygen consumption as a result of decreased 
preload and negative inotropy and chronotropy.
Platelet inhibition induced by oral P2Y12 receptor antagonists may 
be delayed in patients with ongoing MI. Morphine may also further re­
duce absorption, delay the onset of action, and decrease the antipla­
telet effect of oral P2Y12 receptor inhibitors in MI patients, although 
this effect may vary between the different P2Y12 inhibitors.153,156– 
158 Further research is ongoing in this area, but at present it should 
be noted that currently available clinical data have not demonstrated 
any increase in the risk of adverse clinical outcomes as a result of any 
interaction between morphine and antiplatelet agents in the setting of 
ACS.159–161
4.2.2.4. Intravenous beta-blockers
Few RCTs testing early i.v. beta-blockers have been performed in 
the era of invasive management for patients with a working diagnosis 
of STEMI. Not all beta-blockers appear to exert the same


<!-- PAGE 26 -->

### Page 26

cardio-protective effect in the context of ongoing acute coronary oc­
clusion, with metoprolol demonstrating the greatest protective effect 
in experimental studies.162 Intravenous metoprolol is also the most 
widely tested beta-blocker in trials enrolling patients undergoing 
PPCI.163,164 While the long-term clinical benefits associated with early 
i.v. metoprolol administration are not clear, it is safe when used in pa­
tients without signs of acute HF and has been consistently associated 
with a reduction in the incidence of VF and microvascular obstruction 
(MVO).163–171 Based on these data, i.v. beta-blockers (preferably meto­
prolol) should be considered at the time of presentation in patients 
with a working diagnosis of STEMI undergoing PPCI with no signs of 
acute HF, a systolic blood pressure (SBP) >120 mmHg, and without 
other contraindications.163–166,169 Administration of i.v. beta-blockers 
in patients with suspected NSTE-ACS has not been tested.
5. Acute-phase management of 
patients with acute coronary 
syndrome
5.1. Selection of invasive strategy and 
reperfusion therapy
The definitions of the terms related to invasive strategy and reperfusion 
therapy are presented in Table 3.
Depending on the initial assessment of the ECG, the clinical context 
and haemodynamic stability, patients with suspected ACS should be 
classified as either: 
(i) Patients with a working diagnosis of STEMI. These patients should 
be triaged for immediate reperfusion therapy (i.e. a PPCI strategy 
or fibrinolysis if PPCI is not possible within 120 min of diagnosis) 
(Figure 7).
Or
(ii) Patients with a working diagnosis of NSTE-ACS. For these patients: 
• An inpatient invasive strategy is recommended.
• An immediate invasive strategy is recommended when any very 
high-risk feature is present (Figure 8).
• An early (i.e. within 24 h) invasive strategy should be considered 
when any high-risk features are present (Figure 8).
5.2. Acute coronary syndrome managed 
with invasive strategy
Invasive management strategies are time sensitive. It is recommended that 
patients triaged to an immediate invasive strategy (those with high suspi­
cion of ongoing acute coronary artery occlusion [i.e. persistent 
ST-segment elevation or equivalents] or NSTE-ACS with any very high- 
risk characteristics) receive emergency angiography as soon as possible. 
High-risk NSTE-ACS patients (e.g. ruled in as NSTEMI as per the 0 h/1 h 
or 0 h/2 h ESC algorithms, with dynamic ST-segment or T wave changes, 
with transient ST-segment elevation, or with a Global Registry of Acute 
Coronary Events [GRACE] risk score >140) should be considered for 
an early invasive strategy (i.e. undergoing angiography within 24 h).
5.2.1. Primary percutaneous coronary intervention 
strategy for ST-elevation myocardial infarction
In patients with a working diagnosis of STEMI, a PPCI strategy (i.e. im­
mediate angiography and PCI as needed) is the preferred reperfusion 
strategy, provided it can be performed in a timely manner (i.e. within 
Recommendation Table 3 — Recommendations for the 
initial management of patients with acute coronary 
syndrome
Recommendations
Classa
Levelb
Hypoxia
Oxygen is recommended in patients with 
hypoxaemia (SaO2 <90%).
I
C
Routine oxygen is not recommended in patients 
without hypoxaemia (SaO2 >90%).148,172
III
A
Symptoms
Intravenous opioids should be considered to relieve 
pain.
IIa
C
A mild tranquilizer should be considered in very 
anxious patients.
IIa
C
Intravenous beta-blockers
Intravenous beta-blockers (preferably metoprolol) 
should be considered at the time of presentation in 
patients undergoing PPCI with no signs of acute heart 
failure, an SBP >120 mmHg, and no other 
contraindications.163–167,169
IIa
A
Pre-hospital logistics of care
It is recommended that the pre-hospital 
management of patients with a working diagnosis of 
STEMI is based on regional networks designed to 
deliver reperfusion therapy expeditiously and 
effectively, with efforts made to make PPCI available 
to as many patients as possible.145
I
B
It is recommended that PPCI-capable centres deliver 
a 24/7 service and are able to perform PPCI without 
delay.173,174
I
B
It is recommended that patients transferred for PPCI 
bypass the emergency department and CCU/ICU 
and are transferred directly to the catheterization 
laboratory.137,175–178
I
B
It is recommended that EMS transfer patients with 
suspected STEMI to a PCI-capable centre, bypassing 
non-PCI centres.
I
C
Continued
It is recommended that ambulance teams are trained 
and equipped to identify ECG patterns suggestive of 
acute coronary occlusion and to administer initial 
therapy, including defibrillation, and fibrinolysis when 
applicable.142
I
C
It is recommended that all hospitals and EMS 
participating in the care of patients with suspected 
STEMI record and audit delay times and work 
together to achieve and maintain quality targets.
I
C
© ESC 2023
CCU, cardiac care unit; ECG, electrocardiogram; EMS, emergency medical services; ICU, 
intensive care unit; i.v., intravenous; PPCI, primary percutaneous coronary intervention; 
SaO2, saturation of oxygen; SBP, systolic blood pressure; STEMI, ST-elevation myocardial 
infarction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3745


<!-- PAGE 27 -->

### Page 27

120 min of the ECG-based diagnosis, Figure 7). RCTs have shown that if 
the delay to treatment is similar, PPCI is superior to fibrinolysis in reducing 
mortality, non-fatal reinfarction, and stroke.52,179 However, in some cir­
cumstances, PPCI is not an immediate option and fibrinolysis should be 
initiated expeditiously as part of a pharmaco-invasive strategy, provided 
the patient has presented within 12 h of symptom onset (see Section 5.3).
There is a lack of contemporaneous data to inform the treatment delay 
limit at which the advantage of PCI over fibrinolysis is lost. For simplicity, an 
absolute time of 120 min from STEMI diagnosis to PCI-mediated reperfu­
sion (i.e. wire crossing of the infarct-related artery [IRA]) rather than a rela­
tive PCI-related delay over fibrinolysis has been chosen. Given the 
recommended time interval of 10 min from STEMI diagnosis to administra­
tion of a bolus of fibrinolytics (see below), the 120 min absolute time delay 
would correspond to a relative PCI-related delay in the range of 110– 
120 min. This is within the range of the times identified as the limit of delay 
below which PCI should be chosen in older studies and registries.176,180–184
For patients who undergo fibrinolysis, rescue PCI is indicated if fibrin­
olysis fails (i.e. ST-segment resolution <50% within 60–90 min of fi­
brinolytic administration) or in the presence of haemodynamic or 
electrical instability, worsening ischaemia, or persistent chest 
pain.184,185 Patients with successful fibrinolysis should undergo early 
invasive angiography (i.e. within 2–24 h from the time of the lytic bolus 
injection) (see Section 5.3).186
Patients with a working diagnosis of STEMI who present to a 
non-PCI centre should be immediately transferred to a PCI-capable 
centre (Figure 7) for a timely PPCI strategy. If PPCI is not feasible within 
120 min, patients should undergo immediate fibrinolysis followed by 
transfer to a PCI centre without waiting for signs of reperfusion. For 
patients presenting after 12 h from symptom onset, a PPCI strategy 
is preferred over fibrinolysis in all cases.
Emergency coronary artery bypass grafting (CABG) surgery should 
be considered for patients with a patent IRA but with unsuitable anat­
omy for PCI, and either a large myocardial area at jeopardy or with CS. 
In patients with MI-related mechanical complications who require cor­
onary revascularization, CABG is recommended at the time of surgical 
repair. In STEMI patients with failed PCI or with an acute coronary oc­
clusion not amenable to PCI, emergency CABG is infrequently per­
formed because the benefits of surgical revascularization in this 
setting are less certain.185,187,188 Because there will be a delay to reper­
fusion with CABG in this situation, the probability of myocardial salvage 
to a degree sufficient to impact on prognosis is considered low. In add­
ition, the surgical risks of CABG in this setting may be elevated.
Onset of symptoms
FMC
location
Mode of 
FMC
Patient self presents to hospital
PCI centre
Non-PCI centre
Ambulance
Patient calls 
EMS
or or
Patient with symptoms of ACS and
ECG consistent with STEMI
Total 
ischaemic 
time
Patient self 
presents
Patient calls
 EMS
PPCI
strategy
Reperfusion
PPCI
strategy
Fibrinolysis strategy
Immediate transfer 
to PCI centre for primary PCI
Immediate transfer 
to PCI centre
 after fibrinolysis
Patient delay
System delay
EMS delay
Total ischaemic time
YES
NO
Aim: 
<60 min to wire crossing 
Determine 
therapeutic 
strategy
Aim:
<90 min to wire crossing
Aim:
<10 min to lytic bolus
PCI possible in <120 min?
Total ischaemic time and sources of delay to reperfusion
Figure 7 Modes of presentation and pathways to invasive management and myocardial revascularization in patients presenting with STEMI. ACS, acute 
coronary syndrome; ECG, electrocardiogram; EMS, emergency medical services; FMC, first medical contact; PCI, percutaneous coronary intervention; 
PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.


<!-- PAGE 28 -->

### Page 28

5.2.1.1. Invasive strategy in ST-elevation myocardial infarction late 
presenters
While routine immediate angiography and PCI (if indicated) are clearly 
associated with clinical benefit in patients presenting within 12 h of 
symptom onset, the value of a routine PPCI strategy in STEMI patients 
presenting later than 12 h after symptom onset is less well established.
A small RCT in 347 STEMI patients presenting 12–48 h after symp­
tom onset and without persistent symptoms reported that a routine 
PPCI strategy improved myocardial salvage and long-term survival com­
pared with conservative treatment.189,190 This observation is supported 
by a recent analysis of data from three nationwide observational studies 
from the FAST-MI (French Registry of Acute ST-elevation and 
non-ST-elevation Myocardial Infarction) programme, which showed a 
significant lower rate of all-cause death at 1 month (2.1% vs. 7.2%) 
and after a median follow-up of 58 months (30.4% vs. 78.7%) with an in­
vasive strategy in comparison to conservative treatment.191 However, in 
stable patients with persistent occlusion of the IRA 3–28 days after MI, 
the large (n = 2166) Occluded Artery Trial (OAT) reported no clinical 
benefit from routine coronary intervention with medical management in 
comparison to medical management alone.192,193 A meta-analysis of 
trials testing whether late recanalization of an occluded IRA is beneficial 
also showed no benefit of reperfusion.194 Therefore, routine PCI of an 
occluded IRA in STEMI patients presenting >48 h after onset of symp­
toms and without persistent symptoms is not indicated.192,193 These pa­
tients should be managed in the same way as patients with chronic total 
occlusion according to the ESC Guidelines for the diagnosis and manage­
ment of chronic coronary syndromes (CCS).195
5.2.2. Immediate invasive strategy for non-ST 
elevation acute coronary syndrome
An immediate invasive strategy refers to emergency (i.e. as soon as pos­
sible) angiography and PCI if indicated. This is recommended for pa­
tients with a working diagnosis of NSTE-ACS and any of the 
following very high-risk criteria: 
• Haemodynamic instability or CS.
• Recurrent or ongoing chest pain refractory to medical treatment.
• Acute HF presumed secondary to ongoing myocardial ischaemia.
• Life-threatening arrhythmias or cardiac arrest after presentation.
• Mechanical complications.
• Recurrent dynamic ECG changes suggestive of ischaemia (particularly 
with intermittent ST-segment elevation).
5.2.3. Routine vs. selective invasive strategy
A routine invasive strategy with inpatient coronary angiography is re­
commended for patients with a confirmed diagnosis of NSTEMI or a 
working diagnosis of NSTE-ACS and a high index of suspicion for 
UA. In patients with a working diagnosis of NSTE-ACS, multiple 
RCTs comparing routine vs. selective invasive strategies have been 
conducted and their results have been pooled in several meta- 
analyses.196–200 The available evidence indicates that a routine invasive 
strategy does not reduce all-cause mortality risk in the overall popula­
tion of NSTE-ACS patients, but reduces the risk of composite ischae­
mic endpoints, particularly in high-risk patients. A routine invasive 
strategy can increase the risk of peri-procedural complications and 
bleeding. However, most of the available evidence is based on old 
RCTs that were conducted before the implementation of several im­
portant developments in PCI, including radial access, modern 
drug-eluting stents (DES), complete functional revascularization for 
multivessel disease (MVD), improved co-adjuvant pharmacological 
therapies, and contemporary biomarker assays.
5.2.3.1. Early vs. delayed invasive strategy for non-ST elevation acute 
coronary syndrome
An early invasive strategy refers to routine invasive angiography (and 
PCI if needed) within 24 h of presentation. This should be considered 
in patients with a working diagnosis of NSTE-ACS and any of the fol­
lowing high-risk criteria: 
• A confirmed diagnosis of NSTEMI based on current recommended 
ESC hs-cTn algorithms.
• Dynamic ST-segment or T wave changes.
• Transient ST-segment elevation.
• A GRACE risk score >140.
Several meta-analyses have pooled data from multiple RCTs assessing 
different timing intervals of invasive angiography among NSTE-ACS pa­
tients. None of these studies observed superiority of early invasive strat­
egies compared with routine invasive strategies for death or non-fatal MI, 
although early invasive strategies were associated with a lower risk 
of recurrent/refractory ischaemia and a shorter duration of hospital 
stay.201–203 A collaborative meta-analysis comparing an early vs. a delayed 
invasive strategy using a modified individual patient data approach ob­
served no difference in mortality overall but a survival benefit in high-risk 
patients, including those with a GRACE risk score >140 and those with 
positive troponin, although tests for interaction were inconclusive.202
The largest meta-analysis to date (17 RCTs >10 000 patients) reported 
that, in all-comers with NSTE-ACS, early ICA only significantly reduced 
the risk of recurrent ischaemia and duration of stay, with no significant re­
ductions in all-cause mortality, MI, admission for HF, or repeat revascular­
ization.203 The main limitation of the interpretation of meta-analyses of 
these RCTs is the variability of the time to invasive angiography in the in­
dividual trials: while invasive angiography was virtually always performed 
within 24 h of randomization in the early invasive strategy groups, the 
time from randomization to angiography was heterogeneous in the de­
layed invasive groups. In many trials, delayed angiography was performed 
within 24 h of randomization (albeit later than in the early angiography 
arm of the respective trial). Additionally, the diagnosis of NSTEMI was 
not based on the current recommended ESC hs-cTn algorithms. 
Moreover, studies assessing the value of a GRACE risk score >140 to 
guide the timing of ICA and revascularization in the era of hs-cTn for 
the diagnosis of NSTEMI are lacking. Further detail on the interaction be­
tween treatment effect according to GRACE score and its components in 
individual trials is provided in the Supplementary data online. Data from 
observational studies is concordant with trial data, without a strong signal 
of benefit with early versus delayed coronary angiography.204
A selective invasive approach after appropriate ischaemia testing or 
detection of obstructive CAD by CCTA is recommended in patients 
without very high- or high-risk features and a low index of suspicion 
for NSTE-ACS. These patients should be managed as per the ESC 
Guidelines for the management of CCS.195 A selective invasive ap­
proach is also appropriate for patients with NSTEMI or UA who are 
not deemed good candidates for coronary angiography.
5.2.4. Summary of invasive strategies for patients 
with non-ST elevation acute coronary syndrome
In summary, very high-risk NSTE-ACS patients are recommended to 
undergo an immediate invasive strategy with emergency angiography 
ESC Guidelines                                                                                                                                                                                          3747


<!-- PAGE 29 -->

### Page 29

and PCI if required. High-risk NSTE-ACS patients are recommended 
to undergo an inpatient invasive strategy and should be considered 
for an early invasive strategy (i.e. within 24 h). For patients who do 
not meet any of the very high-risk or high-risk criteria (generally 
patients with clinical suspicion for NSTE-ACS and non-elevated tro­
ponins or patients with elevated troponins not meeting the criteria 
for MI), the strategy can be tailored based on the degree of clinical 
suspicion. For patients with a high index of suspicion for UA, an 
FMC
FMC
location
PCI centre
Non-PCI centre
Ambulance
Immediate transfer
Early/inpatient transfer or
Very high riska
Very high risk
Risk stratify and determine 
therapeutic 
strategy 
Inpatient transfer
In patients without very-high or high-risk features and a low index of suspicion for unstable angina
(if required)
High riska
High risk
Non-high risk
Selective invasive strategy 
(Class I)
Inpatient invasive
 strategy
(Class I)
Inpatient invasive
 strategy
(Class I)
Early (<24 h)
invasive strategy
(Class IIa)
Immediate invasive strategy
(Class I)
Non-high risk
Patient with symptoms of ACS and ECG consistent with NSTE-ACS
Haemodynamic instability or cardiogenic shock
Recurrent or ongoing chest pain refractory to medical treatment
Acute heart failure presumed secondary to ongoing myocardial ischaemia
Life-threatening arrhythmias or cardiac arrest after presentation
Mechanical complications
Recurrent dynamic ECG changes suggestive of ischaemia
Confirmed diagnosis of NSTEMI based on ESC algorithms
GRACE risk score >140
Transient ST-segment elevation
Dynamic ST-segment or T wave changes
Figure 8 Selection of invasive strategy and reperfusion therapy in patients presenting with NSTE-ACS. ACS, acute coronary syndrome; CS, cardiogenic 
shock; ECG, electrocardiogram; FMC, first medical contact; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; 
NSTE-ACS, non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; UA, 
unstable angina. This figure summarizes the selection of invasive strategy and reperfusion therapy in patients presenting with ACS. aRisk criteria: Patients 
who meet any one of the ‘very high-risk’ NSTE-ACS criteria should undergo an immediate invasive strategy; these very high-risk criteria include haemo­
dynamic instability or CS, recurrent or refractory chest pain despite medical treatment, life-threatening arrhythmias, mechanical complications of MI, HF 
clearly related to ACS, and recurrent dynamic ST-segment or T wave changes, particularly with intermittent ST-segment elevation. Patients with 
NSTE-ACS who meet any of the ‘high-risk’ criteria (confirmed NSTEMI as per the hs-cTn-based ESC algorithm, NSTE-ACS with GRACE score >140, dy­
namic ST-segment or T wave changes, or transient ST-segment elevation) should be considered for early invasive angiography (i.e. within 24 h) and should 
undergo an inpatient invasive strategy. An invasive strategy during hospital admission is recommended in NSTE-ACS patients with high-risk criteria or with a 
high index of suspicion for UA. In selected patients a selective invasive strategy can also be an option. See Recommendation Table 4 for full details.


<!-- PAGE 30 -->

### Page 30

inpatient invasive strategy is recommended. Conversely, for patients 
with a low index of suspicion, a selective invasive approach is 
recommended.
5.3. Fibrinolysis and pharmaco-invasive 
strategy in patients with ST-elevation 
myocardial infarction
5.3.1. Benefit and indication of fibrinolysis
Fibrinolytic therapy is an important reperfusion strategy for STEMI pa­
tients presenting within 12 h of symptom onset when PPCI cannot be 
performed in a timely manner; it prevents 30 early deaths per 1000 pa­
tients treated within 6 h of symptom onset.205 The largest absolute treat­
ment benefit is seen among those patients at the highest risk, including the 
elderly. Successful reperfusion is generally associated with significant im­
provement in ischaemic symptoms, ≥50% ST-segment resolution, 
and haemodynamic stability. The doses of fibrinolytic agents and concomi­
tant antithrombotic therapies are given in the Fibrinolysis and Pharmaco- 
invasive Strategy provided in the Supplementary data online, Section 6.3.
5.3.1.1. Pre-hospital fibrinolysis
If trained medical or allied health staff can interpret the ECG on site, or 
transmit the ECG for remote interpretation, it is recommended to ini­
tiate fibrinolytic therapy in the pre-hospital setting. A fibrin-specific 
agent (i.e. tenecteplase, alteplase, or reteplase) is the preferred agent. 
The goal is to start fibrinolytic therapy within 10 min of the STEMI diag­
nosis. Fibrinolytic therapy initiation should not be delayed by waiting for 
the results of cardiac biomarker testing. In a meta-analysis of six rando­
mized trials (n = 6434), pre-hospital fibrinolysis compared with in- 
hospital fibrinolysis reduced early mortality by 17%, particularly when 
administered in the first 2 h after symptom onset.51,206 These, and 
more recent, data support the pre-hospital initiation of fibrinolytic 
treatment when a reperfusion strategy is indicated.145,207–209 The 
STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial 
demonstrated that pre-hospital fibrinolysis followed by an early PCI 
strategy was associated with a similar outcome to transfer for PPCI 
in STEMI patients presenting within 3 h of symptom onset who could 
not undergo PPCI within 1 h of FMC, although a slight excess of intra­
cranial bleeding was observed with the investigational strategy.184,210
This excess in intracranial bleeding was blunted by halving the dose 
of tenecteplase in patients >75 years of age.
5.3.1.2. Angiography and percutaneous coronary intervention after 
fibrinolysis (pharmaco-invasive strategy)
It is recommended that patients should be transferred to a PCI centre 
immediately after initiation of lytic therapy (Figure 7). In cases of failed 
fibrinolysis or evidence of re-occlusion or re-infarction with recurrence 
of ST-segment elevation, immediate angiography and rescue PCI are in­
dicated.185,211 In this setting, re-administration of fibrinolysis is not 
beneficial and is discouraged.185 Even if it is likely that fibrinolysis is suc­
cessful (e.g. ST-segment resolution >50% at 60–90 min; typical reper­
fusion arrhythmia; and disappearance of chest pain), routine early 
angiography (i.e. within 2–24 h) is recommended. Several randomized 
trials have shown that routine early angiography with subsequent PCI 
(if required) after fibrinolysis reduced the rates of re-infarction and re­
current ischaemia in comparison to a ‘watchful waiting’ strategy (i.e. a 
strategy in which angiography and revascularization were performed 
only in patients with spontaneous or induced severe ischaemia or LV 
dysfunction, or in patients with a positive outpatient ischaemia 
test).186,209,212–215 A network meta-analysis including 15 357 STEMI pa­
tients treated with fibrinolytic therapy (n = 4212), PPCI (n = 6139), or 
fibrinolysis followed by routine immediate or early PCI (n = 5006) in­
vestigated whether STEMI patients should be transferred to a 
PCI-capable facility immediately (defined as a facilitated PCI approach) 
or within a day (e.g. <24 h, defined as a pharmaco-invasive ap­
proach).209 After PPCI, the pharmaco-invasive strategy was the second 
most favourable approach, with an odds ratio (OR) for death of 0.79 
(95% confidence interval [CI], 0.59–1.08) compared with conventional 
fibrinolytic therapy. This supports the safety of transferring STEMI pa­
tients to a PCI-capable centre for angiography within 2–24 h. The bene­
fit of routine early PCI after fibrinolysis was demonstrated without an 
increased risk of adverse events (stroke or major bleeding), and across 
the spectrum of the investigated patient subgroups.209,216 Therefore, 
early angiography with subsequent PCI if required is the recommended 
standard of care after successful fibrinolysis (Figure 7). Observational 
analysis of registry data has also provided some further support for 
the use of a pharmaco-invasive strategy.130
The optimal time delay between successful fibrinolysis and PCI has 
not been clearly defined; there has been a wide variation in this time 
delay in trials, ranging from a median of 1.3 to 17 h.184,185,206,215,217
Based on these data, a time window for PCI of 2–24 h after successful 
lysis is recommended.
5.3.1.2.1. Comparison of fibrinolytic agents. Some information on 
comparisons of fibrinolytic agents is provided in the Supplementary 
data online, Section 6.3.1.
5.3.1.2.2. Hazards of fibrinolysis and contraindications. Some infor­
mation regarding the hazards of, and contraindications to, fibrinolysis is 
provided in the Supplementary data online, Section 6.3.2.
5.4. Patients not undergoing reperfusion
The management of ACS patients not undergoing reperfusion is dis­
cussed in the Supplementary data online, Section 5.2.
5.4.1. Patients who are not candidates for invasive 
coronary angiography
Information regarding the management of NSTE-ACS patients who are 
not candidates for invasive angiography is provided in the 
Supplementary data online, Section 5.2.1.
5.4.2. Patients with coronary artery disease not 
amenable to revascularization
Information regarding the management of ACS patients with CAD that 
is not amenable to revascularization is provided in the Supplementary 
data online, Section 5.2.2.
ESC Guidelines                                                                                                                                                                                          3749


<!-- PAGE 31 -->

### Page 31

### 6 Antithrombotic therapy

Antithrombotic treatment is an important component of the manage­
ment of all patients presenting with ACS. The specific choice and com­
bination of therapy, the time of its initiation, and the treatment duration 
depend on various patient and procedural factors. Treatment decisions 
must be made weighing the benefits of antithrombotic therapy against 
the risk of bleeding, including severe, life-threatening bleeding.231,232
Recommended anticoagulant and antiplatelet drugs and their dosing 
(for use during and after ACS) are summarized in Table 6 and illustrated 
in Figure 9.
Recommendation Table 4 — Recommendations for re­
perfusion therapy and timing of invasive strategy
Recommendations
Classa
Levelb
Recommendations for reperfusion therapy for patients with 
STEMI
Reperfusion therapy is recommended in all patients 
with a working diagnosis of STEMI (persistent 
ST-segment elevation or equivalentsc) and symptoms 
of ischaemia of ≤12 h duration.51,182
I
A
A PPCI strategy is recommended over fibrinolysis if 
the anticipated time from diagnosis to PCI is 
<120 min.52,218,219
I
A
If timely PPCI (<120 min) cannot be performed in 
patients with a working diagnosis of STEMI, 
fibrinolytic therapy is recommended within 12 h of 
symptom onset in patients without 
contraindications.176,183
I
A
Rescue PCI is recommended for failed fibrinolysis 
(i.e. ST-segment resolution <50% within 60–90 min 
of fibrinolytic administration) or in the presence of 
haemodynamic or electrical instability, worsening 
ischaemia, or persistent chest pain.184,185
I
A
In patients with a working diagnosis of STEMI and a 
time from symptom onset >12 h, a PPCI strategy is 
recommended in the presence of ongoing symptoms 
suggestive of ischaemia, haemodynamic instability, or 
life-threatening arrhythmias.220
I
C
A routine PPCI strategy should be considered in 
STEMI patients presenting late (12–48 h) after 
symptom onset.189–191,221
IIa
B
Routine PCI of an occluded IRA is not recommended 
in STEMI patients presenting >48 h after symptom 
onset and without persistent symptoms.189,192,193
III
A
Transfer/interventions after fibrinolysis
Transfer to a PCI-capable centre is recommended in 
all patients immediately after fibrinolysis.184– 
186,212,213,222–224
I
A
Emergency angiography and PCI of the IRA, if 
indicated are recommended in patients with 
new-onset or persistent heart failure/shock after 
fibrinolysis.185,225
I
A
Angiography and PCI of the IRA, if indicated, is 
recommended between 2 and 24 h after successful 
fibrinolysis.186,212,213,217,224
I
A
Continued
Invasive strategy in NSTE-ACS
An invasive strategy during hospital admission is 
recommended in NSTE-ACS patients with high-risk 
criteria or a high index of suspicion for unstable 
angina.196–200
I
A
A selective invasive approach is recommended in 
patients without very high- or high-risk NSTE-ACS 
criteria and with a low index of suspicion for 
NSTE-ACS.196–200
I
A
An immediate invasive strategy is recommended in 
patients with a working diagnosis of NSTE-ACS and 
with at least one of the following very high-risk 
criteria: 
• Haemodynamic instability or cardiogenic shock
• Recurrent or refractory chest pain despite medical 
treatment
• In-hospital life-threatening arrhythmias
• Mechanical complications of MI
• Acute heart failure presumed secondary to 
ongoing myocardial ischaemia
• Recurrent dynamic ST-segment or T wave changes, 
particularly intermittent ST-segment elevation.
I
C
An early invasive strategy within 24 h should be 
considered in patients with at least one of the 
following high-risk criteria: 
• Confirmed diagnosis of NSTEMI based on current 
recommended ESC hs-cTn algorithms
• Dynamic ST-segment or T wave changes
• Transient ST-segment elevation
• GRACE risk score >140202,226–230
IIa
A
© ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; ESC, European Society of 
Cardiology; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity 
cardiac troponin; IRA, infarct-related artery; MI, myocardial infarction; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial 
infarction; PPCI, primary percutaneous coronary intervention; STEMI, ST-elevation 
myocardial infarction. 
aClass of recommendation. 
bLevel of evidence. 
cST-segment elevation equivalents are presented in Supplementary data online, Figure S2.


<!-- PAGE 32 -->

### Page 32

Table 6 Dose regimen of antiplatelet and anticoagulant drugs in acute coronary syndrome patients
I. Antiplatelet drugs
Aspirin
LD of 150–300 mg orally or 75–250 mg i.v. if oral ingestion is not possible, followed by oral MD of 75–100 mg o.d.; no specific dose adjustment in 
CKD patients.
P2Y12 receptor inhibitors (oral or i.v.)
Clopidogrel
LD of 300–600 mg orally, followed by an MD of 75 mg o.d.; no specific dose adjustment in CKD patients. 
Fibrinolysis: at the time of fibrinolysis an initial dose of 300 mg (75 mg for patients older than 75 years of age).
Prasugrel
LD of 60 mg orally, followed by an MD of 10 mg o.d. In patients with body weight <60 kg, an MD of 5 mg o.d. is recommended. In patients aged 
≥75 years, prasugrel should be used with caution, but a MD of 5 mg o.d. should be used if treatment is deemed necessary. No specific dose 
adjustment in CKD patients. Prior stroke is a contraindication for prasugrel.
Ticagrelor
LD of 180 mg orally, followed by an MD of 90 mg b.i.d.; no specific dose adjustment in CKD patients.
Cangrelor
Bolus of 30 mcg/kg i.v. followed by 4 mcg/kg/min infusion for at least 2 h or the duration of the procedure (whichever is longer). 
In the transition from cangrelor to a thienopyridine, the thienopyridine should be administered immediately after discontinuation of cangrelor 
with an LD (clopidogrel 600 mg or prasugrel 60 mg); to avoid a potential DDI, prasugrel may also be administered 30 min before the cangrelor 
infusion is stopped. Ticagrelor (LD 180 mg) should be administered at the time of PCI to minimize the potential gap in platelet inhibition during 
the transition phase.
GP IIb/IIIa receptor inhibitors (i.v.)
Eptifibatide
Double bolus of 180 mcg/kg i.v. (given at a 10-min interval) followed by an infusion of 2.0 mcg/kg/min for up to 18 h. 
For CrCl 30–50 mL/min: first LD, 180 mcg/kg i.v. bolus (max 22.6 mg); maintenance infusion, 1 mcg/kg/min (max 7.5 mg/h). Second LD (if PCI), 
180 mcg/kg i.v. bolus (max 22.6 mg) should be administered 10 min after the first bolus. Contraindicated in patients with end-stage renal disease 
and with prior ICH, ischaemic stroke within 30 days, fibrinolysis, or platelet count <100 000/mm3.
Tirofiban
Bolus of 25 mcg/kg i.v. over 3 min, followed by an infusion of 0.15 mcg/kg/min for up to 18 h. 
For CrCl ≤60 mL/min: LD, 25 mcg/kg i.v. over 5 min followed by a maintenance infusion of 0.075 mcg/kg/min continued for up to 18 h. 
Contraindicated in patients with prior ICH, ischaemic stroke within 30 days, fibrinolysis, or platelet count <100 000/mm3.
II. Anticoagulant drugs
UFH
Initial treatment: i.v. bolus 70–100 U/kg followed by i.v. infusion titrated to achieve an aPTT of 60–80 s. 
During PCI: 70–100 U/kg i.v. bolus or according to ACT in case of UFH pre-treatment.
Enoxaparin
Initial treatment: for treatment of ACS 1 mg/kg b.i.d. subcutaneously for a minimum of 2 days and continued until clinical stabilization. In patients 
whose CrCl is below 30 mL per minute (by Cockcroft–Gault equation), the enoxaparin dosage should be reduced to 1 mg per kg o.d. 
During PCI: for patients managed with PCI, if the last dose of enoxaparin was given less than 8 h before balloon inflation, no additional dosing is 
needed. If the last s.c. administration was given more than 8 h before balloon inflation, an i.v. bolus of 0.3 mg/kg enoxaparin sodium should be 
administered.
Bivalirudin
During PPCI: 0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for 4 h after the procedure. 
In patients whose CrCl is below 30 mL/min (by Cockcroft–Gault equation), maintenance infusion should be reduced to 1 mg/kg/h.
Fondaparinux
Initial treatment: 2.5 mg/d subcutaneously. 
During PCI: A single bolus of UFH is recommended. 
Avoid if CrCl <20 mL/min.
© ESC 2023
ACS, acute coronary syndrome; ACT, activated clotting time; aPPT, activated partial thromboplastin time; b.i.d., bis in die (twice a day); CKD, chronic kidney disease; CrCl, creatinine 
clearance; DDI, drug–drug interactions; ICH, intracranial haemorrhage; i.v. intravenous; LD, loading dose; MD, maintenance dose; o.d., once a day; PPCI, primary percutaneous coronary 
intervention; s.c. subcutaneous; UFH, unfractionated heparin.
ESC Guidelines                                                                                                                                                                                          3751


<!-- PAGE 33 -->

### Page 33

6.1. Antiplatelet therapy in the acute 
phase
6.1.1. Oral antiplatelet therapy
Antiplatelet drugs play a key role in the acute phase of treatment for 
ACS. Table 6 summarizes the dosing regimens of the available oral 
and i.v. antiplatelet drugs. The choice of antiplatelet regimen should 
take the bleeding risk of the patient into account. Factors associated 
with an elevated bleeding risk have been detailed by the Academic 
Research Consortium on High Bleeding Risk (ARC-HBR).233 The 
presence of one major or two minor ARC-HBR risk factors indicates 
high bleeding risk (HBR). Of note, the presence of multiple major risk 
factors is associated with a progressive increase in the bleeding risk.234
Aspirin treatment is started with a loading dose (LD) as soon as pos­
sible, followed by maintenance treatment (Table 6).235 Current evi­
dence supports an aspirin maintenance dose (MD) of 75–100 mg 
once a day (o.d.).236,237
Based on the results of the phase III PLATelet inhibition and patient 
Outcomes (PLATO) and TRial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet InhibitioN with Prasugrel 
Eptifibatide
Tirofiban
Clopidogrel
Aspirin
Ticagrelor
Prasugrel
Cangrelor
Rivaroxaban
Apixaban
Edoxaban
UFH
Enoxaparin
Dabigatran
Bivalirudin
Fondaparinux
GP IIb/IIIa
TxA2
P2Y12 receptor
Thromboxane receptor
Thrombin receptor
ADP
P
P
Plaque rupture or plaque erosion
Platelet activation
TF:FVIIa
Aggregation of activated platelets
Fibrinogen
Fibrin
FXa
Thrombin
Mature fibrin clot
Figure 9 Antithrombotic treatments in acute coronary syndrome: pharmacological targets. ADP, adenosine diphosphate; FVIIa, Factor VIIa; FXa, Factor Xa; 
GP, glycoprotein; TF, tissue factor; TxA2, thromboxane A2; UFH, unfractionated heparin. Drugs with oral administration are shown in blue and drugs with 
preferred parenteral administration in red.


<!-- PAGE 34 -->

### Page 34

Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) studies, 
dual antiplatelet therapy (DAPT) including aspirin and a potent P2Y12 
receptor inhibitor (prasugrel or ticagrelor) is recommended as the de­
fault DAPT strategy for ACS patients.238,239 Clopidogrel, which is char­
acterized by less effective and more variable platelet inhibition, should 
only be used when prasugrel or ticagrelor are contraindicated/not avail­
able, or in some patients considered otherwise at HBR (e.g. ≥1 major 
or ≥2 minor ARC-HBR criteria).233,240–242 In addition, the use of clopi­
dogrel may be considered in older patients (e.g. ≥70 years).242,243
Prasugrel should be considered in preference to ticagrelor for ACS 
patients who proceed to PCI. The Intracoronary Stenting and 
Antithrombotic Regimen Rapid Early Action for Coronary Treatment 
(ISAR-REACT) 5 RCT is the largest head-to-head comparison of 1-year 
DAPT with prasugrel vs. DAPT with ticagrelor in patients with ACS 
planned for invasive evaluation, >80% of whom underwent PCI.244 A 
treatment strategy with prasugrel (LD given as soon as possible after ran­
domization for patients undergoing PPCI and after delineation of coron­
ary anatomy for patients presenting with NSTE-ACS) vs. ticagrelor (LD 
given as soon as possible after randomization in all cases) significantly re­
duced the composite endpoint of death, MI, or stroke (6.9% vs. 9.3%, P =  
0.006) without any increase in bleeding complications (4.8% vs. 5.4%, P =  
0.46). Limitations of this study include an open-label design and limited 
data on medically managed or CABG-treated patients.
6.1.2. Timing of loading dose of oral antiplatelet 
therapy
Both aspirin and oral P2Y12 inhibitors achieve platelet inhibition more 
rapidly following an oral LD. Pre-treatment refers to a strategy in which 
an antiplatelet drug, usually a P2Y12 receptor inhibitor, is given before 
coronary angiography and, therefore, before the coronary anatomy is 
known. Although a potential benefit with pre-treatment in the setting 
of ACS has been hypothesized, large-scale randomized trials supporting 
a routine pre-treatment strategy with P2Y12 receptor inhibitors are 
lacking. Caution in relation to pre-treatment may be of particular rele­
vance in patients at HBR (e.g. those receiving an oral anticoagulant 
[OAC]).
6.1.2.1. Pre-treatment in patients with suspected ST-elevation 
myocardial infarction
The Administration of Ticagrelor in the Cath Lab or in the Ambulance 
for New ST Elevation Myocardial Infarction to Open the Coronary 
Artery (ATLANTIC) trial is the only randomized study testing the 
safety and efficacy of different timings of P2Y12 receptor inhibitor initi­
ation in patients with a working diagnosis of STEMI undergoing PPCI.245
In this trial, patients were randomized to receive a ticagrelor LD either 
during transfer to a PPCI centre or immediately before angiography.245
The median difference between the timing of P2Y12 receptor inhibitor 
loading with the two treatment strategies was 31 min. In this study, the 
pre-treatment strategy failed to meet the pre-specified primary end­
point of improved ST-segment elevation resolution or Thrombolysis 
In Myocardial Infarction (TIMI) flow before intervention. Rates of major 
and minor bleeding events were identical in both treatment arms. 
These results were supported by real-world data obtained from the 
SWEDEHEART (Swedish Web-System for Enhancement and 
Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies) registry in STEMI patients.246
Prasugrel pre-treatment has not been directly investigated in patients 
with STEMI.
6.1.2.2. Pre-treatment in patients with non-ST-elevation acute 
coronary syndrome
The randomized A Comparison of Prasugrel at the Time of 
Percutaneous Coronary Intervention or as Pretreatment at the Time 
of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction 
(ACCOAST) trial not only demonstrated a lack of benefit with respect 
to ischaemic outcomes with prasugrel pre-treatment, but also a sub­
stantially higher bleeding risk.247 In this study, the median time from first 
LD to the start of coronary angiography in the pre-treatment group 
was 4.4 h. With respect to pre-treatment data for ticagrelor, the 
ISAR-REACT 5 trial showed that a ticagrelor-based strategy with rou­
tine pre-treatment was inferior to a prasugrel-based strategy with a de­
ferred LD in NSTE-ACS patients.244 The DUBIUS (Downstream 
Versus Upstream Strategy for the Administration of P2Y12 Receptor 
Blockers) trial also attempted to address this question but was stopped 
early for futility as there was no difference between upstream vs. down­
stream oral P2Y12 administration in patients with NSTE-ACS (both 
NSTEMI and UA) scheduled for coronary angiography within 72 h of 
hospital admission.248
6.1.2.3. Summary of pre-treatment strategies
In patients with a working diagnosis of STEMI undergoing PPCI, pre- 
treatment with a P2Y12 receptor inhibitor may be considered.245 In pa­
tients with a working diagnosis of NSTE-ACS, routine pre-treatment 
with a P2Y12 receptor inhibitor before knowing the coronary anatomy 
in patients anticipated to undergo an early invasive strategy (i.e. <24 h) 
is not recommended.244,245,247 For patients with a working diagnosis of 
NSTE-ACS, where there is an anticipated delay to invasive angiography 
(i.e. >24 h), pre-treatment with a P2Y12 receptor inhibitor may be con­
sidered according to the bleeding risk of the patient. In all ACS patients 
proceeding to PCI who did not receive P2Y12 receptor inhibitor pre- 
treatment, an LD is recommended at the time of PCI.
6.1.3. Intravenous antiplatelet drugs
Peri-interventional i.v. antiplatelet drugs include P2Y12 receptor inhibi­
tors (cangrelor) and glycoprotein (GP) IIb/IIIa inhibitors (eptifibatide 
and tirofiban). Most of the trials evaluating GP IIb/IIIa inhibitors in 
PCI-treated ACS patients pre-date the era of routine DAPT, in particu­
lar, early initiation of DAPT including an LD of a potent P2Y12 receptor 
inhibitor.249,250 There is no strong evidence for any additional benefit 
with the routine use of GP IIb/IIIa inhibitors in ACS patients scheduled 
for coronary angiography. Nevertheless, their use should be considered 
for bailout if there is evidence of no-reflow or a thrombotic complica­
tion during PCI. Another potential use for GP IIb/IIIa inhibitors is in the 
setting of high-risk PCI in patients who have not been pre-treated with 
P2Y12 receptor inhibitors.
Cangrelor is a direct reversible, short-acting P2Y12 receptor inhibitor 
that has been evaluated during PCI for CCS and ACS in clinical trials 
against clopidogrel, both with administration before (Cangrelor versus 
Standard Therapy to Achieve Optimal Management of Platelet 
Inhibition [CHAMPION PCI]) and after (CHAMPION PLATFORM 
and CHAMPION PHOENIX [A Clinical Trial Comparing Cangrelor 
to Clopidogrel Standard Therapy in Subjects Who Require 
Percutaneous Coronary Intervention]) PCI.251–253 A meta-analysis of 
these trials showed that the benefit of cangrelor with respect to major 
ischaemic endpoints was counterbalanced by an increase in minor 
bleeding complications.254 It is also important to note that the benefit 
of cangrelor with respect to ischaemic endpoints was attenuated in 
CHAMPION PCI with upfront administration of clopidogrel, and 
ESC Guidelines                                                                                                                                                                                          3753


<!-- PAGE 35 -->

### Page 35

data for its use in conjunction with ticagrelor or prasugrel treatment are 
limited. Due to its proven efficacy in preventing intra-procedural and 
post-procedural stent thrombosis in P2Y12 receptor inhibitor-naïve pa­
tients, cangrelor may be considered on a case-by-case basis in P2Y12 re­
ceptor inhibitor-naïve ACS patients undergoing PCI, including in 
patients for whom it may not be feasible to give oral drugs in the setting 
of emergent PCI (e.g. CS patients and/or patients on mechanical 
ventilation).
6.2. Anticoagulant treatment in the acute 
phase
Anticoagulation is an important component of the initial treatment of 
ACS and of the peri-procedural treatment for ACS patients managed 
with an invasive strategy. Therefore, parenteral anticoagulation is re­
commended for all ACS patients at the time of diagnosis.255 Table 6
provides an overview of the relevant anticoagulant drugs and their dos­
ing in ACS patients.
In general, a crossover between anticoagulants should be avoided in 
patients with ACS (especially between unfractionated heparin [UFH] 
and low-molecular-weight heparin [LMWH]), with the exception of 
adding UFH to fondaparinux when a patient presenting with 
NSTE-ACS proceeds to PCI after a period of fondaparinux treatment 
(see below for further detail).256,257 Anticoagulants should generally be 
discontinued immediately after PCI, except in specific clinical settings 
such as the confirmed presence of LV aneurysm with thrombus forma­
tion or AF requiring anticoagulation. In addition, for bivalirudin in pa­
tients with STEMI undergoing PCI, a full dose post-PCI infusion is 
recommended.
In this section of the guideline, we summarize the recommendations 
for anticoagulant treatment in the acute phase for patients with STEMI 
undergoing PPCI and for patients with NSTE-ACS undergoing angiog­
raphy (and PCI if indicated).
6.2.1. Anticoagulation in patients with ST-elevation 
myocardial infarction undergoing primary 
percutaneous coronary intervention
Unfractionated heparin has been established as the standard of care in 
patients with STEMI undergoing PPCI due to its favourable risk/benefit 
profile. In these patients, anticoagulation should be given during the in­
vasive procedure. High-quality evidence with respect to the benefit of 
administering anticoagulation at an earlier time point in patients under­
going a PPCI strategy is lacking.
Alternatives to UFH that should be considered in patients with 
STEMI undergoing PPCI include enoxaparin (a LMWH) and bivalirudin 
(a direct thrombin inhibitor). The ATOLL (STEMI Treated With 
Primary Angioplasty and Intravenous Lovenox or Unfractionated 
Heparin) trial reported a reduction in the primary endpoint at 30 
days (incidence of death, complication of MI, procedure failure, or ma­
jor bleeding) with enoxaparin in comparison to UFH in patients with 
STEMI undergoing PPCI.258
In the BivaliRudin with prolonged full-dose Infusion durinG primary 
PCI versus Heparin Trial 4 (BRIGHT-4), 6016 patients with STEMI 
undergoing PPCI were randomized to either bivalirudin (with a full 
dose post-PCI infusion) or UFH.259 The use of GP IIb/IIIa inhibitors 
was restricted to patients who experienced thrombotic complications. 
The primary endpoint (a composite of all-cause mortality or Bleeding 
Academic Research Consortium [BARC] type 3–5 bleeding at 30 
days), the individual components of the primary endpoint, and definite 
or probable stent thrombosis were all significantly reduced in the 
bivalirudin group.259 Based on the totality of the available data, bivalir­
udin with a full-dose post-PCI infusion should be considered as an alter­
native to UFH, although further studies to confirm these findings in 
non-East Asian populations are required. Bivalirudin is also the recom­
mended alternative to UFH in patients presenting with ACS who have a 
history of heparin-induced thrombocytopaenia. Additional information 
about bivalirudin, including evidence tables summarizing the relevant 
clinical trials, is provided in the Supplementary data online.
Based on the results of the OASIS-6 (The Safety and Efficacy of 
Fondaparinux Versus Control Therapy in Patients With ST Segment 
Elevation Acute Myocardial Infarction) trial, fondaparinux is not recom­
mended in patients with STEMI undergoing PPCI.260
To summarize, parenteral anticoagulation is recommended for pa­
tients with STEMI undergoing PPCI and UFH is the default choice of 
anticoagulant at present. Enoxaparin and bivalirudin should be consid­
ered as alternatives to UFH in these patients but fondaparinux is not 
recommended.
6.2.2. Anticoagulation in patients with 
non-ST-elevation acute coronary syndrome 
undergoing angiography and percutaneous coronary 
intervention if indicated
Patients with NSTE-ACS are also recommended to receive parenteral 
anticoagulation. In patients with NSTE-ACS who are anticipated to 
undergo immediate or early (i.e. <24 h from the time of diagnosis) in­
vasive angiography and PCI if indicated, parenteral anticoagulation at 
the time of diagnosis is recommended, and UFH has been historically 
established as the anticoagulant of choice. However, in a meta-analysis 
of trials comparing UFH with enoxaparin, mortality and major bleeding 
was not different between both agents in patients with NSTE-ACS or 
stable patients scheduled for PCI.261 Therefore, enoxaparin should be 
considered as an alternative to UFH in these patients (especially in cases 
where monitoring of clotting times is complex).
NSTE-ACS patients who do not undergo early invasive angiography 
(i.e. within 24 h of diagnosis) will have an extended initial treatment 
phase consisting of only pharmacological treatment. In these patients, 
fondaparinux therapy is recommended in preference to enoxaparin 
while awaiting invasive angiography, based on the favourable outcomes 
demonstrated with fondaparinux in comparison to enoxaparin in the 
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes 
(OASIS-5) trial.262 Of note, guiding catheter thrombus formation was 
of concern with fondaparinux and, therefore, a full-dose bolus of 
UFH should be given if the patient proceeds to PCI. The potential im­
pact of contemporary changes in clinical practice (including radial ac­
cess, early catheterization, and infrequent GP IIb/IIIa inhibitor 
therapy) on the treatment effect observed in OASIS-5 should also be 
considered. If fondaparinux is not available, enoxaparin should be con­
sidered for these patients.
Intravenous enoxaparin should also be considered as an anticoagu­
lant for PCI in patients with NSTE-ACS in whom subcutaneous (s.c.) 
enoxaparin was used while awaiting coronary angiography.261
In summary, parenteral anticoagulation is recommended for patients 
with NSTE-ACS. For patients with NSTE-ACS undergoing immediate 
or early angiography (± PCI if indicated), UFH is recommended but en­
oxaparin should be considered as an alternative to UFH. For patients 
with NSTE-ACS who are not anticipated to undergo early angiography, 
fondaparinux (with a UFH bolus at time of PCI) is recommended in 
preference to enoxaparin, although enoxaparin should be considered 
if fondaparinux is not available.


<!-- PAGE 36 -->

### Page 36

6.3. Maintenance antithrombotic therapy 
after revascularization
While continuation of anticoagulation after PCI is not necessary in the 
vast majority of patients (i.e. those without an indication for long-term 
OAC), post-interventional antiplatelet treatment is mandatory in ACS 
patients. Following PCI, a default DAPT regimen consisting of a potent 
P2Y12 receptor inhibitor (prasugrel or ticagrelor) and aspirin is 
generally recommended for 12 months, irrespective of the stent 
type, unless there are contraindications.236,238,239,244,263 In specific clin­
ical scenarios, the default DAPT duration can be shortened (<12 
months), extended (>12 months), or modified (switching DAPT, 
DAPT de-escalation). The recommended default antithrombotic treat­
ment options for ACS patients without an indication for OAC are 
shown in Figure 10.
Routine 
antiplatelet pretreatment
ACS
(Class I)
PPCI
(Class IIb)
ACS
+
(Class I)
(Class I)
Proceeding to PCI
(Class IIa)
Prasugrel
Ticagrelor
>
NSTE-ACSb
(Class III)
Anticoagulation
Choice of 
P2Y12 inhibitorc 
Default DAPT
strategy for the first 12 months after ACSc
Default strategy beyond the first
12 months after ACS
Invasive Coronary Angiography
If prasugrel and ticagrelor 
are unavailable, contraindicated, 
or cannot be tolerated
Angiography 
<24 h
(Class I)
UFH
PPCI
(Class IIa)
Enoxaparin
PPCI
(Class III)
Fondaparinux
Aspirin
Aspirin
P2Y12 inhibitor
(Class I)
Aspirin
P2Y12 inhibitor
Prasugrel
Ticagrelor
Clopidogrel
P2Y12 inhibitor
1
3
6
Time
(months)
9
12
NSTE-ACS
STEMI
(Class IIa)
Enoxaparin
Angiography
<24 h
(Class I)
Fondaparinuxa
Angiography
>24 h
(Class I)
UFH
PPCI
PPCI
(Class IIa)
Bivalirudin
Figure 10 Recommended default antithrombotic therapy regimens in acute coronary syndrome patients without an indication for oral anticoagulation. 
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, per­
cutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; UFH, unfractionated heparin. Algorithm for antithrombotic therapy in 
ACS patients without an indication for oral anticoagulation undergoing invasive evaluation. aFondaparinux (plus a single bolus of UFH at the time of PCI) is 
recommended in preference to enoxaparin for NSTE-ACS patients in cases of medical treatment or logistical constraints for transferring the NSTE-ACS 
patient to PCI within 24 h of symptom onset. bRoutine pre-treatment with a P2Y12 receptor inhibitor in NSTE-ACS patients in whom coronary anatomy 
is not known and early invasive management (<24 h) is planned is not recommended, but pre-treatment with a P2Y12 receptor inhibitor may be considered in 
NSTE-ACS patients who are not expected to undergo an early invasive strategy (<24 h) and do not have HBR. cClopidogrel is recommended for 12 months 
DAPT if prasugrel and ticagrelor are not available, cannot be tolerated, or are contraindicated, and may be considered in older ACS patients (typically defined 
as older than 70–80 years of age).
ESC Guidelines                                                                                                                                                                                          3755


<!-- PAGE 37 -->

### Page 37

6.3.1. Shortening dual antiplatelet therapy
Several RCTs and meta-analyses have compared standard 12-month 
DAPT with ≤6 months DAPT followed by aspirin monotherapy in 
ACS patients.264–267 In some of these trials, the reduction in bleeding 
events associated with abbreviated DAPT regimens came at the cost 
of an increase in the rates of ischaemic complications. In a large-scale 
network meta-analysis, 3-month DAPT but not 6-month DAPT was as­
sociated with higher rates of MI or stent thrombosis in ACS patients.264
A number of large RCTs have investigated DAPT duration further 
shortened to 1–3 months followed by P2Y12 receptor inhibitor mono­
therapy in patients with and without ACS.268–271 In general, low to 
intermediate ischaemic risk patients were included, and early mono­
therapy with clopidogrel or ticagrelor was used. Some trials included 
a comparison with more prolonged DAPT than usual in the control 
arm. Patients with STEMI tended to be excluded or under-represented.
The TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk 
Patients After Coronary Intervention) trial examined the effect of tica­
grelor monotherapy vs. ticagrelor plus aspirin for 1 year after 3 months 
of DAPT (ticagrelor and aspirin) on clinically relevant bleeding. This 
study enrolled ‘high-risk’ patients as per the trial inclusion criteria, 
which meant that the enrolled patients had at least one clinical feature 
and one angiographic feature associated with a high risk of ischaemic or 
bleeding events. However, in order to be randomized the patients were 
also required to have not experienced a major bleeding or ischaemic 
event in the 3 months following hospital discharge.271 STEMI patients 
were excluded from this study. Bleeding events (BARC type 2, 3, or 
5 bleeding) were significantly reduced by omitting aspirin after 3 
months, without a signal of increased ischaemic risk. A dedicated sub­
group analysis suggested these findings were consistent in 4614 patients 
with NSTEMI/UA.272 In the TICO (Ticagrelor Monotherapy After 3 
Months in the Patients Treated With New Generation Sirolimus 
Stent for Acute Coronary Syndrome) trial, ticagrelor monotherapy 
vs. ticagrelor plus aspirin for up to 1 year after 3 months of DAPT (ti­
cagrelor and aspirin) was tested in 3056 ACS patients (36% STEMI).273
Net adverse clinical events and major bleeding events were significantly 
reduced with ticagrelor monotherapy, and major adverse cardiac and 
cerebrovascular events were not significantly different. Limitations of 
this study included the selected population assessed and the lower 
than expected event rates. A study-level meta-analysis of outcomes 
in a population of patients (with both ACS and CCS) fitted with a 
DES also reported a beneficial effect of shortened DAPT for 1–3 
months on major bleeding events, as well as a neutral effect on death, 
MI, and stroke.274
The STOPDAPT-2-ACS (ShorT and OPtimal Duration of Dual 
AntiPlatelet Therapy-2 Study for the Patients With ACS) trial investi­
gated a short DAPT strategy in ACS patients.275 At 1–2 months, pa­
tients were randomized to either clopidogrel monotherapy or 
continued DAPT for 12 months. Non-inferiority of the investigational 
strategy for the composite endpoint of cardiovascular (CV) or bleeding 
events was not proven, suggesting that systematic very short duration 
DAPT (i.e. <3 months) followed by clopidogrel monotherapy is not a 
useful strategy in ACS patients.
The MASTER DAPT (Management of High Bleeding Risk Patients Post 
Bioresorbable Polymer Coated Stent Implantation With an Abbreviated 
Versus Prolonged DAPT Regimen) trial examined a strategy of abbre­
viated DAPT (1 month) followed by either aspirin or P2Y12 inhibitor 
monotherapy vs. DAPT ≥3 months (standard therapy) in a cohort of 
4579 HBR patients (49% ACS, 12% STEMI) undergoing PCI with a bioab­
sorbable polymer-coated stent.276 Net adverse clinical events and major 
adverse cardiac or cerebral events were comparable between the 
groups, whereas major or clinically relevant non-major bleeding events 
were significantly reduced in the abbreviated therapy group.
6.3.2. De-escalation from potent P2Y12 inhibitor to 
clopidogrel
The need to switch between oral P2Y12 receptor inhibitors is not 
uncommon as a consequence of bleeding complications (or concern re­
garding bleeding), non-bleeding side effects (e.g. dyspnoea on ticagrelor, 
allergic reactions), and socioeconomic factors.277,278 As such, switching 
between oral P2Y12 receptor inhibitors may be considered in selected 
cases.
P2Y12 receptor inhibitor de-escalation (i.e. switching from prasugrel/ 
ticagrelor to clopidogrel) in ACS patients may be considered as an al­
ternative strategy to the default treatment regimen in order to reduce 
the risk of bleeding events. However, it is important to note that there 
is a potential risk of increased ischaemic events with de-escalation and 
this strategy is not recommended in the first 30 days after the index 
ACS event. In the TROPICAL-ACS (Testing Responsiveness to 
Platelet Inhibition on Chronic Antiplatelet Treatment For Acute 
Coronary Syndromes) trial (44% NSTE-ACS, 56% STEMI), an approach 
of DAPT de-escalation from prasugrel to clopidogrel (at 2 weeks after 
ACS) was guided by platelet function testing and was non-inferior to 
standard treatment with prasugrel at 1 year after PCI in terms of net 
clinical benefit.279 In the Cost-effectiveness of CYP2C19 Genotype 
Guided Treatment With Antiplatelet Drugs in Patients With 
ST-segment-elevation Myocardial Infarction Undergoing Immediate 
PCI With Stent Implantation: Optimization of Treatment (POPular 
Genetics) trial, DAPT de-escalation from ticagrelor/prasugrel to clopi­
dogrel guided by CYP2C19 genotyping in ACS patients undergoing 
PPCI within the previous 48 h was non-inferior to standard treatment 
with ticagrelor or prasugrel at 12 months with respect to thrombotic 
events and resulted in a lower incidence of bleeding.280
The single-centre TOPIC (Timing of Platelet Inhibition After Acute 
Coronary Syndrome) trial used an unguided de-escalation approach in 
645 ACS patients (60% NSTE-ACS, 40% STEMI) from ticagrelor/prasu­
grel to clopidogrel after 1 month of DAPT with ticagrelor/prasugrel 
and aspirin. Net adverse clinical events and bleeding events were reduced, 
whereas the rate of ischaemic endpoints was unchanged.281 The 
TALOS-AMI (TicAgrelor versus CLOpidogrel in Stabilised Patients with 
Acute Myocardial Infarction) trial investigated unguided de-escalation in 
2697 ACS patients (46% NSTEMI/UA, 54% STEMI) from ticagrelor to clo­
pidogrel after 1 month of DAPT with ticagrelor and aspirin.282 This uni­
form unguided de-escalation strategy led to significant 12-month 
reductions in net adverse clinical events and bleeding events. The 
HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for 
Treatment of Coronary Artery Diseases Trial—Comparison of 
REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS 
Patients) trial tested a different method of de-escalation—a reduction 
in prasugrel dose rather than switching to clopidogrel. In this trial, 2338 
low-risk ACS patients <75 years of age (14% STEMI, 25% NSTEMI, and 
61% UA) were randomized to low-dose prasugrel (5 mg daily) or 
standard-dose prasugrel (10 mg daily) after 1 month of DAPT with 
standard-dose prasugrel.283 Prasugrel dose de-escalation was associated 
with fewer net adverse clinical events and bleeding events, mainly by re­
ducing bleeding events without an increase in ischaemic events. It should 
be noted that the TALOS-AMI and HOST-REDUCE-POLYTECH-ACS 
trials only included East Asian populations.


<!-- PAGE 38 -->

### Page 38

6.3.3. Summary of alternative antiplatelet strategies 
to reduce bleeding risk in the first 12 months after 
acute coronary syndrome
Considering the totality of evidence from the scientific literature, alterna­
tives to the default strategy of 12 months DAPT in patients with ACS in­
clude shortening the DAPT duration to 1 or 3–6 months (depending on 
the balance of bleeding and ischaemic risks) and de-escalating DAPT from 
prasugrel/ticagrelor-based DAPT to clopidogrel-based DAPT. However, 
it should be noted that much of the evidence on these strategies in ACS 
patients is derived from trials powered primarily for bleeding outcomes, 
many of which had a non-inferiority design and were, therefore, not pow­
ered to detect potentially relevant differences in ischaemic outcomes. The 
patient populations enrolled in these studies were also often relatively se­
lected, often excluding or under-representing the highest risk ACS pa­
tients. As such, it is important to reflect that even meta-analyses of the 
available randomized evidence cannot overcome the potential selection 
bias at the point of entry in the relevant randomized trials.
These important limitations explain why these strategies should at 
present remain considered as alternative strategies to the default of 
12 months DAPT. From a practical perspective, this means that these 
strategies should not be employed as a default strategy in the wider 
ACS population but can be considered when there is a specific motiv­
ation for their use (i.e. aiming to reduce the risk of bleeding events in 
HBR patients or if there are other specific concerns regarding a 
12-month 
potent 
P2Y12 
inhibitor-based 
DAPT 
regimen). 
De-escalation of antiplatelet therapy in the first 30 days is not recom­
mended, but de-escalation of P2Y12 receptor inhibitor therapy may be 
considered as an alternative strategy beyond 30 days after an ACS, in 
order to reduce the risk of bleeding events. DAPT abbreviation strat­
egies (followed preferably by P2Y12 inhibitor monotherapy within the 
first 12 months post-ACS) should be considered in patients who are 
event-free after 3–6 months of DAPT and who are not high ischaemic 
risk, with the duration of DAPT guided by the ischaemic and bleeding 
risks of the patient. For HBR patients, aspirin or P2Y12 receptor inhibi­
tor monotherapy after 1 month of DAPT may be considered. Please 
see Recommendation Table 6 for full details. These alternative antipla­
telet strategies to reduce bleeding risk in the first 12 months after ACS 
are also summarized in Figure 11.
0
1
3
6
9
12
Antiplatelet strategies to reduce bleeding risk in the first 12 months after ACS
Abbreviated DAPT strategies
DAPT de-escalation strategies
Time
(Months)
In HBR
patients only
1 month 
DAPT
3 month 
DAPT
6 month 
DAPT
P2Y12 inhibitor or 
aspirin monotherapy
In HBR and 
non-HBR patients
Potent P2Y12 inhibitor-based DAPT
Aspirin + Prasugrel
Aspirin + Clopidogrel
Aspirin + Ticagrelor
OR
De-escalation
Change from potent P2Y12
inhibitor to clopidogrel
Figure 11 Alternative antiplatelet strategies to reduce bleeding risk in the first 12 months after an ACS. ACS, acute coronary syndrome; DAPT, dual 
antiplatelet therapy; HBR, high bleeding risk; PFT, platelet function test.
ESC Guidelines                                                                                                                                                                                          3757


<!-- PAGE 39 -->

### Page 39

To summarise, antiplatelet strategies to reduce bleeding risk in the first 
12 months after an ACS can be divided into abbreviated DAPT strategies 
and DAPT de-escalation strategies. Twelve-month DAPT (preferably 
with prasugrel or ticagrelor) remains the default strategy for patients 
with ACS (Figure 10) and these strategies should only be used as alterna­
tives to this strategy, in general driven by a motivation to reduce the risk 
of bleeding events (i.e. if the patient is HBR or if there are other specific 
concerns regarding 12-month potent P2Y12 inhibitor-based DAPT).
The specific alternative antiplatelet strategies employed (i.e. choice 
of P2Y12 inhibitor, duration of DAPT, choice of SAPT agent) to reduce 
bleeding risk should be chosen based on the bleeding risk of the patient 
(HBR or not) and these recommendations are summarized in 
Recommendation Table 6.
Recommendation Table 5 — Recommendations for 
antiplatelet and anticoagulant therapy in acute coronary 
syndrome
Recommendations
Classa
Levelb
Antiplatelet therapy
Aspirin is recommended for all patients without 
contraindications at an initial oral LD of 150–300 mg 
(or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for 
long-term treatment.284,285
I
A
In all ACS patients, a P2Y12 receptor inhibitor is 
recommended in addition to aspirin, given as an initial 
oral LD followed by an MD for 12 months unless 
there is HBRc.238,239,263,286
I
A
A proton pump inhibitor in combination with DAPT 
is recommended in patients at high risk of 
gastrointestinal bleeding.287,288
I
A
Prasugrel is recommended in P2Y12 receptor 
inhibitor-naïve patients proceeding to PCI (60 mg 
LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged 
≥75 years or with a body weight <60 kg).239
I
B
Ticagrelor is recommended irrespective of the 
treatment strategy (invasive or conservative) 
(180 mg LD, 90 mg b.i.d. MD).238
I
B
Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is 
recommended when prasugrel or ticagrelor are not 
available, cannot be tolerated, or are 
contraindicated.263,289
I
C
If patients presenting with ACS stop DAPT to 
undergo CABG, it is recommended they resume 
DAPT after surgery for at least 12 months.
I
C
Prasugrel should be considered in preference to 
ticagrelor for ACS patients who proceed to 
PCI.244,290
IIa
B
GP IIb/IIIa receptor antagonists should be considered 
if there is evidence of no-reflow or a thrombotic 
complication during PCI.
IIa
C
In P2Y12 receptor inhibitor-naïve patients 
undergoing PCI, cangrelor may be considered.251–254
IIb
A
In older ACS patients,d especially if HBR,c clopidogrel 
as the P2Y12 receptor inhibitor may be 
considered.242,243,291
IIb
B
Continued
Pre-treatment with a P2Y12 receptor inhibitor may 
be considered in patients undergoing a primary PCI 
strategy.244,245
IIb
B
Pre-treatment with a P2Y12 receptor inhibitor may 
be considered in NSTE-ACS patients who are not 
expected to undergo an early invasive strategy 
(<24 h) and do not have HBRc.263
IIb
C
Pre-treatment with a GP IIb/IIIa receptor antagonist 
is not recommended.292
III
A
Routine pre-treatment with a P2Y12 receptor 
inhibitor in NSTE-ACS patients in whom coronary 
anatomy is not known and early invasive 
management (<24 h) is planned is not 
recommended.244,247,248,293–295
III
A
Anticoagulant therapy
Parenteral anticoagulation is recommended for all 
patients with ACS at the time of diagnosis.255,296
I
A
Routine use of a UFH bolus (weight-adjusted i.v. 
bolus during PCI of 70–100 IU/kg) is recommended 
in patients undergoing PCI.
I
C
Intravenous enoxaparin at the time of PCI should be 
considered in patients pre-treated with 
subcutaneous enoxaparin.256,261,297
IIa
B
Discontinuation of parenteral anticoagulation should 
be considered immediately after an invasive 
procedure.
IIa
C
Patients with STEMI
Enoxaparin should be considered as an alternative to 
UFH in patients with STEMI undergoing PPCI.258,261,298
IIa
A
Bivalirudin with a full-dose post PCI infusion should 
be considered as an alternative to UFH in patients 
with STEMI undergoing PPCI.259,299,300–303
IIa
A
Fondaparinux is not recommended in patients with 
STEMI undergoing PPCI.260
III
B
Patients with NSTE-ACS
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is not anticipated, 
fondaparinux is recommended.262,304
I
B
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is anticipated, enoxaparin 
should be considered as an alternative to UFH.256
IIa
B
Combining antiplatelets and OAC
As the default strategy for patients with atrial 
fibrillation and CHA2DS2-VASc score ≥1 in men and 
≥2 in women, after up to 1 week of triple 
antithrombotic therapy following the ACS event, 
dual antithrombotic therapy using a NOAC at the 
recommended dose for stroke prevention and a 
single oral antiplatelet agent (preferably clopidogrel) 
for up to 12 months is recommended.305–310
I
A
During PCI, a UFH bolus is recommended in any of 
the following circumstances: 
• if the patient is on a NOAC
• if the INR is <2.5 in VKA-treated patients.
I
C
Continued


<!-- PAGE 40 -->

### Page 40

6.4. Long-term treatment
By default, DAPT consisting of a potent P2Y12 receptor inhibitor in add­
ition to aspirin is recommended for a minimum of 12 months after an 
ACS event; exceptions include patients for whom surgery is urgently 
needed, patients in whom OAC is indicated, and patients in whom the 
risk of bleeding is too high for other reasons.238,239,263 After PCI for 
ACS, ischaemic and bleeding events both markedly decrease over time. 
Further information regarding long-term antithrombotic strategies (i.e. 
beyond 12 months) is provided in the Supplementary data online.
6.4.1. Prolonging antithrombotic therapy beyond 12 
months
Prolonged 
antithrombotic 
therapy 
options: 
See 
Supplementary data online, Figure S4; Tables S7 and S8 for additional in­
formation.314–319
In patients with an indication for OAC with VKA in 
combination with aspirin and/or clopidogrel, careful 
regulation of the dose intensity of VKA with a target 
INR of 2.0–2.5 and a time in the therapeutic range 
>70% should be considered.305–308,311
IIa
B
When rivaroxaban is used and concerns about HBR 
prevail over ischaemic stroke, rivaroxaban 15 mg o.d. 
should be considered in preference to rivaroxaban 
20 mg o.d. for the duration of concomitant SAPT or 
DAPT.307
IIa
B
In patients at HBR,c dabigatran 110 mg b.i.d. should 
be considered in preference to dabigatran 150 mg 
b.i.d. for the duration of concomitant SAPT or 
DAPT, to mitigate bleeding risk.305
IIa
B
In patients requiring anticoagulation and treated 
medically, a single antiplatelet agent in addition to an 
OAC should be considered for up to 1 year.308,312
IIa
B
In patients treated with an OAC, aspirin plus 
clopidogrel for longer than 1 week and up to 1 
month should be considered in those with high 
ischaemic risk or with other anatomical/procedural 
characteristics that are judged to outweigh the 
bleeding risk.e
IIa
C
In patients requiring OAC, withdrawing antiplatelet 
therapy at 6 months while continuing OAC may be 
considered.313
IIb
B
The use of ticagrelor or prasugrel as part of triple 
antithrombotic therapy is not recommended.
III
C
© ESC 2023
ACS, acute coronary syndrome; b.i.d., bis in die (twice a day); CHA2DS2-VASc, Congestive 
heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke or transient ischaemic 
attack, Vascular disease; DAPT, dual antiplatelet therapy; GP, glycoprotein; HBR, high 
bleeding risk; INR, international normalized ratio; i.v., intravenous; LD, loading dose; MD, 
maintenance dose; NOAC, non-vitamin K antagonist oral anticoagulant; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; OAC, oral anticoagulant; PPCI, primary 
percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, 
ST-elevation myocardial infarction; UFH, unfractionated heparin; VKA, vitamin K 
antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cHBR should be assessed in a structured manner, e.g. presence of a single major or two 
minor characteristics as defined by ARC-HBR (see section 8.2.2.3 in Supplementary data 
online). 
dThe definition of older patients varies across trials, ranging from 70 to 80 years of age. 
Frailty and comorbidities should also be taken in consideration. 
eSee Antiplatelet therapy in patients requiring oral anticoagulation Section 6.2 in 
Supplementary data online for more information on high-risk features of stent-driven 
recurrent events.
Recommendation Table 6 — Recommendations for  
alternative antithrombotic therapy regimens
Recommendations
Classa
Levelb
Shortening/de-escalation of antithrombotic therapy
In patients who are event-free after 3–6 months of 
DAPT and who are not high ischaemic risk, single 
antiplatelet therapy (preferably with a P2Y12 
receptor inhibitor) should be considered.264,268– 
271,273,274,276,313,320
IIa
A
De-escalation of P2Y12 receptor inhibitor treatment 
(e.g. with a switch from prasugrel/ticagrelor to 
clopidogrel) may be considered as an alternative 
DAPT strategy to reduce bleeding risk.279–282,321,322
IIb
A
In HBR patients, aspirin or P2Y12 receptor inhibitor 
monotherapy after 1 month of DAPT may be 
considered.276,313
IIb
B
De-escalation of antiplatelet therapy in the first 30 
days after an ACS event is not recommended.238,323
III
B
Prolonging antithrombotic therapy
Discontinuation of antiplatelet treatment in patients 
treated with an OAC is recommended after 12 
months.324,325
I
B
Adding a second antithrombotic agent to aspirin for 
extended long-term secondary prevention should be 
considered in patients with high ischaemic risk and 
without HBRc.314–318
IIa
A
Adding a second antithrombotic agent to aspirin for 
extended long-term secondary prevention may be 
considered in patients with moderate ischaemic risk 
and without HBRc.314–318
IIb
A
P2Y12 inhibitor monotherapy may be considered as 
an alternative to aspirin monotherapy for long-term 
treatment.326,327
IIb
A
© ESC 2023
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; 
OAC, oral anticoagulant. 
aClass of recommendation. 
bLevel of evidence. 
cThe evidence supporting this approach (prolonged treatment with a second 
antithrombotic agent) is based on trials in which the duration of prolonged treatment 
was as follows: mean of 23 months (COMPASS), mean of 18 months (DAPT trial), and 
median of 33 months (PEGASUS-TIMI 54). Therefore, the benefits and risks associated 
with continuation of these respective treatments beyond these time points is at present 
unclear.
ESC Guidelines                                                                                                                                                                                          3759


<!-- PAGE 41 -->

### Page 41

6.5. Antiplatelet therapy in patients 
requiring oral anticoagulation
6.5.1. Acute coronary syndrome patients requiring 
anticoagulation
In 6–8% of patients undergoing PCI, long-term OAC is indicated 
and should also be continued during the invasive procedure. 
Interruption of the long-term OAC and bridging with parenteral antic­
oagulants may lead to an increase in thrombo-embolic episodes and 
bleeds.328–330 In patients undergoing PCI, it is unknown whether it is 
safer to bridge non-vitamin K antagonist (VKA) OACs (NOACs) with 
parenteral anticoagulants or to continue NOACs without additional 
parenteral anticoagulation. In VKA-treated patients, no parenteral antic­
oagulation is needed if the international normalized ratio (INR) is 
>2.5.311,331,332 Strategies to minimize PCI-related complications in pa­
tients on OAC are listed in Table 7.
Evidence on the management of ACS patients with an indication for 
long-term OAC undergoing PCI is derived from subgroups of 
RCTs.305–309,333 Patients with STEMI (who generally carry a higher 
atherothrombotic risk) were under-represented (∼10% of the study 
populations) in the major RCTs.305,307–309 Pivotal trials testing the 
benefit of NOACs as part of the antithrombotic regimen in patients 
with an indication for long-term anticoagulation undergoing PCI are dis­
cussed in the Supplementary data online.
All of these trials were individually powered to address the safety of 
the tested strategy with regard to bleeding events, but not to reliably as­
sess differences in individual ischaemic endpoints. In a meta-analysis of all 
four NOAC-based RCTs comparing dual antithrombotic therapy (DAT) 
with triple antithrombotic therapy (TAT) in AF patients undergoing PCI 
(encompassing 10 234 patients), the primary safety endpoint 
(International Society on Thrombosis and Haemostasis major or clinically 
relevant non-major bleeding) was significantly lower with DAT vs. TAT 
(relative risk [RR] 0.66, 95% CI, 0.56–0.78; P <0.001).310 There were 
no significant differences in all-cause and CV death, stroke, or trial- 
defined major adverse cardiovascular events (MACE). However, DAT 
was associated with a borderline increased risk of MI (RR 1.22, 95% 
CI, 0.99–1.52; P = 0.07) and a significant increase in stent thrombosis 
(RR 1.59, 95% CI, 1.01–2.50; P = 0.04). This translates into an absolute 
reduction in major bleeding events of 2.3% compared with an absolute 
increase in stent thrombosis of 0.4%, without an effect on overall 
MACE. When interpreting the results of these studies, an important gen­
eral point is that the treatment effect is confounded by the use of 
NOACs in the DAT treatment arms and VKAs in the TAT arms.
Secondary analyses from the AUGUSTUS (An Open-Label, 2 × 2 
Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety 
of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin 
Placebo in Patients With Atrial Fibrillation and Acute Coronary 
Syndrome or Percutaneous Coronary Intervention) trial indicate that 
the stent thrombosis rate was highest within the first 30 days after ran­
domization, with higher rates in the non-aspirin group.334 Aspirin treat­
ment reduced ischaemic events (CV death, MI, stroke, stent 
thrombosis) but also increased major bleeding events in the first 30 
days. Aspirin treatment did not impact on ischaemic event rates after 
30 days and for up to 6 months, but did increase the bleeding risk during 
this time period.334,335 In the MASTER DAPT trial, 4579 HBR patients 
were allocated to 1 month vs. 6 months of DAPT after implantation of a 
biodegradable-polymer sirolimus-eluting stent; half of the patients pre­
sented with ACS and a third were on OAC treatment.276 A sub-analysis 
of this study reported that stopping DAPT after 1 month and stopping 
single antiplatelet therapy (SAPT) after 6 months while maintaining 
OAC was safe with respect to ischaemic events in patients taking clin­
ically indicated long-term OAC therapy.313
In patients with ACS, the indication for OAC should be re-assessed 
and treatment continued only if a compelling indication exists (e.g. par­
oxysmal, persistent, or permanent AF with a CHA2DS2-VASc 
[Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mel­
litus, Stroke or transient ischaemic attack, Vascular disease] score ≥1 in 
men and ≥2 in women; mechanical heart valve; or recent/a history of 
recurrent or unprovoked deep vein thrombosis or PE). Although 
they have been tested in a minority of patients in the major RCTs, in 
the absence of robust safety and efficacy data, the use of prasugrel or 
ticagrelor as part of TAT is not recommended. The intensity of OAC 
should be carefully monitored, with a target INR of 2.0–2.5 in patients 
treated with VKA (with the exception of individuals with a mechanical 
prosthetic valve in the mitral position).
Overall, in patients with AF without mechanical prosthetic valves or 
moderate to severe mitral stenosis, the evidence supports the use of 
NOACs over VKAs as they reduce bleeding risk. DAT with a NOAC 
at the recommended dose for stroke prevention and SAPT (preferably 
clopidogrel, which was used in >90% of patients in the major RCTs) is 
recommended as the default strategy for up to 12 months after up to 1 
week of TAT (with NOAC and DAPT consisting of aspirin and clopido­
grel) (Figure 12)—the up to 1 week duration of TAT is based on the 
median treatment duration in the investigational arm of the 
AUGUSTUS trial.308 Although none of the available RCTs were de­
signed to detect differences in ischaemic events, the numerically higher 
risk of stent thrombosis and MI is offset by the lower risk of bleeding, 
with a resultant neutral effect on total mortality.310,336–338
Table 7 Suggested strategies to reduce bleeding risk 
related to percutaneous coronary intervention
• Anticoagulant doses adjusted to body weight and renal function, 
especially in women and older patients
• Radial artery approach as default vascular access
• Proton pump inhibitors in patients on dual antiplatelet therapy at 
higher-than-average risk of gastrointestinal bleeds (i.e. history of 
gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic 
non-steroidal anti-inflammatory drug/corticosteroid use), or two or 
more of: 
(a) Age ≥65 years
(b) Dyspepsia
(c) Gastro-oesophageal reflux disease
(d) Helicobacter pylori infection
(e) Chronic alcohol use
• In patients on OAC: 
(a) PCI performed without interruption of VKAs or NOACs
(b) In patients on VKAs, do not administer UFH if INR >2.5
(c) In patients on NOACs, regardless of the timing of the last 
administration of NOACs, add low-dose parenteral 
anticoagulation (e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg)
• Aspirin is indicated but avoid pre-treatment with P2Y12 receptor 
inhibitors
• GP IIb/IIIa receptor inhibitors only for bailout or peri-procedural 
complications
© ESC 2023
GP, glycoprotein; INR, international normalized ratio; i.v., intravenous; NOAC, non-vitamin 
K antagonist oral anticoagulant; OAC, oral anticoagulation/anticoagulant; PCI, 
percutaneous coronary intervention; UFH, unfractionated heparin; VKA, vitamin K 
antagonist.


<!-- PAGE 42 -->

### Page 42

At variance with the default strategy, DAT may be shortened to 6 
months by withdrawing the antiplatelet therapy in certain patients; 
for example, in patients with multiple HBR factors. In patients with 
high ischaemic risk or other anatomical/procedural characteristics 
that outweigh the bleeding risk, TAT should be prolonged for up to 
1 month, followed by DAT for up to 12 months.
There is currently limited evidence to support the use of OAC with 
ticagrelor or prasugrel as DAT after ACS and/or PCI as an alternative to 
TAT; ticagrelor was used in 5–12% and prasugrel in 1–2% of patients, 
respectively, in the four pivotal RCTs.305,307–309,339
In medically managed ACS patients, current data support DAT over 
TAT, with a single antiplatelet agent (most commonly clopidogrel) for at 
least 6 months.308 In the AUGUSTUS trial, ∼24% of enrolled patients pre­
sented with medically managed ACS.308 In these patients, apixaban signifi­
cantly reduced bleeding events compared with a VKA, while no significant 
differences were observed in death or ischaemic events. The use of aspirin, 
in comparison to placebo, led to more bleeding events but no significant 
differences in death, hospitalization, or ischaemic events were observed.308
Regarding the need to continue with any antiplatelet agent beyond 
12 months after ACS and/or PCI in patients with an indication for 
OAC, the AFIRE (Atrial Fibrillation and Ischemic Events With 
Rivaroxaban in Patients With Stable Coronary Artery Disease) trial 
randomized 2236 AF patients treated with PCI or CABG more than 
1 year earlier or with documented CAD to receive either rivaroxaban 
monotherapy or combination therapy with rivaroxaban plus a single 
antiplatelet agent.324 Rivaroxaban monotherapy was non-inferior to 
combination therapy for the primary efficacy composite endpoint of 
stroke, systemic embolism, MI, UA requiring revascularization, or over­
all death, and superior with regard to the primary safety endpoint of 
major bleeding. This trial and another prematurely terminated trial sup­
port the recommendation to stop antiplatelet therapy after 12 months 
and continue with OAC monotherapy in most patients.325
0 weeks up to 1 week up to 1 month
6 months
3 months
9 months
12 months
Beyond
12 months
Patients with ACS and an indication for OAC
Default strategy
TAT: (N)OAC + DAPT
(Class I)
DAT: (N)OAC + SAPT
(Class I)
DAT: (N)OAC + SAPT
(Class I)
TAT: (N)OAC + DAPT
(Class IIa)
(N)OAC monotherapy
(Class I)
(N)OAC monotherapy
(Class I)
DAT: 
(N)OAC + SAPT
(Class I)
(N)OAC
monotherapy
(Class IIb)
Strategy to reduce ischaemic riska
Time from ACS
Figure 12 Antithrombotic regimens in patients with acute coronary syndrome and an indication for oral anticoagulation. ACS, acute coronary syndrome; 
ARC-HBR, Academic Research Consortium for High Bleeding Risk; DAPT, dual antiplatelet therapy; DAT, dual antithrombotic therapy; NOAC, non-vitamin 
K antagonist oral anticoagulant; OAC, oral anticoagulation/anticoagulant; SAPT, single antiplatelet therapy; TAT, triple antithrombotic therapy; VKA, vitamin K 
antagonist. OAC: preference for a NOAC over VKA for the default strategy and in all other scenarios if no contraindications. For both TAT and DAT regimens, 
the recommended doses for the NOACs are as follows: Apixaban 5 mg b.i.d., Dabigatran 110 mg or 150 mg b.i.d., Edoxaban 60 mg o.d., Rivaroxaban 15 mg or 20 
mg o.d. NOAC dose reductions are recommended in patients based on certain criteria for each of the NOACs (including renal function, body weight, concomi­
tant medications and age). SAPT: preference for a P2Y12 receptor inhibitor (usually clopidogrel) over aspirin. See Bleeding risk assessment in Supplementary data 
online, Section 8.2.2.3 for details on the ARC-HBR criteria. In addition, patients with a PRECISE-DAPT score of ≥25 are regarded as high bleeding risk. aSee 
Supplementary material online, Table S9 for examples of high-risk features of stent-driven recurrent events.
ESC Guidelines                                                                                                                                                                                          3761


<!-- PAGE 43 -->

### Page 43

6.5.2. Patients requiring vitamin K antagonists or 
undergoing coronary artery bypass surgery
In patients for whom a VKA is mandated (e.g. patients with mechanical 
prosthetic valves), DAT with a VKA and SAPT (preferably clopidogrel) 
is indicated after an up to 1-week period of TAT (with aspirin and clo­
pidogrel).306 A network meta-analysis has reported that compared 
with TAT (consisting of VKA plus aspirin and clopidogrel), DAT 
(VKA plus clopidogrel) was associated with a trend towards a reduction 
in TIMI major bleeding, with no significant difference observed in 
MACE.336
In ACS patients undergoing CABG with an established indication for 
OAC, anticoagulation in combination with SAPT should be resumed 
after CABG as soon as possible and TAT should be avoided.
6.6. Antithrombotic therapy as an adjunct 
to fibrinolysis
ISIS-2 (Second International Study Of Infarct Survival) demonstrated 
that the benefits of aspirin and fibrinolytics (i.e. streptokinase) were 
additive.340 The first dose of aspirin (162–325 mg) should be chewed 
or given i.v. and a low dose (75–100 mg) given orally daily from the 
next day thereafter. Clopidogrel added to aspirin reduces the risk of 
CV events and overall mortality in patients treated with fibrinolysis 
and should be added to aspirin following lytic therapy.341,342 Based 
on the available RCTs, there is insufficient evidence to support or refute 
improved outcomes with ticagrelor or prasugrel in patients with STEMI 
treated with thrombolytics.343–345 There is no evidence that adminis­
tration of GP IIb/IIIa receptor inhibitors improves myocardial perfusion 
or outcomes in patients treated with fibrinolysis, and it may increase 
the risk of bleeding events.346
Parenteral anticoagulation is recommended until revascularization, if 
performed. Despite an increased risk of major bleeding, the net clinical 
benefit favoured enoxaparin over UFH in the ASsessment of the 
Safety and Efficacy of a New Thrombolytic 3 (ASSENT 3) trial (n =  
6095).347 In the large Enoxaparin and Thrombolysis Reperfusion for 
Acute myocardial infarction Treatment–Thrombolysis In Myocardial 
Infarction 25 (ExTRACT–TIMI 25) trial (n = 20 506), a lower dose 
of enoxaparin was given to patients ≥75 years old and to those 
with impaired renal function (estimated creatinine clearance 
<30 mL/min). Enoxaparin was associated with a reduction in the 
risk of death and re-infarction at 30 days when compared with a 
weight-adjusted UFH dose, but at the cost of a significant increase 
in non-cerebral bleeding complications. The net clinical benefit (i.e. ab­
sence of death, non-fatal infarction, and intracranial haemorrhage) fa­
voured enoxaparin.348,349 In the large OASIS-6 trial, fondaparinux was 
superior to placebo or UFH in preventing death and re-infarction, es­
pecially in patients who received streptokinase.260,350 In a large trial 
with streptokinase, significantly fewer re-infarctions were seen with bi­
valirudin given for 48 h compared with UFH, although at the cost of a 
modest non-significant increase in non-cerebral bleeding complica­
tions.351 Bivalirudin has not been studied with fibrin-specific agents, 
and there is no evidence to support direct thrombin inhibitors as an 
adjunct to fibrinolysis.260,350
Weight-adjusted i.v. tenecteplase, low-dose aspirin, clopidogrel given 
orally, and enoxaparin i.v. followed by s.c. administration until the time 
of PCI (revascularization) represents the most extensively studied 
antithrombotic regimen as part of a pharmaco-invasive strat­
egy.184,186,213,346,352 Further information on fibrinolytic therapy, includ­
ing antithrombotic co-therapies and contraindications is provided in 
Supplementary data online, Tables S10 and S11.
6.7. Antithrombotic therapy in patients 
not undergoing reperfusion
Patients with a final diagnosis of ACS who do not undergo reperfusion 
should receive a P2Y12 receptor inhibitor in addition to aspirin, maintained 
over 12 months unless there is HBR. Among ACS patients who are med­
ically managed without revascularization, the combination of aspirin and ti­
cagrelor for up to 12 months has demonstrated a benefit in comparison to 
aspirin and clopidogrel.238,361The combination of aspirin and prasugrel can 
also be justified in preference to aspirin and clopidogrel if coronary angiog­
raphy has been performed and CAD is confirmed.239,362 As such, potent 
P2Y12 inhibitor-based DAPT is a reasonable option for patients with a final 
diagnosis of ACS not undergoing reperfusion, unless concerns over the 
bleeding risk prevail (e.g. based on ARC-HBR criteria).238,361 A DAPT regi­
men based on clopidogrel and aspirin may provide a good net clinical bene­
fit among older ACS patients.242,363 Further information regarding 
antithrombotic therapy in ACS patients who do not undergo reperfusion 
is provided in the Supplementary data online.
7. Acute coronary syndrome with 
unstable presentation
In some cases, ACS patients can present with haemodynamic com­
promise (i.e. out-of-hospital cardiac arrest [OHCA] and/or CS).
Recommendation Table 7 — Recommendations for 
fibrinolytic therapy
Recommendations
Classa
Levelb
Fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is 
recommended to initiate this treatment as soon as 
possible after diagnosis in the pre-hospital setting 
(aim for target of <10 min to lytic bolus).206,353–355
I
A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or 
reteplase) is recommended.356,357
I
B
A half-dose of tenecteplase should be considered in 
patients >75 years of age.184
IIa
B
Antiplatelet co-therapy with fibrinolysis
Aspirin and clopidogrel are recommended.340–342
I
A
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated 
with fibrinolysis until revascularization (if performed) 
or for the duration of hospital stay (up to 8 
days).260,347,348,350,357–360
I
A
Enoxaparin i.v. followed by s.c. is recommended as 
the preferred anticoagulant.347,348,357–360
I
A
When enoxaparin is not available, UFH is 
recommended as a weight-adjusted i.v. bolus, 
followed by infusion.357
I
B
In patients treated with streptokinase, an i.v. bolus of 
fondaparinux followed by an s.c. dose 24 h later 
should be considered.260
IIa
B
© ESC 2023
i.v., intravenous; s.c, subcutaneous; UFH, unfractionated heparin. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

7.1. Out-of-hospital cardiac arrest in acute 
coronary syndrome
While a small minority of all patients with ACS present as OHCA, ACS 
is the most common cause of OHCA.364–366 In patients with OHCA, 
resuscitation efforts should follow the European Resuscitation 
Council Guidelines.367 The majority of adult cardiac arrest cases are 
associated with obstructive CAD and ACS should be included in the 
differential diagnosis.365,368 Therefore, ICA can be part of the post- 
resuscitation management for patients who are estimated to have a 
high probability of acute coronary occlusion (e.g. persistent 
ST-segment elevation or equivalents and/or haemodynamic and/or 
electrical instability).367,369 Neurological status (e.g. comatose vs. non- 
comatose) and survival probability (i.e. favourable benefit/risk ratio vs. 
futility) should also be included in the decision-making algorithm.
Despite the lack of dedicated trials, patients with return of spontan­
eous circulation (ROSC) and persistent ST-segment elevation should, in 
general, undergo a PPCI strategy (immediate ICA and PCI if indicated), 
based on the overall clinical situation and a reasonable benefit/risk ratio. 
Based on registry reports, emergent ICA and PCI are associated with 
good outcomes in this setting, particularly in patients who are non- 
comatose at initial assessment.368,370,371
The management of patients with ROSC without evidence of 
ST-segment elevation should be individualized according to haemo­
dynamic and neurological status. In OHCA with an initial shockable 
rhythm and without ST-segment elevation or equivalents and without 
CS, routine immediate ICA is not superior to a delayed invasive strategy 
based on data from the COACT (Coronary Angiography after Cardiac 
Arrest) and TOMAHAWK (Immediate Unselected Coronary 
Angiography Versus Delayed Triage in Survivors of Out-of-hospital 
Cardiac Arrest Without ST-segment Elevation) RCTs.372,373 Smaller, 
underpowered trials (EMERGE [EMERGEncy versus delayed coronary 
angiogram in survivors of out-of-hospital cardiac arrest with no obvious 
non-cardiac cause of arrest], PEARL [A Pilot Randomized Clinical Trial 
of Early Coronary Angiography Versus No Early Coronary 
Angiography for Post-Cardiac Arrest Patients Without ECG ST 
Segment Elevation], and COUPE [Coronariography in OUt of 
hosPital Cardiac arrEst]) have also pointed to the same conclu­
sion.372–377 Further detail on these trials is provided in the 
Supplementary data online, Evidence Tables.
Based on data from the COACT and TOMAHAWK trials, it appears 
reasonable to delay ICA in haemodynamically stable patients with re­
suscitated OHCA without ST-segment elevation or equivalents. Initial 
evaluation in the ED or intensive cardiac care unit (ICCU) should focus 
on excluding non-coronary causes (cerebrovascular events, respiratory 
failure, non-cardiogenic shock, PE, or intoxication). Echocardiography is 
also useful in the evaluation of these patients. The decision to perform 
selective coronary angiography (and PCI if indicated) should also con­
sider factors associated with poor neurological outcome and the likeli­
hood of ACS.
In patients who remain unresponsive after ROSC, monitoring of 
core temperature and actively preventing fever (defined as a tempera­
ture >37.7°C) is recommended to improve neurological out­
come.367,378–385 A recent study compared device-based temperature 
control of 36°C for 24 h followed by targeting of 37°C for either 12 
or 48 h (for total intervention times of 36 and 72 h, respectively) or un­
til the patient regained consciousness in 789 patients with OHCA of a 
presumed cardiac cause (∼45% with ST segment elevation on ECG; im­
mediate coronary angiography performed in 92% and PCI in 43%). This 
study reported comparable outcomes with both strategies with 
respect to the primary endpoint (death, severe disability, or coma) at 
90 days.384 In all comatose survivors, evaluation of neurological progno­
sis no earlier than 72 h after admission is recommended.367,378–383,386
7.1.1. Systems of care
There is increasing evidence suggesting that specialized hospitals for pa­
tients following OHCA (referred to as cardiac arrest centres) may be 
associated with clinical benefits.367 See Supplementary data online, 
Section 7.1.1 for expanded information on this topic.
7.2. Cardiogenic shock complicating acute 
coronary syndrome
Early revascularization with either PCI or CABG is recommended for 
patients with AMI complicated by CS, based on the results of the 
SHOCK (Should We Emergently Revascularize Occluded Coronaries 
Recommendation Table 8 — Recommendations for 
cardiac arrest and out-of-hospital cardiac arrest
Recommendations
Classa
Levelb
Cardiac arrest and OHCA
A PPCI strategy is recommended in patients with 
resuscitated cardiac arrest and an ECG with 
persistent ST-segment elevation (or 
equivalents).368,387,388
I
B
Routine immediate angiography after resuscitated 
cardiac arrest is not recommended in 
haemodynamically stable patients without persistent 
ST-segment elevation (or equivalents).373–377
III
A
Temperature control
Temperature control (i.e. continuous monitoring of 
core temperature and active prevention of fever [i.e. 
>37.7°C]) is recommended after either 
out-of-hospital or in-hospital cardiac arrest for adults 
who remain unresponsive after return of 
spontaneous circulation.378–385,389
I
B
Systems of care
It is recommended that healthcare systems 
implement strategies to facilitate transfer of all 
patients in whom ACS is suspected after resuscitated 
cardiac arrest directly to a hospital offering 24/7 PPCI 
via one specialized EMS.390–392
I
C
Transport of patients with OHCA to a cardiac arrest 
centre according to local protocols should be 
considered.391,393
IIa
C
Evaluation of neurological prognosis
Evaluation of neurological prognosis (no earlier than 
72 h after admission) is recommended in all 
comatose survivors after cardiac arrest.386
I
C
© ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; EMS, emergency medical 
services; OHCA, out-of-hospital cardiac arrest; PPCI, primary percutaneous coronary 
intervention. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3763


<!-- PAGE 45 -->

### Page 45

for Cardiogenic Shock) trial.394–396 While most patients will proceed to 
PCI at the time of diagnostic angiography if myocardial revascularization 
is indicated, surgical revascularization represents a valuable treatment 
option in patients in whom attempted PCI of the IRA has failed or if 
the coronary anatomy is not amenable to PCI.395,397,398 In the presence 
of CS due to AMI-related mechanical complications, surgical or percu­
taneous treatment may also be indicated and the strategy should be 
decided based on discussion between members of the Heart Team.
In the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock 
II) trial, intra-aortic balloon pump (IABP) use was not associated with 
lower 30-day mortality.399 Therefore, in the absence of mechanical com­
plications, the routine use of an IABP is not recommended for CS com­
plicating AMI. The role of mechanical circulatory devices (veno-arterial 
extracorporeal membrane oxygenation [VA-ECMO], micro-axial 
pump) in the AMI setting is not well established and large-scale rando­
mized trials are warranted.400,401 The Extracorporeal Membrane 
Oxygenation in the Therapy of Cardiogenic Shock trial randomized 
122 patients (51% with STEMI) with rapidly deteriorating or severe CS 
to either immediate implementation of VA-ECMO or an initially conser­
vative strategy (which allowed for downstream use of VA-ECMO).402
The immediate implementation of VA-ECMO did not result in improved 
clinical outcomes.402 However, the interpretation of this trial is challen­
ging because of the ∼40% crossover rate to VA-ECMO in the conserva­
tive arm, the inclusion of heterogenous phenotypes of CS, and inclusion 
of crossover in the combined primary endpoint. As a result of these lim­
itations, this trial cannot adequately answer if mechanical circulatory sup­
port (MCS) is able to reduce mortality in this setting.
It is important to note that while there is still a lack of high-quality 
randomized data supporting the use of MCS in ACS patients presenting 
with CS, some recent observational analyses have reported that the use 
of intravascular LV assist devices may be associated with an increased 
risk of adverse events in comparison to IABP in this setting, including 
mortality and bleeding.401,403 Therefore, while MCS may be considered 
in selected patients with ACS and severe/refractory CS, caution should 
be exercised in this regard until further randomized data are available. 
The management of patients with CS complicating AMI and MVD is 
presented in Section 10.
8. Management of acute coronary 
syndrome during hospitalization
8.1. Coronary care unit/intensive cardiac 
care unit
Following reperfusion, it is recommended to admit high-risk ACS pa­
tients (including all STEMI patients) to a coronary care unit (CCU) or 
ICCU. Conditions in patients with ACS that act as acute risk modifiers 
include ongoing myocardial ischaemia (e.g. failed reperfusion), acute HF 
and/or hypoperfusion, CS, cardiac arrest with coma, malignant (life- 
threatening) cardiac arrhythmias, high-degree atrioventricular block, 
and acute renal failure (with oliguria). All ICCUs must have appropriate 
diagnostic facilities to guide the delivery of pharmacological and invasive 
treatment. The staff should be thoroughly familiar with the manage­
ment of all aspects of ACS, including: arrhythmias, HF, mechanical 
circulatory support, invasive and non-invasive haemodynamic monitor­
ing (arterial and pulmonary artery pressures), respiratory monitoring, 
mechanical ventilation, and temperature control.408 The CCU/ICCU 
should also be able to manage patients with renal and pulmonary dis­
ease. The desirable organization, structure, and criteria of CCU/ 
ICCUs have been detailed in an ESC–Acute CardioVascular Care 
Association position paper.408
8.1.1. Monitoring
It is recommended to initiate ECG monitoring as soon as possible in all 
patients with ACS in order to detect life-threatening arrhythmias and al­
low prompt defibrillation if indicated. ECG monitoring for arrhythmias 
and new ST-segment elevation/depression is recommended for at least 
24 h after symptom onset in all high-risk patients with ACS, including 
all STEMI patients.409 Longer monitoring could be considered in patients 
at intermediate to high risk of cardiac arrhythmias (i.e. those with more 
than one of the following criteria: haemodynamically unstable, presenting 
with major arrhythmias, left ventricular ejection fraction [LVEF] <40%, 
failed reperfusion, additional critical coronary stenoses of major vessels, 
or complications related to PCI). Further monitoring for arrhythmias will 
be dependent on the estimated risk. When a patient leaves the ICCU or 
equivalent, monitoring may be continued by telemetry. It is recom­
mended that personnel adequately equipped and trained to manage life- 
threatening arrhythmias and cardiac arrest accompany patients who are 
transferred between facilities during the time window in which they re­
quire continuous rhythm monitoring.409
8.1.2. Ambulation
Early ambulation (i.e. out of bed on day 1) is recommended in the ma­
jority of patients with ACS. This is facilitated by using radial access for 
Recommendation Table 9 — Recommendations for 
cardiogenic shock
Recommendations
Classa
Levelb
Immediate coronary angiography and PCI of the IRA 
(if indicated) is recommended in patients with CS 
complicating ACS.394,396,404
I
B
Emergency CABG is recommended for ACS-related 
CS if PCI of the IRA is not feasible/unsuccessful.394,395
I
B
In cases of haemodynamic instability, emergency 
surgical/catheter-based repair of mechanical 
complications of ACS is recommended, based on 
Heart Team discussion.
I
C
Fibrinolysis should be considered in STEMI patients 
presenting with CS if a PPCI strategy is not available 
within 120 min from the time of STEMI diagnosis and 
mechanical complications have been ruled out.184,354
IIa
C
Continued
In patients with ACS and severe/refractory CS, 
short-term mechanical circulatory support may be 
considered.402
IIb
C
The routine use of an IABP in ACS patients with CS 
and without mechanical complications is not 
recommended.399,405–407
III
B
© ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CS, cardiogenic 
shock; IABP, intra-aortic balloon pump; IRA, infarct-related artery; PPCI, primary 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

invasive management. Patients with extensive myocardial damage, HF, 
hypotension, or arrhythmias may initially rest in bed before assessment 
of myocardial function and clinical stabilization. Prolongation of bed rest 
and limitation of physical activity may occasionally be required in pa­
tients with large infarcts or severe complications.
8.1.3. Length of stay in the intensive cardiac care unit
The optimal length of stay in the ICCU and hospital should be individua­
lized according to the patient’s clinical situation, taking into account 
their baseline cardiac risk and comorbidities, baseline mental/functional 
status, and social support.410,411 Of note, the majority of adverse in- 
hospital events occur early after admission and the initiation of 
treatment.
8.2. In-hospital care
8.2.1. Length of hospital stay
The impact of both successful reperfusion and knowledge of the coron­
ary anatomy (due to increasing rates of ICA) has resulted in progressive 
reductions in the length of stay after ACS, alongside significant reduc­
tions in 30-day mortality, suggesting that discharge within 72 h is not as­
sociated with late mortality.411–417 Candidates for early discharge after 
PCI can be identified using simple criteria.413,414 In one study, patients 
meeting the following criteria were considered to be ‘low risk’ and suit­
able for early discharge: age <70 years, LVEF >45%, one- or two-vessel 
disease, successful PCI, and no persistent arrhythmias.413 A recently 
published consensus document also presents a template and flow chart 
to support reasonable decision-making regarding post-procedural 
length of stay for a broad spectrum of patients undergoing PCI.418
Early (i.e. same day) transfer to a local hospital following successful 
PPCI is routine practice. This can be done safely under adequate mon­
itoring and supervision in selected patients (i.e. patients without signs or 
symptoms consistent with ongoing myocardial ischaemia, without ar­
rhythmias, who are haemodynamically stable, who are not requiring 
vasoactive or mechanical support, and who are not scheduled for fur­
ther revascularization).419
8.2.2. Risk assessment
Early and late risk stratification soon after presentation is useful to aid 
decision-making in patients presenting with ACS.
8.2.2.1. Clinical risk assessment
All patients with ACS (in particular, patients with STEMI) should have 
an early assessment of short-term risk, including an evaluation of the ex­
tent of myocardial damage, the achievement of successful reperfusion, 
and the presence of clinical markers of high risk of further events (i.e. 
older age, tachycardia, hypotension, Killip class >I, anterior MI, previous 
MI, elevated initial serum creatinine, history of HF, peripheral arterial 
disease or anaemia). Several risk scores have been developed based 
on readily identifiable parameters in the acute phase before reperfu­
sion.420,421 A number of prognostic models that aim to estimate the 
longer-term risk of all-cause mortality, or the combined risk of all-cause 
mortality or MI, have also been developed. These models have been 
formulated into clinical risk scores and, among these, the GRACE risk 
score offers the best discriminative performance and is therefore re­
commended for risk assessment.48,421–425 Additional information re­
garding the GRACE score is provided in the Supplementary data online.
8.2.2.2. Imaging risk assessment
LV dysfunction is a key prognostic factor for patients with ACS.426 It is 
recommended that the LVEF is determined before hospital discharge in 
all patients with ACS. Routine echocardiography after PPCI is recom­
mended to assess resting LV, RV, and valvular function. In addition, 
echocardiography can be used to exclude early post-infarction mechan­
ical complications and LV thrombus. In the limited number of cases in 
which echocardiography is suboptimal or inconclusive, CMR may be 
a valuable alternative.427–431
In patients presenting days after an acute ACS event with a com­
pleted MI, the presence of recurrent angina or documented ischaemia 
and proven viability in a large myocardial territory may help to guide the 
strategy of planned revascularization of an occluded IRA.192,432,433
In patients with a pre-discharge LVEF of ≤40%, re-evaluation of the 
LVEF 6–12 weeks after complete revascularization and optimal medical 
therapy is recommended to assess the potential need for primary pre­
vention implantable cardioverter defibrillator (ICD) implantation.434
Additional parameters that are measured by imaging in these patients 
and that have been used as endpoints in clinical trials include: (i) infarct 
size (CMR, SPECT, and positron emission tomography); (ii) myocar­
dium at risk (SPECT, CMR); (iii) MVO (CMR); and (iv) intra-myocardial 
haemorrhage (CMR). Infarct size, MVO and intra-myocardial haemor­
rhage are predictors of both long-term mortality and HF in STEMI sur­
vivors.435–438
8.2.2.3. Biomarkers for risk assessment
Beyond diagnostic utility, initial cTn levels add prognostic information in 
addition to clinical and ECG variables in terms of predicting the risk of 
short- and long-term mortality. While hs-cTn T and I have comparable 
diagnostic accuracy, hs-cTn T has slightly greater prognostic accuracy 
regarding mortality.61,439–441 Serial measurements are useful to identify 
peak levels of cTn for risk stratification purposes in patients with estab­
lished MI. The higher the hs-cTn levels, the greater the risk of 
death.31,55,442 However, evidence is limited regarding the optimal 
time points of serial hs-cTn measurement. Serum creatinine and 
eGFR should also be determined in all patients with ACS because 
they affect prognosis and are key elements of the GRACE risk score.443
Similarly, natriuretic peptides (brain natriuretic peptide [BNP] and 
N-terminal pro-BNP [NT-pro BNP]) provide prognostic information 
in addition to cTn regarding the risk of death and acute HF, and the de­
velopment of AF.444 Additional information on the use of biomarkers 
for this purpose is presented in the Supplementary data online.
8.2.2.4. Bleeding risk assessment
Major bleeding events are associated with increased mortality in pa­
tients with ACS.231 Further detail on scores that may be considered 
for estimation of bleeding risk is provided in the Supplementary data 
online, including Table S12.
8.2.2.5. Integrating ischaemic and bleeding risks
Major bleeding events affect prognosis in a similar way to spontaneous 
ischaemic complications.445,446 Given the trade-off between ischaemic 
and bleeding risks for any antithrombotic regimen, risk scores may be 
useful to tailor antithrombotic duration and intensity, in order to maxi­
mize ischaemic protection and minimize bleeding risk in the individual 
patient. Specific risk scores have been developed for patients on 
DAPT following PCI, in the settings of both CCS and ACS. Further de­
tail on available scores is provided in the Supplementary data online.
ESC Guidelines                                                                                                                                                                                          3765


<!-- PAGE 47 -->

### Page 47

### 9 Technical aspects of invasive

strategies
9.1. Percutaneous coronary intervention
9.1.1. Vascular access
Timely PCI with concomitant antithrombotic drugs has reduced the 
ischaemic risk in patients with ACS. However, this strategy is also 
associated with an increased bleeding risk, which affects prognosis 
at least as much as ischaemic complications and is associated with im­
paired survival.448,449 Among patients undergoing PCI, access-related 
bleeding accounts for 30–70% of total bleeding events.450 There is 
strong evidence demonstrating that reducing access-site bleeding 
events with the use of radial access translates into significant clinical 
benefits.448,449 The largest randomized trials on this topic in patients 
with ACS are the RadIal Vs femorAL access for coronary intervention 
(RIVAL) trial with 7021 ACS patients and the Minimizing Adverse 
Haemorrhagic Events by TRansradial Access Site and Systemic 
Implementation of angioX (MATRIX) trial with 8404 ACS patients 
(47.6% with STEMI).451,452 These trials have demonstrated signifi­
cantly lower rates of access site-related bleeding, surgical access 
site repair, and blood transfusion with radial compared with femoral 
access. In the MATRIX trial, no significant interaction was observed 
between the type of ACS and the benefit associated with the radial 
approach, suggesting that the results of this trial can be extended 
to patients across the entire spectrum of ACS.453 In a cost- 
effectiveness analysis of the MATRIX trial, radial access was also as­
sociated with significant savings in terms of quality-adjusted life years 
and PCI-related costs.454 Therefore, radial access is recommended as 
the preferred approach in ACS patients undergoing invasive assess­
ment with or without PCI. However, femoral access may still be se­
lectively chosen instead of radial access in certain patients (i.e. 
depending on the haemodynamic situation and other technical as­
pects during the index PCI procedure).
9.1.2. Intravascular imaging/physiology of the 
infarct-related artery
9.1.2.1. Intravascular imaging
As a diagnostic tool, intravascular imaging is useful in ACS patients 
without significant obstructive CAD on coronary angiography. 
Excluding an atherothrombotic cause in the main coronary arteries 
for the ACS may have important clinical implications, not only for im­
mediate invasive management but also for potentially lifelong 
antithrombotic therapies. Intravascular imaging is also useful in cases 
where there is ambiguity regarding the culprit lesion. Culprit lesion 
ambiguity can be present in more than 30% of patients with sus­
pected NSTE-ACS and over 10% of patients may have multiple cul­
prit lesions.455,456 The recommendations for intravascular imaging 
in ACS are presented in Figure 13.
The role of intravascular imaging is well established as a tool to guide 
and optimize PCI. Evidence in support of intravascular ultrasound 
(IVUS) guidance in ACS generally derives from subgroup analyses of all- 
comers trials. Meta-analysis of available randomized trials confirms the 
superiority of IVUS guidance in the reduction of MACE, although a de­
finitive, large-scale, multinational trial is missing.457–459 Smaller RCTs 
have evaluated the role of optical coherence tomography (OCT) 
(see Supplementary data online).460
Recommendation Table 10 — Recommendations for 
in-hospital management
Recommendations
Classa
Levelb
Logistical issues for hospital stay
It is recommended that all hospitals participating in 
the care of high-risk patients have an ICCU/CCU 
equipped to provide all required aspects of care, 
including treatment of ischaemia, severe heart failure, 
arrhythmias, and common comorbidities.
I
C
It is recommended that high-risk patients (including all 
STEMI patients and very high-risk NSTE-ACS 
patients) have ECG monitoring for a minimum of 24 h.
I
C
It is recommended that high-risk patients with 
successful reperfusion therapy and an uncomplicated 
clinical course (including all STEMI patients and very 
high-risk NSTE-ACS patients) are kept in the CCU/ 
ICCU for a minimum of 24 h whenever possible, after 
which they may be moved to a step-down monitored 
bed for an additional 24–48 h.
I
C
Discharge of selected high-risk patients within 48– 
72 h should be considered if early rehabilitation and 
adequate follow-up are arranged.411,413,415,447
IIa
A
Same-day transfer in selected stable patients after 
successful and uneventful PCI should be 
considered.419
IIa
C
Imaging
Routine echocardiography is recommended during 
hospitalization to assess regional and global LV 
function, detect mechanical complications, and 
exclude LV thrombus.
I
C
When echocardiography is suboptimal/inconclusive, 
CMR imaging may be considered.
IIb
C
© ESC 2023
ACS, acute coronary syndrome; CCU, cardiac care unit; CMR, cardiac magnetic resonance; 
ECG, electrocardiogram; ICCU, intensive cardiac care unit; LV, left ventricular; NSTE-ACS, 
non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

9.1.2.2. Intravascular physiology
Intracoronary physiology is increasingly being used in patients with 
ACS to assess the haemodynamic significance of intermediate severity 
non-IRA stenoses (see Section 10). However, PCI of the IRA should 
not be deferred based on invasive epicardial functional assessment 
in patients with ACS. The coronary microcirculation begins to re­
cover within 24 h of PPCI and acute functional assessment of the 
IRA may underestimate the true haemodynamic severity of the cor­
onary stenosis.461 Beyond 1 week from the acute event, fractional 
flow reserve (FFR) measurement has been reported to reliably predict 
abnormal nuclear imaging results.462 Additional information about the 
role of intracoronary physiology in the IRA is presented in the 
Supplementary data online.
9.1.3. Timing of revascularization with percutaneous 
coronary intervention
In some patients with ACS undergoing ICA, an initial conservative man­
agement strategy with optimized guideline-directed medical therapy 
may be considered on a case-by-case basis. The specific circumstances 
include ACS patients with small calibre vessels, an occluded small side 
branch, or concerns regarding non-compliance with antithrombotic 
Working diagnosis: ACS
Clear culprit lesion,
suitable for PCI
No clear culprit lesion
PCI of culprit lesion
Consider further investigations as required
Treat as per imaging findings
Intravascular imaging to guide PCI
(Class lla)
Intravascular imaging
Potential ambiguous 
angiographic findings 
Multivessel disease
Hazy lesion/calcification 
Tortuosity/eccentricity
Potential further investigations
Left ventriculography
Echocardiography
Cardiac MRI
Potential intravascular imaging findings
Coronary plaque pathology
Erosion
Nodule
Rupture
IVUS
or
OCT
Intravascular imaging
(preferably OCT) in patients with ambiguous culprit lesions
(Class llb)
Coronary angiography
SCAD
No lesion
Figure 13 A practical algorithm to guide intravascular imaging in acute coronary syndrome patients. ACS, acute coronary syndrome; IVUS, intravascular 
ultrasound; MRI, magnetic resonance imaging; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; SCAD, spontaneous coronary 
artery dissection.
ESC Guidelines                                                                                                                                                                                          3767


<!-- PAGE 49 -->

### Page 49

therapy. In the context of complex CAD and anticipated complex PCI, 
an initial conservative strategy in medically stabilized patients without 
ongoing symptoms allows time for Heart Team discussion regarding 
the optimal revascularization strategy.
9.1.4. Balloons and stents
New-generation DES are associated with superior safety and improved 
efficacy compared with bare metal stents (BMS) and first-generation 
DES. The Norwegian Coronary Stent Trial (NORSTENT)—the largest 
clinical trial comparing outcomes of patients treated with new- 
generation DES or BMS—reported that the primary endpoint of death 
or MI was comparable in both treatment groups. Both target lesion re­
vascularization (TLR) and stent thrombosis were reduced in the DES 
group and there was no treatment effect by ACS presentation inter­
action for the primary endpoint.463 The COMFORTABLE-AMI 
(Comparison of Biolimus Eluted From an Erodible Stent Coating 
With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) 
and EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal 
Stents in ST Segment Elevation Myocardial Infarction) trials have also 
reported the clinical superiority of DES over BMS in terms of lower 
rates of re-infarction, target lesion revascularization, and stent throm­
bosis.464,465 This clinical benefit was preserved at longer-term follow- 
up.466–468
A strategy of drug-coated balloon (DCB) angioplasty without 
stenting has also been proposed for patients with NSTE-ACS. In the 
small, 
prospective, 
randomized, 
single-centre 
REVELATION 
(REVascularization With PaclitaxEL-Coated Balloon Angioplasty 
Versus Drug-Eluting Stenting in Acute Myocardial InfarcTION) trial, 
DCB PCI vs. DES PCI was investigated in 120 patients undergoing 
PPCI. The primary endpoint of target vessel FFR at 9 months was 
not significantly different between the two groups.469 In the small 
PEPCAD NSTEMI (Bare Metal Stent Versus Drug Coated Balloon 
With Provisional Stenting in Non-ST-Elevation Myocardial Infarction) 
trial, 210 patients were randomized to compare a DCB with primary 
stent treatment (BMS or DES).470 During a mean follow-up period of 
9.2 months, DCB treatment was non-inferior to treatment with a stent, 
with a target lesion failure (primary study endpoint) rate of 3.8% vs. 
6.6% (P = 0.53). Given the limitations of these studies (in particular, 
the relatively small sample sizes), the use of DCB in NSTE-ACS requires 
further investigation in order to better inform future guideline 
recommendations.471
9.1.5. Embolic protection and microvascular salvage 
strategies
9.1.5.1. Thrombus aspiration
Large RCTs have failed to demonstrate a clinical benefit with routine 
manual thrombus aspiration in comparison to conventional PPCI.472– 
474 In an individual patient data meta-analysis, thrombus aspiration 
was associated with fewer CV deaths and with more strokes or transi­
ent ischaemic attacks in the subgroup of patients with high thrombus 
burden (TIMI thrombus Grade 3).475 However, in a sub-analysis from 
TOTAL (a Trial of routine aspiration ThrOmbecTomy with PCI vs. 
PCI ALone in patients with STEMI), routine thrombus aspiration did 
not improve outcomes at 1 year and was also associated with an in­
creased rate of stroke in patients with high thrombus burden.476 In pa­
tients with NSTE-ACS and thrombus-containing lesions, PCI with 
adjunctive thrombus aspiration was not associated with a reduction 
in MVO 4 days after the index procedure or with fewer MACE after 
up to 1 year of follow-up.477 Based on these data, routine thrombus 
aspiration is not recommended, but in cases of large residual thrombus 
burden after opening the vessel with a guide wire or a balloon, throm­
bus aspiration may be considered.
9.1.5.2. Interventions to protect the microcirculation
The damage inflicted on the myocardium during AMI is the result of is­
chaemia and subsequent reperfusion (ischaemia/reperfusion injury). In 
patient-level pooled analyses, infarct size and MVO are independent 
predictors of long-term mortality and HF in survivors of 
STEMI.436,478 Strategies to reduce ischaemia/reperfusion injury in gen­
eral (and MVO in particular) remain an unmet clinical need. Further in­
formation regarding interventions to protect the microcirculation that 
are under clinical or experimental investigation is presented in the 
Supplementary data online.
9.2. Coronary artery bypass grafting
9.2.1. Indication and timing of coronary artery bypass 
grafting in acute coronary syndrome patients
There are no dedicated RCTs comparing percutaneous vs. surgical re­
vascularization in patients with ACS. In the setting of STEMI, CABG 
should be considered only when PPCI is not feasible, particularly in 
the presence of ongoing ischaemia or large areas of jeopardized 
myocardium.479
In patients requiring immediate revascularization in the setting of 
very high-risk NSTE-ACS, PCI is usually preferred for reasons of time­
liness, unless concomitant mechanical complications dictate a prefer­
ence for surgical intervention.
In other patients with ACS, the choice of revascularization modality 
should be made according to the number of diseased vessels and  the gen­
eral principles of myocardial revascularization.250 In patients with MVD, 
the choice of revascularization modality will be influenced by the overall 
anatomical disease complexity and the presence of comorbidities (includ­
ing diabetes) in patients with low predicted surgical risk and mortality who 
are considered suitable for either modality. This is based on data from two 
large-scale individual patient meta-analyses.480,481
9.2.2. Technical considerations specific to acute 
coronary syndrome patients
The patient profile, including the need for emergency or extremely ex­
peditious revascularization, may influence both the technique of CABG 
(including on-pump beating heart CABG) and the choice and use of 
CABG conduits. The need for prompt surgical revascularization in 
emergency circumstances does not facilitate the use of full arterial re­
vascularization due to the prolonged period required for graft harvest­
ing. Accordingly, the use of total venous graft-based CABG or the use 
of single left internal mammary artery plus additional venous grafts may 
be useful in this setting.397
9.3. Spontaneous coronary artery 
dissection
Spontaneous coronary artery dissection (SCAD) is an infrequent cause 
of ACS in general but accounts for a significant proportion of ACS cases 
in young/middle-aged women.482 The pathophysiology underlying SCAD 
is different to that of Type 1 MI and there are some differences in its man­
agement and outcomes. For these reasons, it is of paramount importance 
that an accurate diagnosis is established. Until evidence from ongoing 
prospective trials becomes available, patients with SCAD should receive 
the same pharmacological therapy as other ACS patients.483


<!-- PAGE 50 -->

### Page 50

9.3.1. Intravascular imaging
There are no RCTs to guide management strategies in patients with 
SCAD. The use of intravascular imaging is based on observations re­
ported from clinical cohort studies and expert opinion.482,484,485 In 
cases of diagnostic uncertainty after angiography, the use of intracor­
onary imaging with OCT or IVUS has to be carefully considered. 
There should be sufficient diagnostic uncertainty to justify coronary 
instrumentation, and even if this is the case, other factors like vessel 
tortuosity, vessel diameter, and a distal lesion location may prohibi­
tively increase the risk.482 If the decision is made to perform intravas­
cular imaging, it is imperative to ensure the guide wire is located within 
the true lumen of the coronary artery before advancing the imaging 
catheter.482 In patients with a diagnosis of SCAD on angiography 
and a plan for medical therapy, additional coronary instrumentation 
and intravascular imaging is not recommended on safety 
grounds.482,484,485
9.3.2. Revascularization
Conservative medical management, as opposed to PCI, is generally re­
commended for patients with SCAD.482 In an international case series, 
coronary complications following PCI occurred in >30% of pa­
tients.486–488 In a pooled analysis of three SCAD-PCI cohorts including 
215 patients (94% female) drawn from Dutch, Spanish, and UK regis­
tries, and a matched cohort of conservatively managed SCAD patients 
(n = 221), PCI was associated with complications in ≈40% of cases (in­
cluding 13% with serious complications). PCI is recommended only for 
SCAD with associated symptoms and signs of ongoing myocardial is­
chaemia, a large area of myocardium in jeopardy, and reduced ante­
grade flow. Useful strategies for these patients may include minimal 
plain balloon angioplasty to restore flow, followed by a conservative 
strategy, targeted stenting to seal the proximal and distal ends of the 
dissection, and/or extended stent lengths to prevent propagation of 
the haematoma. In patients with SCAD, CABG is recommended 
when dissection affects the left main or two proximal vessels, if PCI 
is not feasible or unsuccessful, and if there are symptoms and signs of 
ongoing myocardial ischaemia. In a small observational study, patients 
with SCAD treated with CABG had favourable early clinical outcomes, 
with an event rate up to 5 years similar to that of patients treated con­
servatively, despite a significant (68%) rate of graft occlusion at 5 
years.486 The rate of graft occlusion over time can be explained by 
the fact that CABG in these patients may be technically challenging as 
the dissected coronary artery is more prone to anastomosis failure, 
and because spontaneous healing over time may restore the flow in 
the anastomosed vessel.486,489 For this reason, vein grafts should be 
considered in these patients in order to preserve arterial conduits for 
future use.485
10. Management of patients with 
multivessel disease
Approximately half of ACS patients have coronary MVD.500
Management of non-IRA disease varies depending on the clinical 
setting.
10.1. Management of multivessel disease in 
acute coronary syndrome complicated by 
cardiogenic shock
Cardiogenic shock may occur in up to 4–11% of ACS patients, and oc­
curs more frequently in the presence of complete coronary occlu­
sion.501,502 Ischaemia-related HF, acute severe mitral regurgitation, 
and mechanical complications are the major precipitating causes of 
CS in ACS. Irrespective of the mode of presentation (i.e. with or with­
out ST-segment elevation or equivalent ECG patterns), these patients 
should be transferred as soon as possible to a tertiary care centre (e.g. a 
shock centre) where ICA can be performed, supported by specialists 
with relevant experience (the Shock Team).503,504
In the SHOCK trial, which compared emergency revascularization 
with initial medical stabilization in 302 patients with acute MI compli­
cated by CS, ∼60% had anterior MI and 85% had MVD.394 Among 
the patients assigned to emergency revascularization, 64% underwent 
PCI and 36% underwent CABG. There were no differences in mortality 
at 30 days (primary endpoint), but at 6 months mortality was lower in 
the group assigned to revascularization than in the group assigned to 
medical therapy. Based on this evidence, immediate coronary angiog­
raphy, and PCI if feasible, is recommended in patients with acute MI 
complicated by CS. In patients with coronary anatomy unsuitable for 
PCI, emergency CABG is recommended.394
Nearly 80% of ACS patients with CS have MVD. Based on the Culprit 
Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock 
(CULPRIT-SHOCK) trial including ACS patients (both with and with­
out ST-segment elevation or equivalent), PCI during the index 
Recommendation Table 11 — Recommendations for 
technical aspects of invasive strategies
Recommendations
Classa
Levelb
Radial access is recommended as the standard 
approach, unless there are overriding procedural 
considerations.451,452
I
A
PCI with stent deployment in the IRA during the 
index procedure is recommended in patients 
undergoing PPCI.490–494
I
A
Continued
Drug-eluting stents are recommended in preference 
to bare metal stents in all cases.463,466,468
I
A
In patients with spontaneous coronary artery 
dissection, PCI is recommended only for patients 
with symptoms and signs of ongoing myocardial 
ischaemia, a large area of myocardium in jeopardy, 
and reduced antegrade flow.
I
C
Intravascular imaging should be considered to guide 
PCI.495–499
IIa
A
Coronary artery bypass grafting should be 
considered in patients with an occluded IRA when 
PPCI is not feasible/unsuccessful and there is a large 
area of myocardium in jeopardy.
IIa
C
Intravascular imaging (preferably optical coherence 
tomography) may be considered in patients with 
ambiguous culprit lesions.
IIb
C
The routine use of thrombus aspiration is not 
recommended.472–474
III
A
© ESC 2023
IRA, infarct-related artery; PCI, percutaneous coronary intervention; PPCI, primary 
percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3769


<!-- PAGE 51 -->

### Page 51

procedure should be restricted to the IRA only.404
In the 
CULPRIT-SHOCK trial, IRA-only PCI was associated with a significant 
reduction in all-cause death or renal replacement therapy at 30-day 
follow-up (RR 0.83, 95% CI, 0.71–0.96).404 At 1-year follow-up, mortal­
ity did not differ significantly between the two groups.505
For patients undergoing emergency CABG, appropriate peri- 
operative strategies (particularly in relation to prophylactic or on- 
demand mechanical circulatory support) may be considered based on 
pre-operative clinical status (e.g. age, comorbidities, electrical instability, 
the extent of jeopardized myocardium, the duration of ischaemia from 
the time of symptom onset, right ventricular involvement, and the feasi­
bility of cardiac surgery from technical/logistical perspectives). Figure 14
shows the algorithm for the management of patients with ACS and 
MVD.
10.2. Patients with multivessel coronary 
artery disease undergoing primary 
percutaneous coronary intervention
Multivessel disease is evident in approximately half of patients undergo­
ing PPCI and is associated with an adverse prognosis.506,507
Over the past decade, a series of RCTs have provided clinical evidence 
that supports preventive revascularization of non-IRA after successful 
PPCI of the IRA. The pivotal clinical trials (in chronological order) include 
PRAMI (Preventive Angioplasty in Myocardial Infarction), CvLPRIT 
(Complete versus Lesion-only Primary PCI Trial), DANAMI-3– 
PRIMULTI (Third Danish Study of Optimal Acute Treatment of 
Patients with ST-Segment Elevation Myocardial Infarction—Primary 
PCI in Multivessel Disease), COMPARE-ACUTE (Comparison 
Cardiogenic shock
STEMI
Patient with ACS undergoing PCI of IRA with an angiographically significant stenosis in ≥ 1 non-IRA
Complete revascularization,
either during the index procedure or within
45 daysa
(Class I)
NSTE-ACS
Immediate PCI of IRA only
(Class I)
Staged complete revascularization
(Class IIa)
Complete revascularizationb
(Class IIa)
Functional invasive evaluation of the non-IRA
during the index procedure
(Class IIb)
Figure 14 Algorithm for the management of acute coronary syndrome patients with multivessel coronary artery disease. CABG, coronary artery bypass 
grafting; IRA, infarct-related artery; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary inter­
vention; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.aIn patients presenting with STEMI and MVD without CS, 
complete revascularization either during the index PCI procedure or within 45 days, with PCI of non-IRA based on angiographic severity, is recommended. 
bIn patients presenting with NSTE-ACS and MVD, complete revascularization, preferably during the index procedure should be considered. Functional in­
vasive evaluation of non-IRA severity during the index procedure may be considered.


<!-- PAGE 52 -->

### Page 52

Between FFR Guided Revascularization Versus Conventional Strategy in 
Acute STEMI Patients With MVD), and COMPLETE (Complete vs. 
Culprit-only Revascularization to Treat Multivessel Disease After Early 
PCI for STEMI) (further details on these trials is provided in the 
Supplementary data online evidence tables).508–511
In a systematic review of 10 randomized trials that included 7030 pa­
tients with STEMI and MVD, complete revascularization was associated 
with reduced CV mortality compared with IRA-only PCI.512 All-cause 
mortality was comparable in both groups. Complete revascularization 
was also associated with a reduced composite of CV death or new MI, sup­
porting complete revascularization in patients with STEMI and MVD.512
10.3. Timing of non-infarct-related artery 
revascularization in acute coronary 
syndrome
10.3.1. Patients presenting with ST-elevation 
myocardial infarction and multivessel coronary 
artery disease
The previous ESC STEMI Guidelines recommended non-IRA PCI dur­
ing the index procedure. The primary rationale for this recommenda­
tion was that all trials available until then had performed MVD PCI in 
that time frame. However, in the COMPLETE trial, non-IRA PCI in pa­
tients allocated to complete revascularization was performed either 
during hospitalization (67% of cases) or after discharge (33% of cases), 
at a mean time of 23 days after discharge but always within 45 days.511
No treatment effect by timing of PCI interaction was observed. Given 
that the optimal timing of revascularization (immediate vs. staged) has 
still not been investigated in adequately sized randomized trials with a 
superiority design, no recommendation in favour of an immediate vs. 
a staged (i.e. either during index hospitalization or within 45 days of dis­
charge) non-IRA PCI strategy can be formulated. No surgical studies 
have specifically investigated non-IRA revascularization.
10.3.2. Patients presenting with non-ST-elevation 
acute coronary syndrome and multivessel coronary 
artery disease
While there are a large number of studies providing evidence for patients 
presenting with STEMI and MVD, there are fewer data guiding the man­
agement of patients presenting with NSTE-ACS and MVD.513 Currently, 
there is no dedicated trial comparing complete revascularization against 
IRA-only PCI for these patients. Observational studies and meta-analyses 
of non-randomized studies suggest that complete revascularization is as­
sociated with fewer deaths and MACE during follow-up in comparison to 
IRA-only PCI.514,515 However, given that these are analyses of treatment 
effects based on non-randomized studies, the results should be consid­
ered as hypothesis-generating at best and this remains a gap in evidence.
10.4. Evaluation of non-infarct-related 
artery stenosis severity (angiography vs. 
physiology)
Overestimation of the severity of non-IRA lesions during the PPCI proced­
ure when assessed by quantitative coronary angiography as compared 
with a repeated angiogram performed within 9 months has been re­
ported.516 Microvascular constriction may also occur in the non-IRAs, 
leading to some variation in functional measurements between baseline 
and follow-up, although the impact on decision-making may be mo­
dest.517–520 A sub-analysis of the FAME (Fractional Flow Reserve versus 
Angiography for Multivessel Evaluation) trial reported that 65% of lesions 
in the angiographic severity range of 50–70% diameter stenosis, and 20% of 
lesions in the range 71–90%, have an FFR value above 0.80.521
The PRIME-FFR registry included 533 ACS patients and reported that 
systematic FFR measurement led to a change in the management strategy 
in 38% of cases (e.g. from CABG to PCI or to medical treatment), without 
an impact on MACE, death/MI, or angina symptoms at 1 year.522 A sub­
group analysis of the FAME trial in 328 patients with ACS (UA or 
NSTEMI) and MVD reported that the adoption of FFR to guide PCI re­
sulted in similar risk reductions of MACE compared with patients with 
stable angina, with a lower number of stents implanted and less contrast 
media use.523 The FAMOUS-NSTEMI (Fractional Flow Reserve Versus 
Angiographically Guided Management to Optimise Outcomes in 
Unstable Coronary Syndromes) trial randomized 350 patients with 
NSTE-ACS and at least one coronary stenosis (with diameter stenosis 
>30%) to either angiography-guided or FFR-guided management (medical 
therapy, PCI, or CABG), and demonstrated that a higher proportion of 
patients in the FFR-guided management group were initially treated 
with medical therapy. The FLOWER-MI (Flow Evaluation to Guide 
Revascularization in Multivessel ST-Elevation Myocardial Infarction) study 
randomized 1171 patients undergoing PPCI with MVD to complete re­
vascularization guided by FFR or angiography. Compared with an 
angiography-guided approach, an FFR-guided strategy did not reduce 
the risk of death, MI, or urgent revascularization at 1 year.524 PCI was per­
formed in 66.2% of patients in the FFR-guided group and in 97.1% of the 
angiography-guided group. In FLOWER-MI, complete revascularization 
during the index procedure was only performed in 4% of patients in 
both groups, and functional evaluation was mainly undertaken at the 
time of the second procedure.524 However, based on the study design, 
complete revascularization could also be performed during a separate 
staged procedure as early as possible before hospital discharge and within 
5 days of the initial procedure.
A meta-analysis of 10 RCTs (including 3031 patients undergoing PPCI) 
assessed outcomes in patients with complete revascularization vs. 
IRA-only PCI according to whether the decision to carry out non-IRA 
preventive PCI was based on angiography alone or on angiography plus 
FFR.525 Preventive PCI of the non-IRA was associated with a significant 
reduction in cardiac death and non-fatal MI only when the decision to 
proceed with non-IRA PCI was based solely on angiography. Similar find­
ings were reported in another meta-analysis of seven RCTs including a 
total of 6597 patients undergoing PPCI.526 In patients randomised to 
the complete revascularization arm, an angiography-guided strategy 
(≥70% diameter stenosis) for non-IRA lesions was associated with lower 
rates of recurrent MI, whereas an FFR-guided (≤0.80 for lesions with 
≤90% diameter stenosis) guided approach was not. In another 
meta-analysis, which pre-dated the FLOWER-MI trial, there was no het­
erogeneity in the primary outcome when complete revascularization was 
performed using an FFR-guided strategy (OR 0.78, 95% CI, 0.43–1.44) or 
an angiography-guided strategy (OR 0.61, 95% CI, 0.38–0.97; P = 0.52 for 
interaction).512 A pooled post-hoc patient-level analysis of three RCTs 
(FAME, DANAMI-3–PRIMULTI, and FAMOUS-NSTEMI) in ACS pa­
tients treated with a functionally complete revascularization strategy 
(i.e. PCI of the stenosis with FFR ≤0.80, deferral to medical therapy sten­
osis with FFR >0.80) reported that the residual SYNTAX score (a proxy 
of the residual coronary stenosis deferred to medical therapy) was not 
associated with MACE at 2 years, suggesting that it may be safe to defer 
the management of functionally non-significant stenoses in the 
non-IRA.527 The FRAME AMI (FFR Versus Angiography-Guided 
Strategy for Management of AMI With Multivessel Disease) trial com­
pared selective PCI guided by FFR (PCI if FFR ≤0.80) to routine PCI 
ESC Guidelines                                                                                                                                                                                          3771


<!-- PAGE 53 -->

### Page 53

guided by angiography (PCI if diameter stenosis >50%) of the non-IRA(s) 
in patients presenting with AMI who had undergone successful PCI of the 
IRA (47% STEMI, 53% NSTEMI).528 This study reported that at a median 
follow-up of 3.5 years, the primary endpoint (death, MI, or repeat revas­
cularization) occurred less frequently in patients randomized to the 
FFR-guided strategy, mainly driven by differences in patients presenting 
with NSTEMI. However, the trial was terminated early, with only 562 
out of an intended 1292 patients enrolled, and there was a relatively small 
number of primary outcome events.
10.5. Hybrid revascularization
Hybrid coronary revascularization (HCR) is defined as combined or 
consecutive procedures consisting of an internal mammary artery graft 
to the left anterior descending artery (LAD) and PCI to the other 
non-LAD vessels for the treatment of MVD.529 The preferred surgical 
technique for HCR is a minimally invasive left anterior mini- 
thoracotomy or robotic-assisted left internal mammary artery 
(LIMA)-LAD. The rationale for HCR is to combine the prognostic ben­
efits of a LIMA for grafting of the LAD with the potential benefits of 
contemporary PCI with DES for disease in arteries that would other­
wise be revascularized using vein grafts (which are prone to occlu­
sion).530 There is limited evidence from RCTs to support hybrid 
revascularization. Clinical decision-making in this regard should involve 
the Heart Team. Clinical criteria supporting an HCR strategy in ACS pa­
tients with an indication for CABG may include MVD with LAD suitable 
for CABG and non-LAD lesions suitable for PCI, atheroma in the as­
cending aorta, an unprotected left main coronary artery that is unsuit­
able for PCI, complex LAD disease, advanced age, low LVEF (≤30%), 
frailty, diabetes mellitus, renal failure, prior sternotomy, and the lack 
of available bypass conduits.
11. Myocardial infarction with 
non-obstructive coronary arteries
Myocardial infarction with non-obstructive coronary arteries 
(MINOCA) refers to the clinical situation when a patient presents 
with symptoms suggestive of ACS, demonstrates troponin elevation, 
and has non-obstructive coronary arteries at the time of coronary angi­
ography (defined as coronary artery stenosis <50% in any major epicar­
dial vessel). The reported prevalence of MINOCA varies widely across 
studies (from around 1% to 14% of patients with ACS undergoing angi­
ography).533 MINOCA can be considered as an umbrella term that en­
compasses a heterogeneous group of underlying causes. This includes 
both coronary and non-coronary pathologies, with the latter including 
both cardiac and extra-cardiac disorders (Figure 15).4,18,534–537
Recommendation Table 12 — Recommendations for 
management of patients with multivessel disease
Recommendations
Classa
Levelb
It is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the 
patient’s clinical status and comorbidities, as well as 
their disease complexity, according to the principles 
of management of myocardial 
revascularization.480,481
I
B
Multivessel disease in ACS patients presenting in cardiogenic 
shock
IRA-only PCI during the index procedure is 
recommended.404,505
I
B
Staged PCI of non-IRA should be considered.c
IIa
C
Continued
Multivessel disease in haemodynamically stable STEMI patients 
undergoing PPCI
Complete revascularization is recommended either 
during the index PCI procedure or within 45 
days.508–511,531
I
A
It is recommended that PCI of the non-IRA is based 
on angiographic severity.511,524
I
B
Invasive epicardial functional assessment of 
non-culprit segments of the IRA is not 
recommended during the index procedure.
III
C
Multivessel disease in haemodynamically stable NSTE-ACS 
patients undergoing PCI
In patients presenting with NSTE-ACS and MVD, 
complete revascularization should be considered, 
preferably during the index procedure.513,514
IIa
C
Functional invasive evaluation of non-IRA severity 
during the index procedure may be 
considered.518,527,528,532
IIb
B
© ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; IRA, 
infarct-related artery; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence. 
cBased on ischaemia, symptoms, patient comorbidities, and clinical condition.


<!-- PAGE 54 -->

### Page 54

When a diagnosis is not established following coronary angiography, 
MINOCA represents a working diagnosis as opposed to a final diagno­
sis. It is vital for clinicians to perform further assessments and investiga­
tions to establish the underlying cause of the MINOCA, which will allow 
a final diagnosis to be established and patients to be managed appropri­
ately. Failure to identify the underlying cause of MINOCA may result in 
inadequate or inappropriate therapy.
ICA is the recommended definitive diagnostic test for ACS pa­
tients. If the underlying cause of MINOCA is not established using 
ICA alone, further evaluation using left ventriculography (including 
measurement of LV end-diastolic pressure), functional assessment 
with measurement of microvascular function/coronary reactivity, 
and intravascular imaging can be useful to identify the underlying 
cause.456,538,539 The term ‘functional coronary angiography’ refers 
to the combination of coronary angiography with adjunctive tests 
(e.g. testing for coronary microvascular dysfunction and vasoreactiv­
ity) (Figure 16).
Non-coronary, cardiac causes
Coronary embolism
Coronary microvascular dysfunction
Coronary spasm
Coronary thrombosis
Myocardial bridging
Plaque rupture/erosion
Spontaneous coronary artery dissection
Coronary causes
Acute respiratory distress syndrome
Allergic/hypersensitivity reactions
End-stage renal failure
Inﬂammation
Pulmonary embolism
Sepsis
Stroke
Non-cardiac causes
Cardiac trauma
Cardiomyopathy
Cardiotoxins
Myocarditis
Strenuous exercise
Takotsubo cardiomyopathy
Transplant rejection
Figure 15 Underlying causes for patients with a working diagnosis of myocardial infarction with non-obstructive coronary arteries. This figure outlines 
some of the potential differential diagnoses in patients with a working diagnosis of MINOCA after coronary angiography, but this list is not exhaustive.
ESC Guidelines                                                                                                                                                                                          3773


<!-- PAGE 55 -->

### Page 55

Cath lab assessment
Step 1
Clinical history
Assessments to considera
Ward assessment
Step 2
Post discharge care
Step 3
Detailed angiographic 
assessment ± LV
angiography (incl. LVeDP)
Physical exam
Intravascular imaging
(IVUS/OCT)
ECG assessment
Assess for coronary microvascular dysfunction
± vasoreactivity (ACh testing)
Clinical history
Assessments to considera
CMRI
Physical exam
Blood testsb
ECG assessment
CTPA/CT brainc
Echocardiography
Assessments to considera
The MINOCA diagnostic algorithm
Follow-up clinic evaluation
Repeat echocardiography
Repeat
CMRI
Cardiac rehabilitation
Figure 16 Evaluation of patients with a working diagnosis of MINOCA. ACh, acetylcholine; CMRI, cardiac magnetic resonance imaging; CT, computed 
tomography; CTPA, computed tomography pulmonary angiogram; ECG, electrocardiogram; IVUS, intravascular ultrasound; LV, left ventricular; LVeDP, 
left ventricular end-diastolic pressure; MINOCA, myocardial infarction with non-obstructive coronary arteries; NSTE-ACS, Non-ST elevation acute coron­
ary syndrome; NTpro BNP, N terminal pro brain natriuretic peptide; OCT, optical coherence tomography; STEMI, ST-elevation myocardial infarction; UA, 
unstable angina. Patients presenting with STEMI present directly to catheter lab as per the current standard of care pathway (1). In this context, when non- 
obstructive coronary arteries are identified then further assessment should be considered. When patients are subsequently admitted to the ward then in­
vestigations as shown in (2) should be considered. Patients presenting with NSTE-ACS or UA are often stabilized on the ward (2) prior to transfer to the 
cath lab (1). In this context the order in which the investigations are carried out will vary depending on the location these patients are managed during first 
contact. MINOCA patients require follow-up review (3) and may require repeat assessment using echocardiography and magnetic resonance imaging, de­
pending on the initial findings. aOptions for adjunctive tests. Patients will not require all investigations but instead the appropriate tests should be selected 
based on their presentation and clinical course. bExamples of potential blood tests include: full blood count, renal profile, troponin, C-reactive protein, 
D-dimer, NT-pro BNP. cA CT scan of the brain should be considered if a cranial pathology (i.e. intracranial bleed) is suspected that might have resulted 
in ST elevation.


<!-- PAGE 56 -->

### Page 56

If the underlying cause of MINOCA is not established using functional 
coronary angiography, then non-invasive imaging (i.e. echocardiog­
raphy, CMR, CT) is recommended, as clinically appropriate. CMR is 
one of the key diagnostic tools to determine the underlying cause of 
MINOCA.540–544 CMR can identify the underlying cause in up to 87% 
of patients with a working diagnosis of MINOCA and should be per­
formed as soon as possible after presentation in these patients to maxi­
mize its diagnostic yield, ideally during the index admission.545
Diagnosis of the underlying cause of MINOCA will enable the appro­
priate treatment to be initiated based on the final diagnosis. Secondary 
prevention therapies should be considered for those with evidence of 
coronary atherosclerotic disease and to control risk factors. The man­
agement of takotsubo syndrome is not informed by any prospective 
RCTs, and treatment is largely supportive and empiric.546,547 The treat­
ment of patients with myocarditis has been covered by previous ESC 
documents.548,549 Ischemia with non-obstructive coronary arteries 
(INOCA) has also been described in the context of CCS.550,551
Additional information about MINOCA is provided in the 
Supplementary data online, including Table S13.
12. Special situations
12.1. Type 2 myocardial infarction and 
acute myocardial injury
Pathological processes other than atherothrombosis commonly under­
lie the presentation of patients with acute chest pain with troponin ele­
vation. These include Type 2 MI and myocardial injury as defined in the 
fourth universal definition of MI.1 Type 2 MI is an ischaemic myocardial 
injury in the context of a mismatch between oxygen supply and demand 
that is not related to acute coronary atherothrombosis. This may occur 
in the context of atherosclerosis and an oxygen supply/demand imbal­
ance, with an oxygen supply/demand imbalance alone, secondary to 
vasospasm or coronary microvascular dysfunction, or secondary to 
non-atherosclerotic coronary dissection. These causes of Type 2 MI 
can be divided into those with underlying coronary (e.g. coronary em­
bolus, dissection, spasm, microvascular dysfunction) or non-coronary 
mechanisms (supply demand mismatch due to hypoxia, hypotension, 
anaemia, tachycardia, bradycardia).1 Type 2 MI is common and asso­
ciated with a prognosis similar to Type 1 MI.12
Myocardial injury is characterized by myocyte necrosis and tropo­
nin elevation due to mechanisms other than myocardial ischaemia and 
can be acute (e.g. sepsis, myocarditis, takotsubo) or chronic (e.g. HF, 
cardiomyopathies, severe valve heart disease). Myocardial injury is in­
creasingly appreciated in the era of hs-cTn assays, which are not spe­
cific for MI. In patients who have elevated hs-cTn values and do not 
have evidence of acute myocardial ischaemia, a diagnosis of myocar­
dial injury can be made. It is important to recognize that this diagnosis 
can change if subsequent investigations indicate that the patient meets 
the criteria for MI.
Despite some common risk factors, the pathophysiology of Type 2 
MI is different to that of Type 1 MI. Therefore, the natural history and 
appropriate management strategy of these two conditions also differs 
in some important respects. Type 2 and Type 1 MI require diagnostic 
distinction, which is best achieved by following an algorithmic ap­
proach.1,553 Once patients with suspected Type 2 MI and myocardial 
injury have been stabilized and any precipitating illnesses have been 
treated, targeted echocardiography and/or coronary angiography (in­
vasive or CCTA) can be used to identify contributory (and prognos­
tically important) cardiac conditions and to guide appropriate 
long-term cardiovascular treatments.12 Due to the lack of robust sci­
entific evidence investigating management strategies and the wide 
range of precipitating causes, there are currently no specific recom­
mended pharmacological interventions for patients with Type 2 MI. 
Therefore, management should instead focus on identifying and treat­
ing any precipitating conditions (e.g. anaemia, hypoxia) alongside strict 
control of CV risk factors.
12.2. Complications
12.2.1. Heart failure
Acute HF may occur as a complication of ACS. Acute HF as a result of 
ACS significantly increases the risk of other in-hospital complications, 
including worsening of renal function, respiratory failure, pneumonia, 
and death. De novo acute HF complicating ACS should be distinguished 
from pre-existing HF exacerbated by ACS.554–556 This can be challen­
ging and the presence of acute HF may impede the straightforward 
diagnosis of ACS. Patients with ACS and acute HF are more likely to 
present with resting dyspnoea and clinical signs/symptoms of fluid over­
load. In some clinical scenarios, increased troponin levels in patients 
with acute HF may reflect myocardial injury due to HF rather than myo­
cardial necrosis due to ischaemia.
Patients with ACS complicated by acute HF require urgent and co- 
ordinated management of both conditions. The management of acute 
HF should follow current recommendations included in the ESC 
Guidelines on HF and ancillary documents.557–559 The use of diuretics, 
vasodilators, inotropic agents, and vasopressors should be considered 
according to the established algorithms. Mechanical circulatory support 
may also be considered in selected cases. Invasive respiratory support 
and/or renal replacement therapy may be required in some circum­
stances.557–559
Patients presenting with acute HF (including patients with CS) com­
plicating ACS require immediate ICA.250,394,396 These patients should 
also undergo emergency echocardiography/chest ultrasonography to 
gather information about LV and RV function, regional wall motion ab­
normalities, valvular function, and possible mechanical complica­
tions.250,557,560 In patients with ACS, CS may occur as a result of 
Recommendation Table 13 — Recommendations for 
myocardial infarction with non-obstructive coronary 
arteries
Recommendations
Classa
Levelb
In patients with a working diagnosis of MINOCA, 
CMR imaging is recommended after invasive 
angiography if the final diagnosis is not clear.544,545
I
B
Management of MINOCA according to the final 
established underlying diagnosis is recommended, 
consistent with the appropriate disease-specific 
guidelines.546,550,552
I
B
In all patients with an initial working diagnosis of 
MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying final diagnosis.
I
C
© ESC 2023
CMR, cardiac magnetic resonance; MINOCA, myocardial infarction with non-obstructive 
coronary arteries. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3775


<!-- PAGE 57 -->

### Page 57

extensive ischaemia due to MVD, acute severe mitral regurgitation, and 
mechanical complications. Patients with ACS and CS should be trans­
ferred as soon as possible to a PCI centre where immediate coronary 
angiography, and PCI of the IRA if needed, can be performed.404,505 In 
patients with CS complicating ACS in whom the coronary anatomy is 
not suitable for PCI, emergency CABG is recommended. 
Management of MVD in this context is detailed in Section 10.
The clinical benefit of percutaneous MCS devices and/or VA-ECMO 
in the context of ACS remains unclear.402,561 Micro-axial MCS devices 
have not been associated with lower 30-day mortality in comparison to 
IABP in observational studies.400 In a large retrospective registry of 48  
306 patients (>80% ACS) undergoing PCI with MCS, micro-axial MCS 
support was associated with higher mortality and bleeding rates in com­
parison to IABP.562 Similar results were observed in another 
propensity-matched registry analysis confined to patients with CS, 
where micro-axial MCS support was also associated with more compli­
cations and higher mortality than IABP.563 In the IABP-SHOCK II trial, 
the routine use of IABP in patients with ACS and CS did not reduce 
30-day, 1-year, or 6-year mortality.399,405,407 Based on these data, a 
benefit of LVAD in patients with ACS has not been demonstrated, 
and given that observational data have suggested that this may be asso­
ciated with harm, caution is advised in this regard until further RCT evi­
dence is available.
12.2.2. Mechanical complications
Mechanical complications may occur in the first days following MI, 
most commonly in patients presenting with STEMI. The incidence 
of mechanical complications has fallen significantly in the era of 
PPCI.564 A recent large epidemiological investigation including almost 
9 million ACS patients reported an overall prevalence of mechanical 
complications in 0.27% of STEMI cases and 0.06% of NSTEMI cases, 
with in-hospital mortality rates of 42.4% and 18%, respectively.564
Mechanical complications are life-threatening and therefore require 
prompt identification and management (Supplementary data online, 
Table S14). Sudden hypotension, the recurrence of chest pain, new 
cardiac murmurs suggestive of acute mitral regurgitation or a ven­
tricular septal defect, pulmonary congestion, or jugular vein distension 
should raise suspicion of a mechanical complication. Immediate echo­
cardiographic assessment is indicated when mechanical complications 
are suspected.
The use of temporary MCS for mechanical complications, either to 
improve pre-operative clinical/haemodynamic status or prophylactical­
ly, represents a new trend in management. However, this approach re­
quires more data and evidence in order to determine if it provides a 
clinical benefit.565–568 Surgery is currently regarded as the treatment 
of choice for patients with ACS and mechanical complications, although 
percutaneous strategies are occasionally used in selected candidates 
with a prohibitive risk profile or contraindications to a surgical ap­
proach.569–572 A multidisciplinary approach to the management of 
these patients is of paramount importance, and should apply to all 
stages of care, from the initial stabilization of the patient to discussion 
and application of the therapeutic strategy, including palliative 
care.573,574 Patients with ACS-related mechanical complications should 
be considered for IABP while awaiting surgery.
12.2.3. Left ventricular thrombus
While the incidence of LV thrombus following AMI has declined due to 
advances in reperfusion and antithrombotic therapies, it remains 
relatively common, particularly following anterior STEMI, where it 
can be present in >9% of patients according to a large 
meta-analysis.575,576
Echocardiography remains the first-line imaging test for the detec­
tion of LV thrombus. In patients where the apex is not well visualized 
on regular echocardiography, contrast echocardiography may be con­
sidered for improved image quality. CMR is the gold standard imaging 
modality for the diagnosis and assessment of LV thrombi. 
Contemporary CMR data report LV thrombi in up to 6.3% of all 
STEMI patients and in 12.2% of those with anterior STEMI, suggesting 
that the incidence of LV thrombi may be underestimated with echocar­
diography.577 Patients with LV thrombi that were not evident on echo­
cardiography but were detected by CMR appear to have similar clinical 
outcomes to patients with LV thrombi that were evident on echocar­
diography.578 Therefore, CMR should be considered in patients with 
equivocal echocardiographic images or in patients considered to be 
at a particularly high risk of LV thrombus.
The timing of imaging for LV thrombus may also be relevant, given 
that the identification of LV thrombus has been reported to increase 
in the first 2 weeks post-MI.579 While more contemporary data are re­
quired, these data suggest that a high proportion of LV thrombi may 
develop following hospital discharge, indicating that delayed imaging 
at 2 weeks in high-risk patients may be of value.
Once an LV thrombus has been diagnosed, OAC therapy (warfarin 
or NOAC) should be considered for 3–6 months, guided by repeated 
echocardiography or CMR and with consideration of bleeding risk 
and the need for concomitant antiplatelet therapy.580,581 However, 
there are a lack of prospective randomized data on the optimal antic­
oagulation regimen, anticoagulation duration, and the combination of 
oral anticoagulation with antiplatelet agents in patients with LV 
thrombus following MI.581 The choice of therapy should be tailored 
to the patient’s clinical status and the results of follow-up 
investigations.
12.2.4. Post-acute coronary syndrome pericarditis
Pericardial complications that may develop after an AMI include early 
infarct-associated pericarditis (occurring from a few hours to 4 days 
after AMI, mostly transient), late pericarditis or post-cardiac injury 
(Dressler) syndrome (typically occurring 1–2 weeks after AMI), and 
pericardial effusion.548,582 This topic is discussed further in the 
Supplementary data online.
12.2.5. Arrhythmias
12.2.5.1. Atrial fibrillation
Atrial fibrillation is the most frequent supraventricular arrhythmia in pa­
tients with ACS.583 AF may be pre-existing, first time detected, or of 
new onset during ACS management. Patients with AF have a greater 
number of comorbidities compared with patients without AF and are 
at higher risk of complications.584 In most cases, AF is well tolerated 
and no specific treatment is required, apart from anticoagulation.585
Prompt treatment is required for AF causing acute haemodynamic in­
stability, with electrical cardioversion being the preferred approach. 
Adequate rate control can be achieved by administration of beta- 
blockers depending on the presence of HF and low ejection fraction. 
For patients with depressed LVEF, amiodarone or digoxin could be 
used (preferably amiodarone). In cases of hypotension, digoxin is pre­
ferred over amiodarone or beta-blockers. Patients with AF and risk fac­
tors for thrombo-embolism should be adequately treated with chronic 
oral anticoagulation.585 ACS patients with documented AF of any


<!-- PAGE 58 -->

### Page 58

length have worse short- and long-term prognoses when compared 
with patients in sinus rhythm.584,586 There is some evidence to suggest 
that transient, self-terminating AF during STEMI may be a predictor of 
an increased risk of stroke during long-term follow-up.584,587
12.2.5.2. Ventricular arrhythmias
With the widespread increased uptake of emergency reperfusion ther­
apies for patients with STEMI, the incidence of malignant arrhythmias 
(ventricular tachycardia [VT] and ventricular fibrillation [VF]) has signifi­
cantly declined. Nevertheless, 6–8% of patients with STEMI develop 
haemodynamically significant VT or VF.588 The typical arrhythmia presen­
tation is unstable, frequently polymorphic, and relatively fast VT, often 
degenerating into VF. Urgent reperfusion is most important as ischaemia 
is often the trigger for these arrhythmias. Early administration of i.v. or 
oral beta-blockers reduces the incidence of malignant arrhyth­
mias.163,164,169,589 Beta-blockers or amiodarone are recommended if ma­
lignant arrhythmias occur and lidocaine may be considered if these are 
contraindicated.163,164,169,589,590 The prognostic role of early VT/VF 
within the first 48 h of STEMI is still controversial. Several studies have 
suggested that patients with early VT/VF have increased 30-day mortality 
but no increase in long-term arrhythmic risk.591–593 Another study has 
suggested that while malignant ventricular arrhythmias occurring at the 
time of reperfusion do not confer poor prognosis, sustained VT or VF 
occurring during ongoing ischaemia or late after reperfusion (>48 h) is 
associated with an increase in long-term mortality.594 Sustained VT/VF 
late after reperfusion (>48 h) requires an evaluation for ICD implant­
ation for secondary prevention of sudden cardiac death. Ventricular pre­
mature beats are very frequent during the first 24 h after reperfusion for 
STEMI and no specific therapy is required.
Primary prevention of sudden cardiac death with ICD implantation 
within 40 days after MI is generally not indicated. Patients should be re- 
evaluated for ICD implantation post-revascularization after a period of 
6–12 weeks on evidence-based treatments, although patients with a 
pre-existing impaired LVEF may be considered for ICD implantation 
for primary prevention even within the early post-infarction period. 
Some patients may develop electrical storm and/or incessant VT des­
pite complete revascularization and treatment with anti-arrhythmic 
drugs. Overdrive stimulation may help to control this situation; how­
ever, recurrence of VT/VF upon cessation of stimulation is frequent 
and catheter ablation of such triggers appears to be the preferred treat­
ment option in centres with that expertise. Successful radiofrequency 
ablation has been shown to abolish recurrent VT/VF.595
Non-sustained monomorphic VT is the most common form of ven­
tricular arrhythmia in the early phase of ACS, and usually does not re­
quire anti-arrhythmic treatment. Accelerated idioventricular rhythm at 
reperfusion is frequent and does not require intervention given its be­
nign nature.596
12.2.6. Bleeding
Bleeding is associated with a poor prognosis in ACS patients.231,597,598
The mechanisms by which bleeding increases the risk of death are com­
plex and multifactorial.599 While intracranial or massive haemorrhage 
directly threatens life through fatal brain damage or sudden cardiocir­
culatory collapse, other less severe forms of haemorrhage may increase 
the risk of death through indirect mechanisms. Blood transfusion may 
increase systemic inflammation and represents one of the possible links 
between bleeding and subsequent mortality.600 Bleeding is also a major 
driver of unplanned DAPT discontinuation and the interruption of 
other medication (e.g. statins, beta-blockers).601,602
12.2.6.1. Management of bleeding
See Supplementary data online, Section 12.1.3.1.
Recommendation Table 14 — Recommendations for 
acute coronary syndrome complications
Recommendations
Classa
Levelb
Heart failure
IABP should be considered in patients with 
haemodynamic instability/cardiogenic shock due to 
ACS-related mechanical complications.
IIa
C
LV thrombus
CMR imaging should be considered in patients with 
equivocal echocardiographic images or in cases of 
high clinical suspicion of LV thrombus.577,578
IIa
C
Oral anticoagulant therapy (VKA or NOAC) should 
be considered for 3–6 months in patients with 
confirmed LV thrombus.603
IIa
C
Following an acute anterior MI, a contrast 
echocardiogram may be considered for the 
detection of LV thrombus if the apex is not well 
visualized on echocardiography.604
IIb
C
Atrial fibrillation
Intravenous beta-blockers are recommended when 
rate control is needed in the absence of acute HF or 
hypotension.605
I
C
Intravenous amiodarone is recommended when rate 
control is needed in the presence of acute HF and no 
hypotension.606
I
C
Immediate electrical cardioversion is recommended 
in patients with ACS and haemodynamic 
instability and when adequate rate control 
cannot be achieved promptly with pharmacological 
agents.
I
C
Intravenous amiodarone is recommended to 
facilitate electrical cardioversion and/or decrease risk 
for early recurrence of AF after electrical 
cardioversion in unstable patients with recent-onset 
AF.607,608
I
C
In patients with documented de novo AF during the 
acute phase of ACS, long-term oral anticoagulation 
should be considered depending on the CHA2DS2- 
VASc score, after taking the HAS-BLED score and 
the need for concomitant antiplatelet therapy into 
consideration. NOACs are the preferred 
drugs.583,584,587
IIa
C
Ventricular arrythmias
ICD therapy is recommended to reduce sudden 
cardiac death in patients with symptomatic HF 
(NYHA Class II–III) and LVEF ≤35% despite optimal 
medical therapy for >3 months and at least 6 weeks 
after MI who are expected to survive for at least 1 
year with good functional status.434,609,610
I
A
Continued
ESC Guidelines                                                                                                                                                                                          3777


<!-- PAGE 59 -->

### Page 59

12.3. Comorbid conditions
12.3.1. Patients at high bleeding risk and with blood 
disorders (anaemia and thrombocytopaenia)
Anaemia is more prevalent in elderly/frail ACS patients and in patients 
with multimorbidity (i.e. HF, chronic kidney disease [CKD], diabetes 
mellitus, cancer, and autoimmune diseases). In some cases, severe an­
aemia may precipitate Type 2 MI. Persistent or worsening anaemia in 
patients with ACS is associated with an increased risk of recurrent is­
chaemic events, death, and major bleeding.623–625 According to the 
ARC-HBR, haemoglobin <11 g/dL at the time of PCI constitutes a ma­
jor criterion for HBR, whereas haemoglobin between 11 and 13 g/dL 
(12 g/dL for women) is a minor criterion.
There is no established strategy for treating anaemia in patients with 
ACS. The efficacy and safety of blood transfusion in this clinical scenario 
remains unknown. In the majority of studies investigating different 
transfusion protocols, a liberal blood transfusion strategy has been de­
fined as any red blood cell transfusion at a haemoglobin level <9–10 g/ 
dL, while a restrictive blood transfusion strategy has been defined as any 
transfusion at a haemoglobin level <7–8 g/dL. Observational data sug­
gest that a liberal blood transfusion strategy may be associated with an 
increase in all-cause mortality.626–630 The open-label Restrictive and 
Liberal Transfusion Strategies in Patients With Acute Myocardial 
Infarction (REALITY) trial enrolled 668 ACS patients who were rando­
mized to management with a restrictive (triggered by haemoglobin ≤8) 
or a liberal (triggered by haemoglobin ≤10) transfusion strategy.631 The 
composite outcome (all-cause death, stroke, recurrent MI, or emer­
gency revascularization) at 30 days occurred in a comparable number 
of patients in both arms (11% vs. 14%, RR 0.79, with a one-sided 
97.5% CI of 0.00–1.19), meeting the pre-specified non-inferiority criter­
ion. All components of the composite endpoint were numerically high­
er in the liberal transfusion strategy arm. The trial was not powered to 
detect superiority of the restrictive strategy, and the CI included what 
may be a clinically important harm. The pre-specified 1-year follow-up 
of the REALITY trial yielded contradictory conclusions to the 30-day 
outcomes: at 1 year, the restrictive transfusion strategy (vs. a liberal 
Intravenous beta-blocker and/or amiodarone 
treatment is recommended for patients with 
polymorphic VT and/or VF unless 
contraindicated.611–614
I
B
Prompt and complete revascularization is 
recommended to treat myocardial ischaemia that 
may be present in patients with recurrent VT and/or 
VF.368,388
I
C
Transvenous catheter pacing termination and/or 
overdrive pacing should be considered if VT cannot 
be controlled by repeated electrical cardioversion.
IIa
C
Radiofrequency catheter ablation at a specialized 
ablation centre followed by ICD implantation should 
be considered in patients with recurrent VT, VF, or 
electrical storm despite complete revascularization 
and optimal medical therapy.
IIa
C
Treatment of recurrent VT with haemodynamic 
relevance (despite repeated electrical cardioversion) 
with lidocaine may be considered if beta-blockers, 
amiodarone, and overdrive stimulation are not 
effective/applicable.615
IIb
C
In patients with recurrent life-threatening 
ventricular arrhythmias, sedation or general 
anaesthesia to reduce sympathetic drive may be 
considered.616
IIb
C
ICD implantation or the temporary use of a wearable 
cardioverter defibrillator may be considered <40 
days after MI in selected patients (incomplete 
revascularization, pre-existing LVEF dysfunction, 
occurrence of arrhythmias >48 h after STEMI onset, 
polymorphic VT or VF).
IIb
C
Treatment of asymptomatic and haemodynamically 
irrelevant ventricular arrhythmias with 
anti-arrhythmic drugs is not recommended.
III
C
Bradyarrhythmias
In cases of sinus bradycardia with haemodynamic 
intolerance or high-degree AV block without stable 
escape rhythm:
• i.v. positive chronotropic medication (adrenaline, 
vasopressin, and/or atropine) is 
recommended.617,618
I
C
• temporary pacing is recommended in cases of 
failure to respond to atropine.
I
C
• urgent angiography with a view to 
revascularization is recommended if the patient 
has not received previous reperfusion therapy.
I
C
Implantation of a permanent pacemaker is 
recommended when high-degree AV block does not 
resolve within a waiting period of at least 5 days 
after MI.
I
C
Continued
In selected patients with high-degree AV block in the 
context of an anterior wall MI and acute HF, early 
device implantation (CRT-D/CRT-P) may be 
considered.619,620
IIb
C
Pacing is not recommended if high-degree AV block 
resolves after revascularization or spontaneously.620–622
III
B
© ESC 2023
ACS, acute coronary syndrome; AF, atrial fibrillation; AV, atrioventricular; CHA2DS2-VASc, 
Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, previous Stroke/ 
transient ischaemic attack/thrombo-embolism (doubled), Vascular disease, Age: 65–74, 
Sex 
(female); 
CMR, 
cardiac 
magnetic 
resonance; 
CRT-D/CRT-P, 
cardiac 
resynchronization 
therapy—defribillator/pacemaker; 
HAS-BLED, 
Hypertension, 
Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile 
INR, Elderly, Drug/alcohol usage; HF, heart failure; IABP, intra-aortic balloon pump; ICD, 
implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; 
NYHA, New York Heart Association; STEMI, ST-elevation myocardial infarction; VF, 
ventricular fibrillation; VKA, vitamin K antagonist; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 60 -->

### Page 60

approach) did not achieve non-inferiority in terms of MACE. In add­
ition, a post-hoc analysis of MACE between day 30 and 1 year demon­
strated an increased risk in the restrictive transfusion strategy group.632
Therefore, no formal recommendation as to the optimal transfusion 
strategy (liberal vs. restrictive) in patients with ACS can be made at 
present.
Although there are several classifications to grade the severity 
of thrombocytopaenia, clinically relevant thrombocytopaenia can 
be defined as a platelet count <100 000/μL or a relative drop in platelet 
count of 50% from baseline in the context of ACS. Thrombocytopaenia 
increases the risk of death, major bleeding events, and life-threatening 
thrombotic events.633,634 The ARC-HBR criteria define a platelet count 
<100 000/μL as a major criterion for HBR. Management of GP IIb/IIIa 
inhibitor- and heparin-induced thrombocytopaenia is discussed in the 
Supplementary data online.
12.3.2. Chronic kidney disease
Moderate to severe CKD (stages III–V) is present in more than 30% of 
ACS patients.635 Patients with ACS and concomitant CKD receive less 
interventional and pharmacological treatment and have a worse prog­
nosis than patients with normal kidney function.636–638 Likely contrib­
uting factors to this worse prognosis include a larger number of 
comorbidities and an increased risk of in-hospital complications, includ­
ing serious bleeding complications.639 Although evidence from RCTs is 
lacking, data from observational and registry-based studies indicate 
that ACS patients with moderate to severe CKD have a better 
prognosis with early revascularization than with medical therapy 
alone.640,641
The type and dose of antithrombotic agent (see Supplementary data 
online, Table S15) and the amount of contrast agent should be consid­
ered based on kidney function.635,642 In relation to supplementary i.v. 
hydration during and after revascularization, the evidence around 
choice, timing, and duration of treatment is somewhat conflicting.643
Taking the clinical circumstances and patient characteristics into consid­
eration, i.v. hydration should be considered as part of the management 
of ACS patients with a low eGFR undergoing invasive management to 
minimize the risk of contrast-induced nephropathy.250,635,642,644,645 For 
recommendations on long-term treatment in patients with ACS and 
concomitant CKD, please refer to the 2021 ESC Guidelines on cardio­
vascular disease prevention.646
12.3.3. Diabetes mellitus
ACS patients with diabetes mellitus (DM) may more commonly pre­
sent with non-specific symptoms, which can lead to delays in both diag­
nosis and access to treatment.647,648 Both treatment in the acute phase 
and risk factor management post-ACS is poorer in patients with DM 
and these patients tend to have more advanced CAD at diagnosis. 
These factors likely contribute to the worse long-term prognosis asso­
ciated with ACS in patients with DM, particularly in patients requiring 
insulin treatment.649–651
All patients with ACS, regardless of a history of DM, should have 
their glycaemic status evaluated during hospitalization. Given that 
the ACS itself may give rise to hyperglycaemia due to catechol­
amine-induced stress, a diagnosis of DM made during hospitalization 
should be subsequently confirmed. While several studies have shown 
the benefits of managing hyperglycaemia (>11.0 mmol/L or 200 mg/ 
dL) in hospitalized ACS patients, the risk of hypoglycaemia-related 
events when using intensive insulin therapy should not be ne­
glected.652–654
Glucose lowering is important in order to prevent microvascular 
complications in patients with DM. However, recent trial evidence 
has shown that the reduction in the risk of new ACS events, HF, 
and renal impairment with glucose-lowering medications like so­
dium–glucose co-transporter 2 (SGLT2) inhibitors or glucagon-like 
peptide-1 receptor agonists (GLP-1-RA) is independent of baseline 
glycosylated haemoglobin (HbA1c) levels.655–657 This should be taken 
into consideration when choosing glucose-lowering therapy for pa­
tients with DM and concomitant CAD. For further details, please re­
fer to the 2023 ESC Guidelines on diabetes and cardiovascular 
diseases and the 2021 ESC Guidelines on cardiovascular disease 
prevention.646,658
12.3.4. Older adults with frailty and multimorbidity
12.3.4.1. The older person
Older adults represent an increasing proportion of ACS patients. One 
of the major predictors of adverse outcomes following ACS is age, but 
patients aged ≥75 years are often excluded from or under-represented 
in clinical trials.659,660 Older age is associated with frailty, multimorbid­
ity, and a greater risk of both ischaemic and bleeding events in patients 
with ACS.661 Hs-cTn assays have an excellent diagnostic performance 
in the older person, but the specificity of the test is lower than in young­
er patients, and elevated cTn levels are more commonly associated with 
conditions other than ACS in older patients.662
There are limited data on the optimal management of older adults 
with ACS.663 A small RCT enrolling older patients (≥80 years) with 
NSTE-ACS reported the superiority of an invasive vs. a conservative 
strategy in the reduction of the composite of MI, need for urgent revas­
cularization, stroke, and death. No treatment effect was shown for all- 
cause death and the benefit associated with the invasive strategy was 
diluted with increasing age.664 In the absence of robust clinical trial 
evidence, decisions regarding how to manage older patients should 
be individualized based on patient characteristics (i.e. ischaemic and 
bleeding risks, estimated life expectancy, comorbidities, the need for 
non-cardiac surgery, quality of life, frailty, cognitive and functional im­
pairment, patient values and preferences, and the estimated risks and 
benefits of an invasive strategy).
In the context of STEMI, PPCI has drastically improved outcomes for 
all ages. However, data are limited in the ‘very old’ cohort, with lack of 
formal assessment of frailty or comorbidity.665 In the context of CS and 
cardiac arrest, age is an independent predictor of mortality following 
PCI.666,667 In the absence of robust RCT data, PPCI should be consid­
ered for all patients with STEMI. When PPCI cannot be performed in a 
timely manner, fibrinolysis may be a reasonable strategy in these pa­
tients. For details regarding pharmacotherapy in older patients, please 
see the Supplementary data online.
12.3.4.2. Frailty and multimorbidity
Geriatric syndromes (i.e. frailty and multimorbidity) are associated with 
adverse outcomes in older patients with ACS.668,669 Frailty is a syn­
drome characterized by reduced biological reserve, leading to a failure 
of homeostatic mechanisms following stressor events, including ACS. 
There is a lack of consensus on which frailty assessment tool is optimal 
in older patients with CV disease.670,671
Frail patients with NSTE-ACS less frequently receive ACS pharma­
cotherapies and invasive assessment, have more complex coronary dis­
ease, have longer durations of hospital stay, and are at higher risk of 
death.672 Specifically, frail patients are reported to have a higher rate 
of a composite of all-cause mortality, MI, stroke, unplanned 
ESC Guidelines                                                                                                                                                                                          3779


<!-- PAGE 61 -->

### Page 61

revascularization, and major bleeding.673 Frail older adults with 
NSTE-ACS have poor health-related quality of life (HRQoL) at baseline. 
Invasive management appears to be associated with modest improve­
ments in HRQoL through to 1 year follow-up in these patients. This im­
provement in HRQoL is most marked in frail and pre-frail patients, who 
receive a proportionally larger benefit than robust patients.674 In older 
adults with NSTE-ACS referred for coronary angiography, the pres­
ence of multimorbidity is associated with an increased risk of long-term 
adverse CV events, driven by a higher risk of all-cause mortality.675
Undiagnosed cognitive impairment is also common in older patients 
with NSTE-ACS undergoing ICA, and these patients are more likely 
to experience MACE at 1 year.676
In the absence of robust RCT data to inform healthcare professionals 
about the management of frail patients presenting with ACS, it is re­
commended to adapt a holistic approach to individualize interventional 
and pharmacological treatments after careful evaluation of risks vs. ben­
efits. To aid in decision-making, the routine assessment of frailty (e.g. 
Rockwood Frailty Score) and comorbidity (e.g. Charlson index) in 
ACS patients is recommended. Following risk stratification using frailty 
assessment and evaluation of the comorbidity burden, it may be rea­
sonable to offer optimal medical therapy plus an invasive strategy to frail 
patients at high risk of future CV events and low risk of complications, 
and to offer optimal medical therapy alone to those who are deemed to 
be at low risk of future events with a high risk of developing procedural 
complications. For those patients for whom any form of treatment 
might be futile, then a palliative end-of-life care approach should be 
considered.
12.3.5. Pregnancy
Acute coronary syndrome diagnostic criteria are the same for preg­
nant and non-pregnant patients.677 Pregnant women with STEMI 
should not be managed differently to non-pregnant women. Given 
the high mortality associated with STEMI in pregnancy, PPCI is the 
preferred reperfusion therapy.678 The management plan for pregnant 
women with ACS should be determined by a multidisciplinary team 
consisting of cardiologists, obstetricians, anaesthesiologists, and neo­
natologists, and these patients should be treated in an intensive care 
unit that can provide maternal monitoring and obstetric care.678,679
ACS treatment should not be delayed for delivery. Delivery should 
be ideally postponed for at least 2 weeks post-ACS as there is in­
creased risk of maternal mortality during this time.678 It has been de­
monstrated that SCAD is the most common cause of AMI in 
pregnancy, and this tends to occur mainly in the late pregnancy or 
early post-partum periods.680,681 Further details are provided in the 
Supplementary data online.
12.3.6. Drug abuse
Acute coronary syndrome in the setting of drug abuse is covered in the 
Supplementary data online.
12.3.7. Patients with cancer
The four most common types of cancer in patients with ACS are pros­
tate, breast, colon, and lung.682 Patients with a history of cancer should 
be treated like all other ACS patients, but the management of ACS pa­
tients with active cancer has some specific issues that need to be taken 
into consideration. Outcomes vary across types of cancer and the 
balance between the ischaemic and bleeding risks should be considered 
on an individual basis.
The percentage of ACS patients with a current diagnosis of cancer is 
rising, and currently constitutes ∼3% of patients in large observational 
studies.683 Patients with active cancer presenting with ACS pose im­
portant challenges as there are significant gaps in scientific knowledge. 
Therefore, recommendations based on solid evidence are scarce. 
Patients with active cancer presenting with ACS tend to be older, 
with a larger number of comorbidities and more extensive CAD. 
These patients often have concomitant haematologic and coagulation 
abnormalities that may present a challenge with respect to both the 
use of antithrombotic therapy and the performing of PCI.684
Observational studies have reported that ACS in patients with cancer 
is associated with increased risk of major CV events, bleeding, and car­
diac and non-cardiac mortality.682,683,685,686 As per the ARC-HBR cri­
teria, patients with active cancer diagnosed in the past 12 months are 
considered as HBR.
The diagnosis of ACS in patients with cancer should be based on the 
same principles as in patients without cancer. The management of ACS 
in patients with cancer can be challenging because of frailty, increased 
bleeding risk, thrombocytopaenia, and increased thrombotic risk.687
Temporary interruption of cancer treatment and an urgent multidiscip­
linary approach is recommended.688 Cancer patients with ACS have 
been reported to less frequently undergo invasive management; how­
ever, invasive management (and PCI with DES if needed) is recom­
mended in ACS patients with cancer, as long as the prognosis is >6 
months or, irrespective of the prognosis, if the patient is unstable.689
Retrospective data have reported both a lower use of invasive manage­
ment in cancer patients with STEMI, and better outcomes in patients 
who do undergo invasive management.682,686,689 Invasive management 
in patients with advanced cancer or life expectancy <6 months has 
been reported to not demonstrate a mortality benefit compared 
with a conservative approach and therefore a conservative strategy 
should be considered in these patients.690 When the coronary anatomy 
is not amenable for PCI, CABG surgery can be considered after a multi­
disciplinary team discussion and where the cancer prognosis is >12 
months. Given that they are considered to be HBR, the preferred 
P2Y12 inhibitor for ACS patients with active cancer is clopidogrel.687
Potential drug–drug interactions with cancer therapies should be 
checked when using ticagrelor or clopidogrel, since some 
pharmacokinetic-based drug–drug interactions via CYP450 may occur.
When acute ischaemia is provoked by cancer therapy, alternative 
cancer therapies should be considered after a multidisciplinary team 
discussion. Some specific cancer treatments can have cardiotoxic vas­
cular effects that can lead to ACS (Supplementary data online, 
Table S16). Following ACS, a review of the cancer medications is re­
commended, and any cancer drug associated with thrombosis and MI 
should be stopped. Cancer therapies that are not associated with MI 
can be restarted once revascularization (when indicated) has been com­
pleted and the patient is stabilized on ACS medical therapy without 
complications. Additional information can be found in the 
Supplementary data online, including Supplementary data online, 
Table S16 and in the 2022 ESC Guidelines on cardio-oncology.684
12.3.8. Coronavirus disease (COVID-19)
A section on the impact of Coronavirus disease (COVID-19) on ACS 
management is presented in the Supplementary data online.


<!-- PAGE 62 -->

### Page 62

### 13 Long-term treatment

Secondary prevention after ACS is central to increase quality of life and 
to decrease morbidity and mortality. This should start as early as pos­
sible after the index event.716–718 The topic is covered in detail in the 
2019 CCS Guidelines and the 2021 Prevention Guidelines.195,646
Optimal medical therapy and treatment targets are well defined and 
are summarized in Figure 17. A figure aimed at educating patients on im­
proving their ‘heart health’ after an ACS event is provided in the 
Supplementary data online, Figure S5.
Recommendation Table 15 — Recommendations for 
acute coronary syndrome comorbid conditions
Recommendations
Classa
Levelb
Chronic kidney disease
The use of low- or iso-osmolar contrast media (at 
the lowest possible volume) is recommended for 
invasive strategies.691–693
I
A
It is recommended to assess kidney function using 
eGFR in all patients with ACS.
I
C
It is recommended to apply the same diagnostic and 
therapeutic strategies in patients with CKD (dose 
adjustment may be necessary) as in patients with 
normal kidney function.
I
C
Hydration during and after angiography should be 
considered in patients at risk of contrast-induced 
nephropathy, especially in patients with acute kidney 
injury and/or CKD with eGFR <30 mL/min/ 
1.73 m2.694–697
IIa
B
Diabetes
It is recommended to base the choice of long-term 
glucose-lowering treatment on the presence of 
comorbidities, including heart failure, CKD, and 
obesity.698–704
I
A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.705–707
I
B
It is recommended to frequently monitor blood 
glucose levels in patients with known diabetes 
mellitus or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be 
avoided.708,709
IIa
C
Older adults
It is recommended to apply the same diagnostic and 
treatment strategies in older patients as in younger 
patients.662,664,665,710,711
I
B
It is recommended to adapt the choice and dosage of 
antithrombotic agent, as well as of secondary 
prevention medications, to renal function, 
co-medications, comorbidities, frailty, cognitive 
function, and specific contraindications.363,712
I
B
For frail older patients with comorbidities, a holistic 
approach is recommended to individualize 
interventional and pharmacological treatments after 
careful evaluation of the risks and benefits.668,673,676
I
B
Continued
Patients with cancer
An invasive strategy is recommended in cancer 
patients presenting with high-risk ACS with expected 
survival ≥6 months.682,689,690
I
B
A temporary interruption of cancer therapy is 
recommended in patients in whom the cancer 
therapy is suspected to be a contributing cause of 
ACSc.713,714
I
C
A conservative non-invasive strategy should be 
considered in ACS patients with poor cancer 
prognosisd (i.e. with expected survival <6 months) 
and/or very high bleeding risk.690
IIa
C
Aspirin is not recommended in cancer patients with a 
platelet count <10 000/μL.715
III
C
Clopidogrel is not recommended in cancer patients 
with a platelet count <30 000/μL.
III
C
In ACS patients with cancer and <50 000/μL platelet 
count, prasugrel or ticagrelor are not recommended.
III
C
© ESC 2023
ACS, acute coronary syndrome; CKD, chronic kidney disease; eGFR, estimated glomerular 
filtration rate. 
aClass of recommendation. 
bLevel of evidence. 
cAnticancer therapies associated with high risk of ACS (very common [>10%]) include: 
capecitabine, paclitaxel, cisplatin, carfilzomib, bevacizumab, ramucirumab, aflibercept, 
axitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, ponatinib, and erlotinib. 
dRelated to advanced cancer stage and/or severe irreversible non-CV comorbidities.
ESC Guidelines                                                                                                                                                                                          3781


<!-- PAGE 63 -->

### Page 63

Smoking cessation
Healthy diet
Regular exercise
Healthy weight
Support healthy 
lifestyle choices
Continue optimal pharmacological  and cardio-protective treatment
Reach and sustain risk 
factor treatment targets
Discharge on cardioprotective medications,
start lifestyle management and refer to cardiac rehab
Arrange OPD review to 
manage comorbidities 
and discuss patient goals 
and preferences
1
2
3
Psychosocial management
Antithrombotic therapy
Lipid-lowering therapy
Annual influenza vaccination
Long term treatment after ACS
Treatment goals
Promote drug adherence and persistence
+
other treatments as appropriatea
Systolic BP
<130 mmHg 
and diastolic 
BP <80 mmHg
(if tolerated)b
LDL-C <1.4 mmol/L 
(<55 mg/dL)
HbA1c <53 mmol/mol 
(<7%)c
Figure 17 Long-term management after acute coronary syndrome. ACS, acute coronary syndrome; HbA1c, glycosylated haemoglobin; LDL-C, low- 
density lipoprotein cholesterol; OPD, outpatient department. aSee Recommendation Table 16 for other pharmacological treatments after ACS. bFor pa­
tients ≥70 years of age the systolic target should be <140 mmHg and down to 130 mmHg if tolerated.646 cFor patients with diabetes mellitus.


<!-- PAGE 64 -->

### Page 64

13.1. Cardiac rehabilitation
13.1.1. Comprehensive cardiac rehabilitation
Secondary prevention is most effectively provided through cardiac re­
habilitation (CR).716,717 All ACS patients should participate in a com­
prehensive CR programme, which should start as early as possible 
after the ACS event.716,717,719 CR may be performed in inpatient or 
outpatient settings, taking age, frailty, results of prognostic risk stratifi­
cation, and comorbidities into account.716 Comprehensive CR is a 
multidisciplinary intervention, supervised and performed by a team 
and usually co-ordinated by a cardiologist.716 The core components 
of CR include patient assessment, management and control of CV 
risk factors, physical activity counselling, prescription of exercise train­
ing, dietary advice, tobacco counselling, patient education, psychosocial 
management, and vocational support.716 Several studies have found 
that CR programmes after atherosclerotic cardiovascular disease 
(ASCVD) events or revascularization reduce CV hospitalizations, MI, 
CV mortality and, in some studies, all-cause mortality.720–725 Despite 
proven benefits, the rates of referral to, participation in, and implemen­
tation of CR programmes are low.726–730 Another identified issue is 
that many patients adopt healthier lifestyles during CR but relapse to 
pre-morbid habits when returning to everyday life.731 Therefore, there 
is an unmet need for complementary pathways to the classical centre- 
based CR model. In addition to alternatives to CR, there is also a need 
for stronger endorsement of CR by physicians, cardiologists, and 
healthcare professionals.732,733 It is also important to initiate and estab­
lish a strong partnership between patients and healthcare professionals 
as early as possible.732–734
13.1.2. Digital health
Telerehabilitation may be an effective strategy to maintain a healthy life­
style over time and can support or even partially replace conventional, 
centre-based CR.729 Telerehabilitation means rehabilitation from a dis­
tance, covering all CR core components, including telecoaching, social 
interaction, telemonitoring, and e-learning.735,736 Studies in patients 
with CAD have shown that telerehabilitation can be equivalent to trad­
itional CR in terms of achieving functional improvement, managing risk 
factors, and increasing patient well-being.737–741 Few data are available 
about the effect of telerehabilitation on recurrent events.742
Nevertheless, in a meta-analysis no significant difference was found be­
tween mortality following telehealth interventions and centre-based 
supervised CR.743 Also, most trials have only focused on one of the 
CR core components—exercise training and/or physical activity.742
Therefore, more research on the impact of telerehabilitation on out­
comes is still needed, as are investigations into health and digital literacy 
in CR.
13.1.3. Adherence and persistence
Promotion of both adherence (the extent to which a patient adheres to 
a prescribed treatment or lifestyle advice) and persistence (the length of 
time between initiation and discontinuation of a prescribed treatment 
or lifestyle advice) are key in preventing recurrent CV events after ACS. 
Adherence to medication has been shown to be sub-optimal, ranging 
from 50% in primary prevention to 66% in secondary prevention. It 
is estimated that 9% of ASCVD events in Europe occur as a result of 
sub-optimal medication adherence.646 Contributors to sub-optimal ad­
herence and persistence are multidimensional and include: polyphar­
macy, drug regimen complexity, the doctor–patient relationship, a 
lack of patient-centred care and disease acceptance, concern regarding 
side effects, cognitive ability, mental and physical disorders, financial 
aspects, living alone, and depression.646,744–749 Polypills, which include 
guideline-recommended treatments for secondary prevention, have 
been shown to increase adherence in post-ACS patients and may im­
prove therapeutic targets.750–752 The Secondary Prevention of 
Cardiovascular Disease in the Elderly (SECURE) study is the only 
RCT testing the impact of a strategy based on a polypill (containing as­
pirin, ramipril, and atorvastatin) vs. usual care on hard outcomes in ACS 
patients. The polypill strategy was associated with a significant reduc­
tion in major CV events, driven by a significant 33% reduction in CV 
mortality.753 The use of technology to improve medication adherence 
is also generating interest: mobile phone applications and mobile health 
(mHealth) tools may improve medication adherence, but clinical trials 
of sufficient size and duration are needed.754–756 Finally, it is important 
to recognize that adherence has complex underlying psychological dri­
vers, and therefore a whole-systems approach is mandatory. This 
should include the education of health professionals, the use of patient- 
reported outcomes and experience measures, patient education, and 
patient-centred care.734,757,758
13.2. Lifestyle management
Lifestyle management is one of the cornerstones of comprehensive 
CR.716 While most of the evidence regarding the benefits of a 
healthy lifestyle on prognosis comes from primary prevention, 
studies in secondary prevention settings indicate similar beneficial 
effects.716,724,759–763
13.2.1. Tobacco
Tobacco abstinence is associated with a reduced risk of re-infarction 
(30–40%) and death (35–45%) after ACS.763–765 Measures to promote 
cessation of smoking are therefore a priority after ACS. Interventions 
for smoking cessation should begin during hospitalization using a com­
bination of behavioural interventions, pharmacotherapy, and counsel­
ling.18,766 Many patients continue or resume smoking after ACS, in 
particular patients with depression and environmental exposures.646
During encounters with smokers, the ‘very brief advice’ evidence-based 
intervention should be used to facilitate dialogue between the patient 
and healthcare worker.646 Drug interventions, including nicotine- 
replacement therapy (NRT), bupropion and varenicline, should be con­
sidered along with behavioural support. All forms of NRT are effective, 
and the anti-depressant bupropion aids in long-term smoking cessation 
with similar efficacy to NRT.646,766 Varenicline is the most effective 
medical treatment to support smoking cessation and is safe to use in 
ACS patients.767–770 An average weight gain of 5 kg can be expected 
when a person quits smoking, but it is important to recognize that 
the CV risk from continued smoking outweighs the CV risk from gain­
ing weight.646
E-cigarettes have been used to help smokers quit, but evidence on 
their impact on successful smoking cessation is insufficient, particularly 
with regard to whether using e-cigarettes actually helps the person re­
main tobacco free. While e-cigarettes do contain nicotine, they do not 
contain as many tobacco chemicals as cigarettes. Caution should be gi­
ven with respect to the use of e-cigarettes, as current evidence suggests 
they are harmful to CV health by increasing arterial stiffness, heart rate 
and blood pressure, and by causing endothelial dysfunction.771
13.2.2. Nutrition and alcohol
A healthy diet and eating habits influence CV risk. Adopting a 
Mediterranean-style diet can help reduce CV risk in all individuals, in­
cluding persons at high CV risk and patients with ASCVD.761,762,772
ESC Guidelines                                                                                                                                                                                          3783


<!-- PAGE 65 -->

### Page 65

Supplementary data online, Table S17 summarizes the characteristics of 
a healthy diet that should be adhered to. For further details on nutrition, 
please refer to the 2021 ESC Guidelines on cardiovascular disease 
prevention.646
With regard to alcohol consumption, recent data suggest that alco­
hol abstainers have the lowest risk of CVD outcomes, that any amount 
of alcohol uniformly increases blood pressure and body mass index, and 
that a weekly consumption of >100 g of alcohol is associated with de­
creased life expectancy.773–775 Accordingly, it is recommended to re­
strict alcohol consumption to a maximum of 100 g per week (same 
limit for men and women).646
13.2.3. Physical activity and exercise
Based on extensive data from the general population, sedentary behav­
iour, defined as time spent sitting or lying with low energy expenditure, 
while awake, is an independent risk factor for all-cause mortality.776,777
According to recommendations from the World Health Organization, 
adults with chronic conditions should limit their amount of sedentary 
time, replacing it with physical activity of any intensity (including light in­
tensity).646,778 General physical activity recommendations include a 
combination of regular aerobic physical activity and resistance exercise 
throughout the week, which also forms the basis of recommendations 
for patients post-ACS.646,778 However, it is important to recognize that 
daily physical activity does not replace participation in exercise-based 
CR. With support from multiple randomized trials, exercise training 
is a pivotal part of comprehensive CR and participation in exercise- 
based CR should be offered to all patients after ACS.779
Cardiorespiratory fitness is a strong predictor of future prognosis 
both in the general population and in post-ACS patients.780
13.2.4. Psychological considerations
There is a two-fold risk of anxiety and mood disorders in patients 
with heart disease. Depression, anxiety, and psychological stress 
are associated with worse outcomes. Psychological and pharmaco­
logical interventions can have a beneficial effect and should be consid­
ered for ACS patients with depression, anxiety, and stress.781 It is 
recommended that all patients have their mental well-being assessed 
using validated tools before discharge, with consideration of onward 
psychological referral when appropriate.782 For further details, 
please refer to the 2021 ESC Guidelines on cardiovascular disease 
prevention.646
13.2.5. Resumption of activities
Information on the resumption of activities, sexual activity, and 
environmental factors is presented in the Supplementary data online, 
Section 13.1.2.
13.3. Pharmacological treatment
13.3.1. Antithrombotic therapy
Recommendations for antithrombotic therapy are included in Section 6.
13.3.2. Lipid-lowering therapy
Dyslipidaemia should be managed according to the current dyslipidae­
mia guidelines, with a combination of lifestyle and pharmacological 
interventions.783 Trials have consistently demonstrated that lower low- 
density lipoprotein-cholesterol (LDL-C) levels after ACS are associated 
with lower CV event rates.784 The current treatment goal for second­
ary prevention is to lower LDL-C to <1.4 mmol/L (<55 mg/dL) and to 
achieve a ≥50% LDL-C reduction from baseline. For patients who ex­
perience a second CV event within 2 years (not necessarily of the same 
type as the first event), an LDL-C goal of <1.0 mmol/L (<40 mg/dL) ap­
pears to confer additional benefit.783,785,786
After an ACS event, lipid-lowering treatment should be initiated as 
early as possible, both for prognostic benefit and to increase patient 
adherence after discharge. It is recommended that a high-intensity sta­
tin (e.g. atorvastatin or rosuvastatin) is initiated as early as possible 
after hospital admission, preferably before planned PCI, and pre­
scribed up to the highest tolerated dose in order to reach the LDL-C 
goals.783,787 The intensity of statin therapy should be increased in pa­
tients who were receiving low- or moderate-intensity statin treatment 
before the ACS event. In IMPROVE-IT (Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial), ezetimibe treatment 
early after ACS (within 10 days) was added on top of prior statin ther­
apy or initiated concomitantly in statin-naïve patients (two-thirds of 
patients) and compared with statin monotherapy.788 Treatment with 
ezetimibe was shown to be safe and provided long-term benefits for 
CV outcomes. As such, if patients are on a maximally tolerated statin 
dose, or have no prior statin treatment, and have LDL-C levels which 
indicate it is unlikely that targets will be reached with statin therapy 
alone, initiating ezetimibe in addition to a statin (or statin plus ezeti­
mibe combination treatment) may be considered during the ACS 
hospitalization.783,788 In the ODYSSEY OUTCOMES (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary Syndrome During 
Treatment With Alirocumab) trial, treatment with the proprotein con­
vertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab was in­
itiated as early as 1 month after ACS.786 Treatment with PCSK9 
inhibitors has been shown to be safe and effective in lowering LDL-C 
in patients hospitalized with ACS.789–791 Recent data have also shown 
improvements in plaque phenotype and plaque regression in ACS pa­
tients treated with PCSK9 inhibitors.792,793 Combined with the data 
from trials on the long-term benefits of PCSK9 inhibitors and observa­
tional data on the importance of lowering LDL-C early after ACS, 
PCSK9 inhibitor treatment should be initiated during ACS hospitaliza­
tion in patients who were not at their LDL-C goal despite being on 
statin and ezetimibe treatment before admission.785,786,794–796
In all cases, lipid levels should be re-evaluated 4–6 weeks after each 
treatment or dose adjustment to determine whether treatment goals 
have been achieved and to check for any safety issues; the therapeutic 
regimen can then be adapted accordingly. If the LDL-C goals are not 
achieved with the maximum tolerated dose of a statin alone after 4– 
6 weeks following ACS, adding ezetimibe is recommended.783,788
Initiation of PCSK9 inhibitor treatment is recommended in patients 
who do not reach their LDL-C goal despite maximum tolerated statin 
and ezetimibe therapy.783,785,786 Finally, icosapent ethyl, at a dose of 2 g 
b.i.d., can be used in combination with a statin in patients with ACS and 
triglyceride levels of 1.5–5.6 mmol/L (135–499 mg/dL) despite statin 
treatment.783,797 An algorithm for lipid-lowering management in ACS 
patients is outlined in Figure 18.
For a detailed description of the different lipid-lowering drug classes 
and respective trial data, please refer to the Supplementary data online.


<!-- PAGE 66 -->

### Page 66

13.3.3. Beta-blockers
The clinical benefit of beta-blockers after ACS in patients with reduced 
LVEF is supported by evidence from contemporary trials.557,798–800
However, the evidence for prescribing beta-blockers after uncompli­
cated ACS in patients with LVEF >40% is less well established. With 
the exception of the CAPRICORN (CArvedilol Post-infaRct survIval 
COntRolled evaluatioN) trial, which only recruited patients with 
LVEF ≤40%, all large RCTs testing the benefits of post-MI beta-blocker 
maintenance were performed in the pre-reperfusion era.801 Pooled 
data demonstrated that post-MI beta-blocker therapy reduced the 
Prior treatment
LDL-C <1.4 mmol/L
or 55 mg/dLa
Add ezetimibe
(Class I)
LDL-C <1.4 mmol/L
or 55 mg/dLa
LDL-C <1.4 mmol/L
or 55 mg/dLa
On highest tolerated statin and ezetimibe,
add PCSK9i
(Class I)
LDL-C <1.4 mmol/L
or 55 mg/dLa
Lipid lowering therapy in ACS patients
Y
Y
N
N
N
No change in therapy
No change in therapy
Y
No change in therapy
Y
No change in therapy
Add
PCSK9i
(Class I)
N
LLT-naive,
irrespective of
LDL-C values
Initiate high-potency high-dose statin
(Class I)
Combination therapy with statin and ezetimibe
(Class IIb)
Change to high-potency high-dose statin
(Class I)
On low-potency/
low-dose statin,
irrespective 
of LDL-C values
On highest tolerated statin
On highest tolerated statin and ezetimibe
Combination therapy with statin and ezetimibe
(Class IIb)
On highest tolerated statin,
add ezetimibe
(Class I)
On highest tolerated statin and ezetimibe, add PCSK9i
(Class I)
During admission
Outpatient follow-up
After 4–6 weeks
After further 4–6 weeks
Figure 18 Lipid-lowering therapy in ACS patients. ACS, acute coronary syndrome; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. aConsider LDL-C <1.0 mmol/L if recurrent event.
ESC Guidelines                                                                                                                                                                                          3785


<!-- PAGE 67 -->

### Page 67

risk of death by >20%. These trials mostly enrolled patients with STEMI, 
making the evidence for their benefit in NSTEMI less robust. In addition, 
since these trials were performed, the clinical scenario has changed dra­
matically, with improvements in invasive strategies and associated 
pharmacotherapy resulting in an improved prognosis for patients 
with ACS.718 Modern observational studies and meta-analyses of these 
trials have yielded mixed results, with some studies suggesting a benefit 
of beta-blocker therapy irrespective of LVEF, and others reaching the 
opposite conclusion.557,800,802–804
There is only one small, open-label trial, CAPITAL-RCT (Carvedilol 
Post-Intervention 
Long-Term 
Administration 
in 
Large-scale 
Randomized Controlled Trial), that randomized 801 STEMI patients 
with successful PPCI and preserved LVEF to carvedilol or control.805
During a 3-year follow-up, the incidence of a composite of all-cause death, 
MI, hospitalization for HF, and hospitalization for ACS was not significantly 
different between the two groups. However, the trial was underpowered 
and therefore this scientific question remains open. There are four on­
going pragmatic prospective large-scale RCTs in Europe randomizing 
ACS patients without reduced LVEF to beta-blocker or control: 
REBOOT-CNIC (TREatment With Beta-blockers After myOcardial 
Infarction withOut Reduced Ejection fracTion), 8468 ACS patients with 
LVEF >40%; REDUCE-SWEDEHEART (Evaluation of Decreased Usage 
of Betablockers After Myocardial Infarction in the SWEDEHEART 
Registry), 5000 ACS patients with LVEF ≥50% (NCT03278509); 
BETAMI (BEtablocker Treatment After Acute Myocardial Infarction in 
Patients Without Reduced Left Ventricular Systolic Function), 10 000 
ACS patients with LVEF >40%; and DANBLOCK (Danish Trial of Beta 
Blocker Treatment After Myocardial Infarction Without Reduced 
Ejection Fraction), 3570 ACS patients with LVEF >40%.806–808
The duration of beta-blocker therapy after uncomplicated ACS is 
also another controversial topic. There are some observational studies 
suggesting that the clinical benefit of beta-blocker therapy is restricted 
to the first year after the index ACS event, but the non-randomized na­
ture of the studies limits their conclusions.809 There are two ongoing 
large-scale RCTs testing the impact of beta-blocker withdrawal after 
6–12 months following uncomplicated ACS in patients with preserved 
LVEF: AβYSS (Beta Blocker Interruption After Uncomplicated 
Myocardial Infarction; NCT03498066) and SMART-DECISION 
(Long-term Beta-blocker Therapy After Acute Myocardial Infarction; 
NCT04769362).810
13.3.4. Nitrates and calcium channel blockers
Intravenous nitrates may be useful during the acute phase in STEMI pa­
tients with hypertension or HF, provided there is no hypotension or RV 
infarction. In the ISIS-4 (Fourth International Study of Infarct Survival) 
trial, oral nitrates had no survival benefit in MI patients.811 Their use 
is therefore restricted to the control of residual angina, as recom­
mended in the 2019 ESC Guidelines for the diagnosis and management 
of chronic coronary syndromes.195 Calcium channel blocker use was 
not associated with prognostic benefit in a systematic review including 
28 trials.812 Calcium channel blocker use can be considered in the con­
text of residual angina and for blood pressure control as recommended 
in the 2021 ESC Guidelines on CVD prevention and the 2019 ESC 
Guidelines for the diagnosis and management of CCS.195,646
13.3.5. Renin–angiotensin–aldosterone system 
inhibitors
Angiotensin-converting enzyme (ACE) inhibitors have been demon­
strated to improve outcomes in post-MI patients with additional 
conditions, such as clinical HF and/or LVEF ≤40%, diabetes, CKD, 
and/or hypertension.813–817 A systematic overview of (old) trials of 
ACE inhibition early in STEMI showed that their use is associated 
with a small but significant reduction in 30-day mortality, especially in 
anterior MIs.818
In the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial, 
valsartan was found to be non-inferior to captopril in patients with a 
recent MI plus HF and/or LVEF ≤40%.819
There is established evidence that patients with heart failure with re­
duced ejection fraction (HFrEF), regardless of aetiology, benefit from 
ACE inhibitors.820–823
Angiotensin receptor/neprilysin inhibitors 
(ARNI) have been shown to be superior to ACE inhibitors in patients 
with established HF (of different aetiologies) and LVEF ≤40%.824
However, in the more recent PARADISE-MI (Prospective ARNI vs 
ACE Inhibitor Trial to Determine Superiority in Reducing Heart 
Failure Events After MI), a dedicated study in patients with recent 
ACS (1–7 days) complicated by HF and/or LVEF ≤40%, an ARNI com­
bination (sacubitril plus valsartan) was not associated with a significantly 
lower incidence of death from CV causes or incident HF in comparison 
to the active comparator ramipril.825
In general, ACE inhibitors (or sacubitril plus valsartan as a replace­
ment for them) are recommended for patients with established 
HFrEF regardless of the aetiology.557 These agents may be considered 
for patients with HF with mildly reduced ejection fraction.557 Patients 
who tolerate neither ACE inhibitors nor ARNI are recommended to 
be treated with an angiotensin receptor blocker.
In the Eplerenone Post-AMI Heart failure Efficacy and SUrvival Study 
(EPHESUS), the mineralocorticoid receptor antagonist (MRA) eplere­
none was associated with reduced mortality and CV hospitalizations 
in patients with a recent MI and LV dysfunction with symptoms of ei­
ther 
HF 
or 
diabetes.826
The 
Double-Blind, 
Randomized, 
Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early 
Treatment With Eplerenone In Patients With Acute Myocardial 
Infarction (REMINDER) trial randomized 1012 patients with acute 
STEMI without HF to eplerenone or placebo within 24 h of symptom 
onset.827 The primary endpoint was the composite of CV mortality, re- 
hospitalization, or extended initial hospital stay due to diagnosis of HF, 
sustained VT or VF, ejection fraction ≤40%, or elevated BNP/NT-pro 
BNP at 1 month or more after randomization. Eplerenone was asso­
ciated with a significant reduction in the primary composite endpoint, 
although this difference was primarily driven by BNP levels.827
13.3.6. Medications for diabetes
13.3.6.1. Sodium–glucose co-transporter 2 inhibitors
Pharmacological blockade of SGLT2 induces glycosuria with lowering of 
plasma glucose levels, improving glycaemic control without hypogly­
caemia, and leading to reductions in weight and blood pressure.828 In 
patients with type 2 diabetes and established ASCVD, three trials 
(with empagliflozin, canagliflozin, and dapagliflozin) have demonstrated 
significant CV benefits.656,829,830 In a meta-analysis of these three trials, 
MACE were reduced by 11%, with no clear effect on stroke or MI. This 
benefit was only seen in patients with established ASCVD.698 The ben­
efits of SGLT2 inhibitors may relate more to cardio-renal haemo­
dynamic effects than to atherosclerosis.646 Further recommendations 
for patients with diabetes can be found in the current ESC Guidelines 
on diabetes, pre-diabetes,and cardiovascular diseases.831
In patients with HF regardless of their LVEF, dapagliflozin and empa­
gliflozin have been shown to significantly reduce the risk of worsening 
HF or CV death, both in the presence or absence of type 2


<!-- PAGE 68 -->

### Page 68

diabetes.702,703,832,833 In the EMMY (EMpagliflozin in patients with acute 
MYocardial infarction) trial, empagliflozin led to a significant improve­
ment in NT-pro BNP reduction over 26 weeks post-MI, accompanied 
by a significant improvement in echocardiographic functional and 
structural parameters.834 Ongoing outcome trials in ACS populations 
will be useful to better define the role of these agents in the absence 
of HF.835
13.3.6.2. Glucagon-like peptide-1 receptor agonists
In a systematic review and meta-analysis of seven trials (56 004 patients 
with type 2 diabetes) testing different GLP1-RAs, their use was asso­
ciated with reductions in the incidence of MACE, CV death, all-cause 
mortality, MI, and stroke.699
13.3.7. Proton pump inhibitors
Proton pump inhibitors (PPIs) reduce the risk of upper gastroduodenal 
bleeding in patients treated with antiplatelet agents.287,836,837 Therapy 
with a PPI is indicated for patients receiving any antithrombotic regimen 
who are at high risk of gastrointestinal bleeding (for details see Section 
8.2.2.3, Bleeding risk assessment, in the Supplementary data online).
PPIs that inhibit CYP2C19, particularly omeprazole and esomepra­
zole, may reduce the pharmacodynamic response to clopidogrel, 
though there is no strong evidence that this results in an increased 
risk of ischaemic events or stent thrombosis in clinical trials and propen­
sity score-matched studies.287,288,838–842 Importantly, no interaction 
between the concomitant use of PPIs and aspirin, prasugrel or ticagre­
lor has been observed.
13.3.8. Vaccination
An annual influenza vaccination in patients with stable ASCVD appears 
to be associated with reduced incidence of MI, an improved prognosis 
in patients with HF, and decreased CV risk in adults aged 65 years and 
older.843,844 In addition, influenza vaccination given early after an MI or 
in high-risk CAD has been shown to result in a lower risk of all-cause 
death and CV death at 12 months.845–847 Therefore, influenza vaccin­
ation is recommended for all ACS patients and should be given prefer­
entially during index hospitalization during influenza season for those 
not protected by a seasonal influenza vaccination.
13.3.9. Anti-inflammatory drugs
Inflammation plays a central role in the pathogenesis of atherosclerosis 
and acute coronary events. Several recent trials have tested the role of 
the anti-inflammatory agent colchicine in acute and chronic coronary 
syndromes.848,849 In the Colchicine Cardiovascular Outcomes Trial 
(COLCOT), which enrolled 4745 patients with a recent ACS event, 
low-dose colchicine (0.5 mg daily) was associated with a significant re­
duction of the primary composite endpoint (CV death, resuscitated 
cardiac arrest, MI, stroke, or urgent revascularization) in comparison 
to placebo.850 Of note, pneumonia was more frequent in the colchicine 
group. The Low-dose Colchicine trial-2 (LoDoCo2) enrolled 5522 pa­
tients with CCS (84% of whom had prior ACS) who were randomized 
to colchicine (0.5 mg daily) or placebo.851 The primary endpoint (com­
posite of CV death, MI, stroke, or ischaemia-driven coronary revascu­
larization) rate was significantly lower in the colchicine group; however, 
the incidence of non-CV death was higher in the colchicine group. The 
benefits of colchicine in reducing CV events have been shown to be 
consistent irrespective of history and timing of prior ACS.852
13.3.10. Hormone replacement therapy
For further information on hormone replacement therapy in patients 
with ACS, please see the Supplementary data online.
Recommendation Table 16 — Recommendations for 
long-term management
Recommendations
Classa
Levelb
Cardiac rehabilitation
It is recommended that all ACS patients participate in 
a medically supervised, structured, comprehensive, 
multidisciplinary exercise-based cardiac rehabilitation 
and prevention programme.721–724,853,854
I
A
Lifestyle management
It is recommended that ACS patients adopt a healthy 
lifestyle, including: 
• stopping all smoking of tobacco
• healthy diet (Mediterranean style)
• alcohol restriction
• regular aerobic physical activity and resistance 
exercise
• reduced sedentary time724,761,763,772,773,776,777,855– 
858
I
B
In smokers, offering follow-up support, nicotine 
replacement therapy, varenicline or bupropion, 
individually or in combination, should be 
considered.859–864
IIa
A
Pharmacological treatment
Lipid-lowering therapy
It is recommended that high-dose statin therapy is 
initiated or continued as early as possible, regardless 
of initial LDL-C values.787,865–867
I
A
It is recommended to aim to achieve an LDL-C level 
of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C 
by ≥50% from baseline.868,869
I
A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy after 4–6 weeks, the addition 
of ezetimibe is recommended.788
I
B
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy and ezetimibe after 4–6 
weeks, the addition of a PCSK9 inhibitor is 
recommended.785,786,795,796
I
A
It is recommended to intensify lipid-lowering 
therapyc during the index ACS hospitalization for 
patients who were on lipid-lowering therapy before 
admission.
I
C
For patients with a recurrent atherothrombotic 
event (recurrence within 2 years of first ACS 
episode) while taking maximally tolerated 
statin-based therapy, an LDL-C goal of <1.0 mmol/L 
(<40 mg/dL) may be considered.785,786
IIb
B
Combination therapy with high-dose statin plus 
ezetimibe may be considered during index 
hospitalization.788
IIb
B
Continued
ESC Guidelines                                                                                                                                                                                          3787


<!-- PAGE 69 -->

### Page 69

### 14 Patient perspectives

14.1. Patient-centred care
The management of patients with ACS should not only consider the 
best available evidence with regard to clinical management strategies, 
but also should be mindful of the provision of care that is respectful 
of and responsive to individual patient preferences, needs, and values, 
ensuring that these values are included in clinical decision-making.881
Patient-centred care should be guided by ethical values when consid­
ering a patient’s physical, emotional, and psychological needs. Adopting 
a person-centred care approach after an ACS event improves patient 
outcomes and enhances quality of life.882 Patients who are regarded 
as equal partners in their ACS medical management are more likely 
to actively engage and participate in their own healthcare.883
Educating and involving patients in their care should be seen as a con­
tinuous process. Engaging and educating the patient is a key component 
of ACS care and should take place throughout their patient journey, 
from admission to hospital discharge and cardiac rehabilitation 
(Figure 19).
Beta-blockers
Beta-blockers are recommended in ACS patients 
with LVEF ≤40% regardless of HF symptoms.801,870– 
872
I
A
Routine beta-blockers for all ACS patients regardless 
of LVEF should be considered.798,873–878
IIa
B
RAAS system inhibitors
Angiotensin-converting enzyme (ACE) inhibitorsd 
are recommended in ACS patients with HF 
symptoms, LVEF ≤40%, diabetes, hypertension, and/ 
or CKD.195,813–817,879
I
A
Mineralocorticoid receptor antagonists are 
recommended in ACS patients with an LVEF ≤40% 
and HF or diabetes.826,880
I
A
Routine ACE inhibitors for all ACS patients 
regardless of LVEF should be considered.816,817
IIa
A
Adherence to medication
A polypill should be considered as an option to 
improve adherence and outcomes in secondary 
prevention after ACS.753
IIa
B
Imaging
In patients with pre-discharge LVEF ≤40%, repeat 
evaluation of the LVEF 6–12 weeks after an ACS (and 
after complete revascularization and the institution 
of optimal medical therapy) is recommended to 
assess the potential need for sudden cardiac death 
primary prevention ICD implantation.
I
C
Cardiac magnetic resonance imaging should be 
considered as an adjunctive imaging modality in order 
to assess the potential need for primary prevention 
ICD implantation.
IIa
C
Vaccination
Influenza vaccination is recommended for all ACS 
patients.843,845–847
I
A
Continued
Anti-inflammatory drugs
Low-dose colchicine (0.5 mg once daily) may be 
considered, particularly if other risk factors are 
insufficiently controlled or if recurrent cardiovascular 
disease events occur under optimal therapy.850,851
IIb
A
© ESC 2023
ACS, acute coronary syndrome; CKD, chronic kidney disease; HF, heart failure; ICD, 
implantable cardioverter defibrillator; LDL-C, low-density lipoprotein-cholesterol; LVEF, 
left ventricular ejection fraction; PCSK9, proprotein convertase subtilisin/kexin type 9; 
RAAS, renin–angiotensin–aldosterone system. 
aClass of recommendation. 
bLevel of evidence. 
cIncrease statin potency/dose if the patient was on low-potency/low-dose statin, add 
ezetimibe if the patient was only on statins at highest tolerated dose, or add PCSK9 
inhibitor if the patient was on statins plus ezetimibe. 
dAngiotensin receptor blockers in cases of intolerance.


<!-- PAGE 70 -->

### Page 70

14.2. Shared decision-making
Shared decision-making is a process, during which the patient and a 
healthcare professional work together to make an informed decision 
about the patient’s care.884 During this process, information is pro­
vided, comprehension checked, and the patient is given an opportunity 
to ask questions in order to equip them with the tools needed to make 
an informed decision.
Using a shared decision-making approach during the consent process 
allows the patient’s preferences to be established.884 Discovery of the 
patient’s concerns, goals, preferences, and values should be a central 
component of this process. The use of validated decision aids and 
audio-visual tools may also be helpful to facilitate informed consent 
and promote patient involvement.884–887
14.3. Informed consent
Informed consent should include the components listed in 
Supplementary data online, Table S18.885,888 Informed consent is an op­
portunity to educate patients about the proposed procedure, the asso­
ciated risks and benefits, and any available alternative interventions or 
treatments.886,887 Assessment of the patient’s understanding of the in­
formation given to them during the informed consent process using the 
‘teach back’ technique should be considered (Supplementary data 
online, Figure S6).885,889–891 The teach back method assesses under­
standing by asking patients to state in their own words what they 
need to know or do about their health.
Informed consent is an ethical and legal obligation for medical practi­
tioners and is required before any invasive procedure. The information 
Premorbid condition
Consider all risk factors
Establish medical history and prior medications
Consider psychosocial factors
Hospital admission
Individualize care at triage
Perform a person-centred clinical assessment
Employ shared decision-making
Preparing for discharge
Explain regarding 
long-term treatment
Educate about 
lifestyle modification
Consider mental and emotional health
At every stage, consider physical and psychosocial needs
Taking a person-centred approach to the ACS journey
Figure 19 A person-centred approach to the ACS journey. ACS, acute coronary syndrome.
ESC Guidelines                                                                                                                                                                                          3789


<!-- PAGE 71 -->

### Page 71

should be provided in a simple and clear format. In patients undergoing 
emergency invasive angiography, a shortened informed consent pro­
cess is appropriate. If a shortened informed consent process has 
been used, it is important that there is contact with the patient and/ 
or family member after the intervention when the patient is physically 
and psychologically stable or following the death of the patient.892
Further information can be found in the Supplementary data online.
14.4. Research participation and consent in 
the acute setting
With unstable ACS patients, it is often challenging to obtain their con­
sent for emergency procedures—and even more challenging to enrol 
in clinical trials due to a number of factors, including the necessity for 
prompt clinical care, increased pain and stress levels, and impairment 
of consciousness. Where clinical trials are conducted, patient involve­
ment in enrolment decisions is paramount, if possible.893,894 A short 
witnessed verbal consent, followed by written consent after the acute 
phase, has been shown to be less stressful and more positively re­
ceived than written consent in the acute setting.894 The research 
and consent process must follow the ethical and legal requirements 
in the relevant country. Further information can be found in the 
Supplementary data online.
14.5. Patient satisfaction and expectations
Focusing healthcare around the needs and preferences of patients has 
the potential to improve clinical outcomes, quality of care and patient 
satisfaction, while decreasing healthcare costs and health disparities.881
Patient perception of care is built on interpersonal interactions, the 
quality of clinical communication, delivery of care, and the administra­
tive management of care. ACS patient expectations are summarized 
in Figure 20
and further information can be found in the 
Supplementary data online, Table S19.
...their ACS symptoms to be recognised
...high quality, effective and safe care delivered by professionals
…the right care at the right time
…their physical, mental and emotional wellbeing to be considered
…clear, comprehensible 
information
…shared decision making and respect 
for their preferences
…consideration of,
and support for,
their family and carers
…attention to both
 their physical and 
environmental needs
…a clean and safe hospital environment
ACS patients expect…
Figure 20 Acute coronary syndrome patient expectations. ACS, acute coronary syndrome.


<!-- PAGE 72 -->

### Page 72

14.6. Patient-reported outcome measures 
and patient-reported experience 
measures
Understanding and measuring patient expectations and health out­
comes using patient-reported outcome measures (PROMs) and pa­
tient-reported experience measures (PREMs) is central to improving 
patient satisfaction and delivering patient-centred care.895 The quality 
of care for ACS patients should be measured during the patient’s jour­
ney from initial presentation until discharge. Further information can be 
found in the Supplementary data online. Further information on 
PROMs and PREMs is also provided in the Supplementary data online.
14.7. Preparation for discharge
Many ACS patients may not be fully aware of what has happened to 
them and how to best manage their healthcare after discharge, leading 
to them both wanting and needing more information upon dis­
charge.896 Cognitive impairment can occur as a complication of ACS 
and some patients may have difficulty with instructions for care when 
transitioning towards discharge home.897 Therefore, discharge infor­
mation should be provided in both verbal and written formats and 
should include a discharge letter outlining the key components of the 
evidence-based 
discharge 
plan 
(Supplementary 
data 
online, 
Table S20).898–901 Some important messages aimed at patients on 
how to improve their heart health after ACS are demonstrated in 
Supplementary data online, Figure S5. Moreover, following an ACS 
event, anxiety and depression are frequently encountered and confer 
an increased risk of non-adherence to medications and lifestyle changes, 
subsequent MACE, and death.902–904 Non-adherence also generally in­
creases over time, which has additional impact on clinical outcomes.905
Assessing and identifying these patients and intervening with onward 
psychological referral is recommended.858 Further information can be 
found in the Supplementary data online. A summary of patient con­
cerns and educational needs throughout their ACS journey is also pro­
vided in Supplementary data online, Figure S7.
15. Key messages
Epidemiology of ACS
Acute coronary syndromes encompass a spectrum of conditions that 
include patients with a recent change in clinical symptoms or signs, 
with or without changes on 12-lead ECG and with or without acute ele­
vations in cardiac troponin concentrations. ACS are commonly classi­
fied based on ECG at presentation and the presence or absence of 
troponin elevation into UA, NSTEMI, or STEMI. The incidence of 
STEMI is decreasing whereas the incidence of NSTEMI is increasing. 
While there are some sex differences in the epidemiology of ACS, wo­
men and men receive equal benefit from invasive and non-invasive man­
agement strategies and, in general, should be managed similarly.
Diagnostic tools (ECG, troponin, and non-invasive imaging)
Chest pain/discomfort is the most common symptom initiating the ACS 
diagnostic and therapeutic pathway. High-sensitivity troponin measure­
ments and rapid ‘rule-in’ and ‘rule-out’ algorithms should be used in patients 
with suspected NSTE-ACS. MI is not the only condition resulting in cardi­
omyocyte injury and cardiac troponin elevation, and other conditions 
should also be considered in the differential diagnosis. Non-invasive imaging 
can be useful to increase diagnostic accuracy and optimize risk assessment.
STEMI management networks
Co-ordination between EMS and hospitals with common written proto­
cols is central to the management of STEMI. EMS should transfer patients 
immediately to 24/7 high-volume PCI centres regardless of the initial 
treatment strategy (PPCI or pre-hospital fibrinolysis). EMS should always 
alert the PCI centre immediately after selection of the reperfusion strat­
egy, and patient transfer to the PCI centre should bypass the ED.
Invasive strategy and reperfusion therapy
An invasive strategy is recommended for patients with ACS. Invasive strat­
egies are time sensitive. For STEMI and very high-risk NSTE-ACS, an im­
mediate invasive strategy is recommended. For patients with NSTE-ACS 
an inpatient invasive strategy is recommended; in NSTE-ACS patients 
with high-risk characteristics, an early invasive strategy (<24 h) should 
be considered. If timely (within 120 min from time of diagnosis) PPCI can­
not be performed in patients with STEMI, fibrinolytic therapy is indicated 
within 12 h of symptom onset in patients without contraindications.
Antithrombotic therapy
Antithrombotic therapy is indicated in all ACS patients, regardless of the 
management strategy. This consists of both antiplatelet and anticoagulant 
therapy. Aspirin is recommended for all ACS patients at an initial loading 
dose and a longer-term maintenance dose. In addition to aspirin, a P2Y12 
receptor inhibitor is recommended, and should be maintained over 12 
Recommendation Table 17 — Recommendations for 
patient perspectives in acute coronary syndrome care
Recommendations
Classa
Levelb
Patient-centred care is recommended by assessing 
and adhering to individual patient preferences, needs 
and beliefs, ensuring that patient values are used to 
inform all clinical decisions.744,881,906,907
I
B
It is recommended to include ACS patients in 
decision-making (as much as their condition allows) 
and to inform them about the risk of adverse events, 
radiation exposure, and alternative options. Decision 
aids can be used to facilitate the discussion.908,909
I
B
It is recommended to assess symptoms using 
methods that help patients to describe their 
experience.910
I
C
Use of the ‘teach back’ technique for decision 
support during the securing of informed consent 
should be considered.885,889–891
IIa
B
Continued
Patient discharge information should be provided in 
both written and verbal formats prior to discharge. 
Adequate preparation and education for patient 
discharge using the teach back technique and/or 
motivational interviewing, giving information in 
chunks, and checking for understanding should be 
considered.885,896,911
IIa
B
Assessment of mental well-being using a validated 
tool and onward psychological referral when 
appropriate should be considered.903,904,912,913
IIa
B
© ESC 2023
ACS, acute coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3791


<!-- PAGE 73 -->

### Page 73

months unless there are concerns regarding HBR. Regarding P2Y12 recep­
tor inhibitor choice, prasugrel and ticagrelor are recommended in prefer­
ence to clopidogrel, and prasugrel should be considered in preference to 
ticagrelor for ACS patients who undergo PCI. Pre-treatment (i.e. treat­
ment with a P2Y12 receptor inhibitor prior to coronary angiography) in pa­
tients with NSTE-ACS is not recommended routinely but may be 
considered for patients with STEMI undergoing PPCI. Parenteral anticoa­
gulation is recommended for all patients at the time of diagnosis. 
Discontinuation of parenteral anticoagulation should be considered imme­
diately after the invasive procedure. Some patients with ACS will also have 
an indication for long-term OAC, most commonly AF. In these patients, 
TAT for up to 1 week, followed by DAT using a NOAC at the recom­
mended dose for stroke prevention and a single oral antiplatelet agent 
(preferably clopidogrel), is recommended as the default strategy.
ACS with unstable presentation
A PPCI strategy is recommended in patients with resuscitated cardiac 
arrest and an ECG with persistent ST elevation (or ST elevation equiva­
lents), whereas routine immediate angiography is not recommended in 
patients with an ECG without persistent ST elevation (or equivalents). 
Temperature control (i.e. continuous monitoring of core temperature 
and active prevention of fever [i.e. >37.7°C]) is recommended in pa­
tients with OHCA who remain unresponsive after ROSC. In patients 
with CS complicating ACS, emergency coronary angiography is recom­
mended, whereas the routine use of IABP in ACS patients with CS and 
no mechanical complications is not.
Early care
Following reperfusion, it is recommended to admit high-risk ACS patients, 
including all STEMI patients, to a CCU/ICCU. ECG monitoring for ar­
rhythmias and ST-segment changes is recommended for at least 24 h after 
symptom onset in all high-risk patients with ACS. It is recommended that 
all hospitals participating in the care of high-risk ACS patients have an 
ICCU/CCU equipped to provide all required aspects of care including 
treatment of ischaemia, severe HF, arrhythmias, and common co- 
morbidities. It is also recommended that the LVEF is determined before 
hospital discharge in all patients with ACS. Discharge of high-risk ACS pa­
tients within 48–72 h should be considered in selected patients if early re­
habilitation and adequate follow-up are arranged.
Technical aspects during PPCI
Routine radial access and use of DES are the standard of care during PCI 
for ACS. Intravascular imaging should be considered to guide PCI and 
may be considered in patients with ambiguous culprit lesions. 
Routine thrombus aspiration is not recommended. CABG should be 
considered in patients with an occluded IRA when PCI is not feasible 
or unsuccessful and there is a large area of myocardium in jeopardy. 
In patients presenting with SCAD, PCI is recommended only for pa­
tients with symptoms and signs of ongoing myocardial ischaemia, a large 
area of myocardium in jeopardy, and reduced antegrade flow.
Management of patients with MVD
For patients with MVD, it is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the patient’s clinical status 
and comorbidities, as well as their disease complexity, according to the 
principles of management of myocardial revascularization. For patients 
with MVD presenting with CS, IRA-only PCI during the index procedure 
is recommended. For patients with STEMI undergoing PPCI, complete re­
vascularization is recommended either during the index PCI or within 45 
days. In patients presenting with NSTE-ACS and MVD, complete revascu­
larization should be considered, preferably during the index procedure. 
For patients with STEMI, it is recommended that decisions regarding 
PCI of non-IRA are based on angiographic severity, whereas for patients 
with NSTE-ACS, functional invasive evaluation of non-IRA severity during 
the index procedure may be considered.
MINOCA
The term MINOCA refers to the situation where patients present with 
symptoms suggestive of ACS and demonstrate troponin elevation and 
non-obstructive coronary arteries at the time of coronary angiography, 
i.e. coronary artery stenosis <50% in any major epicardial vessel. 
MINOCA is best considered as a working diagnosis that encompasses a 
heterogenous group of underlying causes (both cardiac and extra-cardiac) 
and is found in 1–14% of patients with ACS. In all patients with an initial 
working diagnosis of MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying cause. CMR imaging is a key diag­
nostic tool in patients with a working diagnosis of MINOCA.
Special patient subsets
Chronic kidney disease: moderate to severe CKD is present in >30% of 
ACS patients. These patients receive less interventional and pharmaco­
logical treatment and have a worse prognosis in comparison to patients 
with normal kidney function. It is recommended to apply the same diag­
nostic and therapeutic strategies in patients with CKD (dose adjustment 
may be necessary) as for patients with normal kidney function.
Older adults: in general, older adults should undergo the same diag­
nostic and treatment strategies, including invasive angiography and re­
vascularization, as younger patients.
Patients with cancer: management of ACS in patients with cancer can 
be challenging for several reasons, including frailty, increased bleeding 
risk, thrombocytopaenia, and increased thrombotic risk. An invasive 
strategy is recommended in cancer patients presenting with high-risk 
ACS with expected survival ≥6 months. A conservative non-invasive 
strategy should be considered in ACS patients with poor cancer prog­
nosis (with expected survival <6 months) and/or very high bleeding risk.
Long-term treatment
Secondary prevention after ACS should be offered to every patient and 
should start as early as possible after the index event. This includes car­
diac rehabilitation, lifestyle management, and pharmacological treat­
ment, and has been shown to both increase quality of life and 
decrease morbidity and mortality. 
Patient perspectives
Some of the key first steps in the timely diagnosis and treatment of ACS 
are reliant on a comprehensive assessment of symptoms. An incom­
plete history or poorly elicited symptoms can result in delay or misdiag­
nosis. Patient-centred care is recommended as a critical tenet of 
routine clinical management and involves consideration of a patient’s 
physical, emotional, and psychological needs.
The provision of care that is respectful of, and responsive to, individ­
ual patient preferences, needs and values, is important in the manage­
ment of patients with ACS. It is recommended, as much as possible, 
to include ACS patients in decision-making. Preparing for discharge be­
gins on admission. Educating and informing the patient using the teach 
back method and educationally appropriate material should be inte­
grated into the patient care pathway.
Quality indicators
Acute coronary syndrome QIs aim to audit practice and improve clin­
ical outcomes in real-life patients by demonstrating the gap between 
optimal guideline-based treatment and actual care of ACS patients. 
Subsequent measures to improve QI attainment can be implemented 
based on the local, regional, and global assessment of QIs.


<!-- PAGE 74 -->

### Page 74

### 16 Gaps in evidence

Table 8 Gaps in evidence
Section
Gaps in evidence
Research recommendations to address 
these gaps
3
Triage and diagnosis
• Observe zone: how can we improve the guidance for and 
management of patients assigned to the observe zone of 
the 0 h/1 h and 0 h/2 h ESC algorithms to improve their 
poor outcome?
• No testing rule: what is the added value of biomarkers 
other than hs-cTn for rapid rule-out of NSTE-ACS 
compared with usual care?
• There is insufficient evidence to set sex-specific 
thresholds for troponin levels.
• The role of non-invasive anatomy (e.g. CCTA) or 
functional imaging (e.g. stress testing strategies) for 
low-risk NSTE-ACS patients should be further evaluated.
• Observe zone: prospectively evaluate changes in the 
0 h/1 h and 0 h/2 h ESC algorithms to improve the 
outcomes of patients assigned to the observe zone.
• No testing rule: randomization of patients to 
strategies with and without new biomarkers to 
evaluate whether their use improves clinical 
outcomes.
• Prospectively evaluate the impact of using 
sex-specific cut-offs on the diagnosis, treatment, 
and outcomes of patients presenting to the ED with 
suspected ACS.
• Adequately powered RCTs testing whether 
non-invasive imaging improves clinical outcomes in 
patients presenting with NSTE-ACS.
4
Initial measures for 
patients presenting with 
suspected STEMI | Initial 
treatment
• The impact of early i.v. beta-blockers on clinical outcomes 
in patients with a working diagnosis of STEMI remains 
unclear.
• Infarct size and microvascular obstruction are the main 
determinants of long-term prognosis. Interventions 
which serve to limit infarct size are needed.
• Patients randomized to i.v. beta-blockers (ideally 
metoprolol) or placebo before PPCI, with hard 
endpoints evaluated.
• Translate cardio-protective therapies from 
experimental to clinical setting by executing 
adequately powered trials.
5
Acute-phase management 
of patients with NSTE-ACS
• The comparison of routine or selective invasive 
assessment in low-risk NSTE-ACS has not been 
adequately evaluated.
• The optimal timing of invasive angiography in high-risk 
NSTE-ACS patients remains uncertain.
• Low-risk patients should be randomized to routine 
or selective invasive strategy.
• RCTs testing different time intervals to perform 
angiography within the 72 h window after the initial 
presentation.
6
Antithrombotic therapy
• Whether pre-treatment with oral P2Y12 receptor 
inhibitors prior to ICA improves clinical outcomes in 
NSTE-ACS patients is uncertain.
• Whether platelet function testing or genetic testing to 
guide de-escalation of oral P2Y12 receptor inhibitors after 
the first month of therapy following PCI improves clinical 
management and outcomes remains unclear.
• The optimal long-term antithrombotic regimen in 
NSTE-ACS patients who have undergone PCI is 
unknown.
• After stopping DAPT, a head-to-head comparison based 
on superiority between aspirin monotherapy and 
clopidogrel monotherapy is required.
• Randomize patients to pre-treatment with oral 
P2Y12 receptor inhibitors or no pre-treatment, 
prior to ICA.
• Randomize ACS patients to prasugrel or ticagrelor, 
both without pre-treatment.
• A strategy based on platelet function testing or 
genetic testing should be prospectively tested in 
patients who may benefit from de-escalating 
antithrombotic therapy.
• RCTs evaluating the benefit-risk balance for 
ischaemic bleeding events for different periods of 
antithrombotic duration.
• A head-to-head randomized comparison testing for 
superiority is needed to compare aspirin vs. 
clopidogrel monotherapy after DAPT.
7
Acute coronary syndrome 
with unstable presentation
• The role of percutaneous MCS devices in patients 
presenting with ACS and CS remains unclear.
• Randomized comparisons between standard of care 
and percutaneous MCS devices in ACS with CS.
8
Management of acute 
coronary syndrome during 
hospitalization
• Clinical improvement through the use of risk stratification 
based on risk prediction models.
• Patients randomized to a particular intervention or 
to usual care based on validated risk prediction 
models.
9
Technical aspects of 
invasive strategies
• Does intravascular imaging-guided revascularization 
strategy improve clinical outcomes in patients  
with ACS?
• Does intracoronary physiology assessment of myocardial 
reperfusion after PPCI improve risk stratification and/or 
stratified medicine for limiting microvascular dysfunction 
and reperfusion injury/MVO post ACS?
• RCTs evaluating the efficacy of an intravascular 
imaging-guided revascularization strategy to 
improve meaningful clinical outcomes in patients 
with ACS.
• Prospectively evaluate whether intracoronary 
physiology assessment of myocardial reperfusion 
better stratifies patient risk.
Continued
ESC Guidelines                                                                                                                                                                                          3793


<!-- PAGE 75 -->

### Page 75

• In ACS patients with an IRA that is unsuitable for stent 
implantation, does drug-coated balloon treatment of the 
IRA improve clinical outcomes?
• Microvascular obstruction associated with PPCI 
represents an unmet clinical need in patients with ACS. 
Development of therapies for the prevention and 
treatment of MVO is urgently needed.
• Does early implementation of MCS in the management of 
high-risk ACS patients improve clinical outcomes?
• Does intracoronary hypothermia reduce infarct size and 
improve clinical outcomes in STEMI patients undergoing 
PPCI?
• What is the optimal antiplatelet strategy in patients 
presenting with SCAD? Specific gaps in knowledge 
surround antithrombotic treatment in the acute and 
post-ACS periods, including the optimal combination and 
duration of treatment.
• Patients with an IRA unsuitable for stent 
implantation randomized to drug-coated balloon 
treatment or usual care to evaluate clinical 
outcomes.
• Pre-clinical and clinical research is needed to 
evaluate cardio-protective therapies aimed at 
reducing microvascular obstruction.
• RCTs evaluating the benefit of using MCS in 
high-risk patients.
• Randomized trials are needed to demonstrate both 
whether intracoronary hypothermia reduces 
myocardial infarct size, and if this translates into 
clinical improvement.
• RCTs evaluating several antiplatelet strategies in 
patients with SCAD with the aim of determining 
which results in the greatest clinical benefit.
10
Management of patients 
with multivessel disease
• Does complete revascularization of NSTE-ACS with 
multivessel CAD improve clinical outcomes vs. 
culprit-only PCI?
• Does management of non-infarct-related CAD with 
intravascular imaging guidance to identify rupture-prone 
atherosclerotic plaque improve clinical outcomes?
• Does FFR-guided management improve clinical outcomes 
vs. standard angiography-guided management in 
NSTE-ACS?
• What is the optimal timing of coronary revascularization 
(immediate vs. index hospitalization vs. staged) for 
non-IRA revascularization in STEMI and NSTE-ACS?
• Does intensive medical therapy improve outcomes in 
patients with MVD compared with standard secondary 
prevention?
• The clinical utility of hybrid coronary revascularization in 
ACS patients with multivessel CAD is uncertain.
• Patients with NSTE-ACS and MVD randomized to 
complete vs. culprit-only PCI.
• RCTs testing whether the use of intravascular 
imaging to guide the management of 
non-infarct-related lesions improves clinical 
outcomes.
• Patients randomized to FFR-guided management vs. 
standard angiography-guided management in 
NSTE-ACS.
• Three-arm study comparing the clinical benefits of 
immediate, in-hospital and staged coronary 
revascularization strategies.
• Patients with MVD randomized to intensive 
secondary prevention vs. usual care to evaluate 
whether the former strategy improves clinical 
outcomes.
• RCTs assessing the clinical benefit of hybrid 
revascularization.
12
Special situations
• How to better differentiate Type 2 from Type 1 MI 
before invasive assessment.
• The optimal management strategy in older adults with 
NSTE-ACS is not known.
• The optimal management strategy in older frail, comorbid 
adults with NSTE-ACS is not known.
• The optimal management strategy in older frail, comorbid 
adults with STEMI is not known.
• Optimal antiplatelet therapy and its duration to manage 
ACS in pregnant patients are not known.
• The optimal management strategy for pregnant women 
with NSTE-ACS is not known.
• There is a need to further evaluate the contribution of 
social determinants of health.
• Prospective evaluation of diagnostic strategies 
aimed at better classifying patients according to 
their type of MI (Type 1 vs. Type 2).
• Further studies recruiting older adults should be 
conducted to evaluate whether the current 
standard of care also benefits this subset of patients.
• Older frail, comorbid patients should not be 
systematically excluded from RCTs.
• Prospective data are needed to better understand 
which antiplatelet therapy regimen is best for 
pregnant women.
• Observational data are needed in patients with ACS 
to evaluate the real impact of social determinants of 
health on clinical outcomes. Randomized 
interventions aimed at reducing social inequalities 
are needed to evaluate how to reduce this gap.
13
Long-term treatment
• To evaluate the uptake, safety, and outcomes for 
alternative forms of cardiac rehabilitation, with a focus on 
telemedicine and eHealth.
• How to improve referral for and uptake of CR, especially 
for groups with low participation, including women, older 
persons, and ethnic minorities.
• Remote cardiac rehabilitation methods need 
randomized data to evaluate their true potential.
• Further monitoring is needed to increase the 
participation of historically under-represented 
patients in CR.
Continued


<!-- PAGE 76 -->

### Page 76

### 17 Sex differences

There are currently no data supporting the differential management of 
ACS based on sex. However, several studies have reported that wo­
men presenting with ACS are treated differently than men.914–918
This includes being less likely than men to receive ICA, timely revascu­
larization, CR, and secondary prevention medications.914–918
Healthcare providers and policymakers should be conscious of this 
potential gender bias in the management of ACS and make a concerted 
effort to ensure that women with ACS receive evidence-based care.
In order to ensure the generalizability of the findings yielded by 
RCTs, patient recruitment should be reflective of real-world popula­
tions from different socioeconomic backgrounds.919 Several studies 
have reported that a disproportionately low proportion of women 
are recruited to CV trials.920–922
Alongside historic under- 
representation of other subsets of patients, including older patients 
and ethnic minorities, this suggests an underlying recruitment bias.923
Increased representation of female patients in future clinical trials is re­
quired to better inform the optimal management of women with 
ACS.924
• The role of personalized medicine in the short- and 
long-term treatment of ACS needs to be further studied.
• How to address additional risk from non-traditional risk 
factors, e.g. cardio-obstetrics, cardio-oncology, and 
inflammatory conditions, needs further attention.
• Inflammation as a treatment target in patients with 
atherosclerosis still needs unravelling, as well as the use of 
biomarkers of inflammation (high-sensivity C-reactive 
protein, interleukins 1 and 6) to guide treatment of 
residual risk.
• The role of lipoprotein (a) in guiding treatment and as an 
independent treatment target needs to be studied further.
• The added cardio-protective role of beta-blockers in 
post-ACS patients without reduced LVEF on otherwise 
optimal medical therapy needs to be clarified.
• The added cardio-protective role of ACE inhibitors/ARBs 
in post-ACS patients without reduced LVEF on otherwise 
optimal medical therapy needs to be clarified.
• The future role of new treatment options, using mRNA- 
and siRNA-based therapies targeting lipid metabolism 
and inflammation, needs to be explored.
• It has to be determined whether SGLT2 inhibitors—in 
the specific group of patients with ACS without heart 
failure or diabetes—improve clinical outcomes, 
regardless of diabetes status.
• Patients randomized to personalized strategies vs. 
usual care are needed to determine the role of 
precision medicine in ACS.
• Prospective cohorts are needed to evaluate 
non-traditional risk factors and residual risk.
• RCTs testing whether management based on the 
use of biomarkers of inflammation improves clinical 
outcomes.
• RCTs testing whether lipoprotein (a) measurement 
to guide medical management further improves 
clinical outcomes.
• Patients randomized to beta-blocker and no 
beta-blocker use to evaluate treatment efficacy in 
patients with ACS and LVEF >40%.
• RCTs evaluating the benefit of using ACE inhibitors/ 
ARBs vs. placebo on top of standard care in ACS 
patients with LVEF >40%.
• Randomized data are needed to evaluate the role of 
mRNA- and siRNA-based therapies in the current 
context of lipid management and lipid targets.
• ACS patients without HF or diabetes should be 
randomized to SGLT2 inhibitors vs. standard of 
care.
14
Patient perspectives
• The feasibility of performing short witnessed verbal 
consent followed by written consent after the acute 
phase needs further evaluation.
• There is a need to assess the contribution of social 
determinants of health on ACS incidence and prognosis.
• The use of validated patient-reported outcome and 
experience measures in evidence-based medicine should 
be increased.
• Quality of life is a relevant outcome not captured in most 
trials.
• Use of validated decision aids and audio-visual tools can 
be helpful to make informed choices that consider 
patients’ values and preferences and promote patient 
involvement.
• Studies comparing verbal vs. written consent to 
evaluate safety endpoints and any ethical concerns.
• The influence of social determinants of health on 
clinical outcomes should be evaluated, as well as 
those interventions aimed at reducing social 
inequalities.
• PROMs/PREMs should have a more prominent role 
in RCTs evaluating patients with ACS.
• Include quality of life as a prominent outcome in 
clinical trials.
• Testing the use of validated decision aids and 
audio-visual tools to improve decisions around 
informed choices.
19
Quality indicators
• There is a lack of implementation studies evaluating 
whether prospectively monitoring and reporting ESC QIs 
for ACS improve clinical outcomes.
• Implementation studies evaluating a quality of care 
programme based on the evaluation of ESC QIs for 
ACS.
General
• Patients included in clinical trials represent a relatively 
small proportion of real-life patients.
• Conduct clinical trials that enrol more 
representative patient populations (e.g. pragmatic 
clinical trials).
© ESC 2023
Ongoing trials addressing some of these gaps in evidence are presented in the Supplementary data online. 
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CR, 
cardiac rehabilitation; CS, cardiogenic shock; DAPT, dual antiplatelet therapy; ED, emergency department; ESC, European Society of Cardiology; FFR, fractional flow reserve; HF, heart failure; ICA, 
invasive coronary angiography; IRA, infarct-related artery; i.v., intravenous; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MINOCA, 
myocardial infarction with non-obstructive coronary arteries; mRNA, messenger ribonucleic acid; MVD, multivessel disease; MVO, microvascular obstruction; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; PREM, patient-reported experience measure; PROM, 
patient-reported outcome measure; QI, quality indicator; RCT, randomized controlled trial; SCAD, spontaneous coronary artery dissection; SGLT2, sodium-glucose co-transporter 2; siRNA, 
small interfering ribodeoxynucleic acid; STEMI, ST-elevation myocardial infarction.
ESC Guidelines                                                                                                                                                                                          3795


<!-- PAGE 77 -->

### Page 77

18. ‘What to do’ and ‘What not to 
do’ messages from the Guidelines
Table 9 ‘What to do’ and ‘What not to do’
Recommendations for clinical and 
diagnostic tools for patients with suspected 
acute coronary syndrome
Classa
Levelb
It is recommended that patients with suspected 
STEMI are immediately triaged for an emergency 
reperfusion strategy.
I
A
It is recommended to base the diagnosis and initial 
short-term risk stratification of ACS on a 
combination of clinical history, symptoms, vital signs, 
other physical findings, ECG, and hs-cTn.
I
B
Twelve-lead ECG recording and interpretation is 
recommended as soon as possible at the point of first 
medical contact, with a target of <10 min.
I
B
Continuous ECG monitoring and the availability of 
defibrillator capacity is recommended as soon as 
possible in all patients with suspected STEMI, in 
suspected ACS with other ECG changes or ongoing 
chest pain, and once the diagnosis of MI is made.
I
B
The use of additional ECG leads (V3R, V4R, and V7– 
V9) is recommended in cases of inferior STEMI or if 
total vessel occlusion is suspected and standard leads 
are inconclusive.
I
B
An additional 12-lead ECG is recommended in 
cases with recurrent symptoms or diagnostic 
uncertainty.
I
C
It is recommended to measure cardiac troponins 
with high-sensitivity assays immediately after 
presentation and to obtain the results within 60 min 
of blood sampling.
I
B
It is recommended to use an ESC algorithmic 
approach with serial hs-cTn measurements (0 h/1 h 
or 0 h/2 h) to rule in and rule out NSTEMI.
I
B
Additional testing after 3 h is recommended if the 
first two hs-cTn measurements of the 0 h/1 h 
algorithm are inconclusive and no alternative 
diagnoses explaining the condition have been made.
I
B
Recommendations for non-invasive imaging in the initial 
assessment of patients with suspected acute coronary 
syndrome
Emergency TTE is recommended in patients with 
suspected ACS presenting with cardiogenic shock or 
suspected mechanical complications.
I
C
Routine, early coronary computed tomography 
angiography in patients with suspected ACS is not 
recommended.
III
B
Continued
Recommendations for the initial management of patients with 
acute coronary syndrome
It is recommended that the pre-hospital 
management of patients with a working diagnosis of 
STEMI is based on regional networks designed to 
deliver reperfusion therapy expeditiously and 
effectively, with efforts made to make PPCI available 
to as many patients as possible.
I
B
It is recommended that PPCI-capable centres deliver 
a 24/7 service and are able to perform PPCI without 
delay.
I
B
It is recommended that patients transferred for PPCI 
bypass the emergency department and CCU/ICU 
and are transferred directly to the catheterization 
laboratory.
I
B
Oxygen is recommended in patients with 
hypoxaemia (SaO2 <90%).
I
C
It is recommended that EMS transfer patients with 
suspected STEMI to a PCI-capable centre, bypassing 
non-PCI centres.
I
C
It is recommended that ambulance teams are trained 
and equipped to identify ECG patterns suggestive of 
acute coronary occlusion and to administer initial 
therapy, including defibrillation, and fibrinolysis when 
applicable.
I
C
It is recommended that all hospitals and EMS 
participating in the care of patients with suspected 
STEMI record and audit delay times and work 
together to achieve and maintain quality targets.
I
C
Routine oxygen is not recommended in patients with 
oxygen saturation >90%.
III
A
Recommendations for reperfusion therapy and timing of 
invasive strategy
Recommendations for reperfusion therapy for patients with 
STEMI
Reperfusion therapy is recommended in all patients 
with a working diagnosis of STEMI (persistent 
ST-segment elevation or equivalents) and symptoms 
of ischaemia of ≤12 h duration.
I
A
A PPCI strategy is recommended over fibrinolysis if 
the anticipated time from diagnosis to PCI is 
<120 min.
I
A
If timely PPCI (<120 min) cannot be performed in 
patients with a working diagnosis of STEMI, 
fibrinolytic therapy is recommended within 12 h of 
symptom onset in patients without 
contraindications.
I
A
Rescue PCI is recommended for failed fibrinolysis 
(i.e. ST-segment resolution <50% within 60–90 min 
of fibrinolytic administration) or in the presence of 
haemodynamic or electrical instability, worsening 
ischaemia, or persistent chest pain.
I
A
Continued


<!-- PAGE 78 -->

### Page 78

In patients with a working diagnosis of STEMI and a 
time from symptom onset >12 h, a PPCI strategy is 
recommended in the presence of ongoing symptoms 
suggestive of ischaemia, haemodynamic instability, or 
life-threatening arrhythmias.
I
C
Routine PCI of an occluded IRA is not recommended 
in STEMI patients presenting >48 h after symptom 
onset and without persistent symptoms.
III
A
Transfer/interventions after fibrinolysis
Transfer to a PCI-capable centre is recommended in 
all patients immediately after fibrinolysis.
I
A
Emergency angiography and PCI of the IRA, if 
indicated is recommended in patients with 
new-onset or persistent heart failure/shock after 
fibrinolysis.
I
A
Angiography and PCI of the IRA, if indicated, is 
recommended between 2 and 24 h after successful 
fibrinolysis.
I
A
Invasive strategy in NSTE-ACS
An invasive strategy during hospital admission is 
recommended in NSTE-ACS patients with high-risk 
criteria or with a high index of suspicion for unstable 
angina.
I
A
A selective invasive approach is recommended in 
patients without very high- or high-risk features and a 
low index of suspicion for NSTE-ACS.
I
A
An immediate invasive strategy is recommended in 
patients with a working diagnosis of NSTE-ACS and 
with at least one of the following very high-risk 
criteria: 
• Haemodynamic instability or cardiogenic shock
• Recurrent or refractory chest pain despite medical 
treatment
• In-hospital life-threatening arrhythmias
• Mechanical complications of MI
• Acute heart failure presumed secondary to 
ongoing myocardial ischaemia
Recurrent dynamic ST-segment or T wave changes, 
particularly intermittent ST-segment elevation.
I
C
Recommendations for antiplatelet and anticoagulant therapy in 
acute coronary syndrome
Antiplatelet therapy
Aspirin is recommended for all patients without 
contraindications at an initial oral LD of 150–300 mg 
(or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for 
long-term treatment.
I
A
In all ACS patients, a P2Y12 receptor inhibitor is 
recommended in addition to aspirin, given as an initial 
oral LD followed by an MD for 12 months unless 
there is high bleeding risk.
I
A
A proton pump inhibitor in combination with dual 
antiplatelet therapy is recommended in patients at 
high risk of gastrointestinal bleeding.
I
A
Continued
Prasugrel is recommended in P2Y12 receptor 
inhibitor-naïve patients proceeding to PCI (60 mg 
LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged 
≥75 years or with a body weight <60 kg).
I
B
Ticagrelor is recommended irrespective of the 
treatment strategy (invasive or conservative) 
(180 mg LD, 90 mg twice a day MD).
I
B
Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is 
recommended when prasugrel or ticagrelor are not 
available, cannot be tolerated, or are contraindicated.
I
C
If patients presenting with ACS stop DAPT to 
undergo CABG, it is recommended they resume 
DAPT after surgery for at least 12 months.
I
C
Pre-treatment with a glycoprotein IIb/IIIa antagonist 
is not recommended.
III
A
Routine pre-treatment with a P2Y12 receptor 
inhibitor in NSTE-ACS patients in whom coronary 
anatomy is not known and early invasive 
management (<24 h) is planned is not 
recommended.
III
A
Anticoagulant therapy
Parenteral anticoagulation is recommended for all 
patients with ACS at the time of diagnosis.
I
A
Routine use of a UFH bolus (weight-adjusted i.v. 
bolus during PCI of 70–100 IU/kg) is recommended 
in patients undergoing PCI.
I
C
Patients with STEMI
Fondaparinux is not recommended in patients with 
STEMI undergoing PPCI.
III
B
Patients with NSTE-ACS
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is not anticipated, 
fondaparinux is recommended.
I
B
Combining antiplatelets and OAC
As the default strategy for patients with atrial 
fibrillation and CHA2DS2-VASc score ≥1 in men and 
≥2 in women, after up to 1 week of triple 
antithrombotic therapy following the ACS event, 
dual antithrombotic therapy using a non-vitamin K 
antagonist oral anticoagulant at the recommended 
dose for stroke prevention and a single oral 
antiplatelet agent (preferably clopidogrel) for up to 
12 months is recommended.
I
A
During PCI, a UFH bolus is recommended in any of 
the following circumstances: 
• if the patient is on a NOAC
• if the INR is <2.5 in VKA-treated patients.
I
C
The use of ticagrelor or prasugrel as part of triple 
antithrombotic therapy is not recommended.
III
C
Continued
ESC Guidelines                                                                                                                                                                                          3797


<!-- PAGE 79 -->

### Page 79

Recommendations for alternative antithrombotic therapy 
regimens
Discontinuation of antiplatelet treatment in patients 
treated with an oral anticoagulant is recommended 
after 12 months.
I
B
De-escalation of antiplatelet therapy in the first 30 
days after ACS is not recommended.
III
B
Recommendations for fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is 
recommended to initiate this treatment as soon as 
possible after diagnosis in the pre-hospital setting 
(aim for target of <10 min to lytic bolus).
I
A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or 
reteplase) is recommended.
I
B
Antiplatelet co-therapy with fibrinolysis
Aspirin and clopidogrel are recommended.
I
A
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated 
with fibrinolysis until revascularization (if performed) 
or for the duration of hospital stay (up to 8 days).
I
A
Enoxaparin i.v. followed by subcutaneous is 
recommended as the preferred anticoagulant.
I
A
When enoxaparin is not available, unfractionated 
heparin is recommended as a weight-adjusted i.v. 
bolus, followed by infusion.
I
B
Recommendations for cardiac arrest and out-of-hospital 
cardiac arrest
A PPCI strategy is recommended in patients with 
resuscitated cardiac arrest and an ECG with 
persistent ST-segment elevation (or equivalents).
I
B
Temperature control (i.e. continuous monitoring of 
core temperature and active prevention of fever [i.e. 
>37.7°C]) is recommended after either 
out-of-hospital or in-hospital cardiac arrest for adults 
who remain unresponsive after return of 
spontaneous circulation.
I
B
Routine immediate angiography after resuscitated 
cardiac arrest is not recommended in 
haemodynamically stable patients without persistent 
ST-segment elevation (or equivalents).
III
A
Systems of care
It is recommended that healthcare systems 
implement strategies to facilitate transfer of all 
patients in whom ACS is suspected after resuscitated 
cardiac arrest directly to a hospital offering 24/7 PPCI 
via one specialized EMS.
I
C
Evaluation of neurological prognosis
Evaluation of neurological prognosis (no earlier than 
72 h after admission) is recommended in all 
comatose survivors after cardiac arrest.
I
C
Continued
Recommendations for cardiogenic shock
Immediate coronary angiography and PCI of the IRA 
(if indicated) is recommended in patients with CS 
complicating ACS.
I
B
Emergency CABG is recommended for  
ACS-related CS if PCI of the IRA is not feasible/ 
unsuccessful.
I
B
In cases of haemodynamic instability, emergency 
surgical/catheter-based repair of mechanical 
complications of ACS is recommended, based on 
Heart Team discussion.
I
C
The routine use of an intra-aortic balloon pump in 
ACS patients with CS and without mechanical 
complications is not recommended.
III
B
Recommendations for in-hospital management
It is recommended that all hospitals participating in 
the care of high-risk patients have an ICCU/CCU 
equipped to provide all required aspects of care, 
including treatment of ischaemia, severe heart failure, 
arrhythmias, and common comorbidities.
I
C
It is recommended that high-risk patients (including all 
STEMI patients and very high-risk NSTE-ACS 
patients) have ECG monitoring for a minimum of 24 h.
I
C
It is recommended that high-risk patients with 
successful reperfusion therapy and an uncomplicated 
clinical course (including all STEMI patients and very 
high-risk NSTE-ACS patients) are kept in the CCU/ 
ICCU for a minimum of 24 h whenever possible, after 
which they may be moved to a step-down monitored 
bed for an additional 24–48 h.
I
C
Recommendations for technical aspects of invasive strategies
Radial access is recommended as the standard 
approach, unless there are over-riding procedural 
considerations.
I
A
PCI with stent deployment in the IRA during the 
index procedure is recommended for patients 
undergoing PPCI.
I
A
Drug-eluting stents are recommended in preference 
to bare metal stents in all cases.
I
A
In patients with spontaneous coronary artery 
dissection, PCI is recommended only for patients 
with symptoms and signs of ongoing myocardial 
ischaemia, a large area of myocardium in jeopardy, 
and reduced antegrade flow.
I
C
The routine use of thrombus aspiration is not 
recommended.
III
A
Recommendations for management of patients with 
multivessel disease
It is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the 
patient’s clinical status and comorbidities, as well as 
their disease complexity, according to the principles 
of management of myocardial revascularization.
I
B
Continued


<!-- PAGE 80 -->

### Page 80

Multivessel disease in ACS patients presenting in cardiogenic 
shock
IRA-only PCI during the index procedure is 
recommended.
I
B
Multivessel disease in haemodynamically stable STEMI patients 
undergoing PPCI
Complete revascularization is recommended either 
during the index PCI procedure or within 45 days.
I
A
It is recommended that PCI of the non-IRA is based 
on angiographic severity.
I
B
Invasive epicardial functional assessment of 
non-culprit segments of the IRA is not 
recommended during the index procedure.
III
C
Recommendations for myocardial infarction with 
non-obstructive coronary arteries
In patients with a working diagnosis of MINOCA 
CMR imaging is recommended after invasive 
angiography if the final diagnosis is not clear
I
B
Management of MINOCA according to the final 
established underlying diagnosis is recommended, 
consistent with the appropriate disease-specific 
guidelines.
I
B
In all patients with an initial working diagnosis of 
MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying final diagnosis.
I
C
Recommendations for acute coronary syndrome complications
Atrial fibrillation
Intravenous beta-blockers are recommended when 
rate control is needed in the absence of acute HF or 
hypotension.
I
C
Intravenous amiodarone is recommended when rate 
control is needed in the presence of acute HF and no 
hypotension.
I
C
Immediate electrical cardioversion is recommended 
in patients with ACS and haemodynamic instability 
and when adequate rate control cannot be achieved 
promptly with pharmacological agents.
I
C
Intravenous amiodarone is recommended to 
facilitate electrical cardioversion and/or decrease risk 
of early recurrence of AF after electrical 
cardioversion in unstable patients with recent-onset 
AF.
I
C
Ventricular arrythmias
Implantable cardioverter defibrillator use is 
recommended to reduce sudden cardiac death in 
patients with symptomatic HF (NYHA Class II–III) 
and LVEF ≤35% despite optimal medical therapy for 
>3 months and at least 6 weeks after MI who are 
expected to survive for at least 1 year with good 
functional status.
I
A
Intravenous beta-blocker and/or amiodarone 
treatment is recommended for patients with 
polymorphic VT and/or VF unless contraindicated.
I
B
Continued
Prompt and complete revascularization is 
recommended to treat myocardial ischaemia that may 
be present in patients with recurrent VT and/or VF.
I
C
Bradyarrhythmias
In cases of sinus bradycardia with haemodynamic 
intolerance or high-degree AV block without stable 
escape rhythm:
• i.v. positive chronotropic medication (adrenaline, 
vasopressin, and/or atropine) is recommended.
• temporary pacing is recommended in cases of 
failure to respond to atropine.
• urgent angiography with a view to 
revascularization is recommended if the patient 
has not received previous reperfusion therapy.
I
C
Implantation of a permanent pacemaker is 
recommended when high-degree AV block does not 
resolve within a waiting period of at least 5 days after 
MI.
I
C
Pacing is not recommended if high-degree AV block 
resolves after revascularization or spontaneously.
III
B
Treatment of asymptomatic and haemodynamically 
irrelevant ventricular arrhythmias with 
anti-arrhythmic drugs is not recommended.
III
C
Recommendations for acute coronary syndrome comorbid 
conditions
Chronic kidney disease
The use of low- or iso-osmolar contrast media (at 
the lowest possible volume) is recommended for 
invasive strategies.
I
A
It is recommended to assess kidney function using 
eGFR in all patients with ACS.
I
C
It is recommended to apply the same diagnostic and 
therapeutic strategies in patients with CKD (dose 
adjustment may be necessary) as in patients with 
normal kidney function.
I
C
Diabetes
It is recommended to base the choice of long-term 
glucose-lowering treatment on the presence of 
comorbidities, including heart failure, CKD, and 
obesity.
I
A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.
I
B
It is recommended to frequently monitor blood 
glucose levels in patients with known diabetes 
mellitus or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Older adults
It is recommended to apply the same diagnostic and 
treatment strategies in older patients as in younger 
patients.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3799


<!-- PAGE 81 -->

### Page 81

It is recommended to adapt the choice and dosage of 
antithrombotic agent, as well as of secondary 
prevention medications, to renal function, 
co-medications, comorbidities, frailty, cognitive 
function, and specific contraindications.
I
B
For frail older patients with comorbidities, a holistic 
approach is recommended to individualize 
interventional and pharmacological treatments after 
careful evaluation of the risks and benefits.
I
B
An invasive strategy is recommended in cancer 
patients presenting with high-risk ACS with expected 
life survival ≥6 months.
I
B
A temporary interruption of cancer therapy is 
recommended in patients in whom the cancer 
therapy is suspected to be a contributing cause of 
ACS.
I
C
Aspirin is not recommended in cancer patients with a 
platelet count <10 000/μL.
III
C
Clopidogrel is not recommended in cancer patients 
with a platelet count <30 000/μL.
III
C
In ACS patients with cancer and <50 000/μL platelet 
count, prasugrel or ticagrelor are not recommended.
III
C
Recommendations for long-term management
It is recommended that all ACS patients participate in 
a medically supervised, structured, comprehensive, 
multidisciplinary exercise-based cardiac 
rehabilitation and prevention programme.
I
A
It is recommended that ACS patients adopt a healthy 
lifestyle, including: 
• stopping all smoking of tobacco
• healthy diet (Mediterranean style)
• alcohol restriction
• regular aerobic physical activity and resistance 
exercise
• reduced sedentary time
I
B
Pharmacological treatment
Lipid-lowering therapy
It is recommended that high-dose statin therapy is 
initiated or continued as early as possible, regardless 
of initial LDL-C values.
I
A
It is recommended to aim to achieve an LDL-C level 
of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C 
by ≥50% from baseline.
I
A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy and ezetimibe after 4–6 
weeks, the addition of a PCSK9 inhibitor is 
recommended
I
A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy after 4–6 weeks, the addition 
of ezetimibe is recommended.
I
B
It is recommended to intensify lipid-lowering therapy 
during the index ACS hospitalization for patients 
who were on lipid-lowering therapy before 
admission.
I
C
Continued
Beta-blockers
Beta-blockers are recommended in ACS patients 
with LVEF ≤40% regardless of HF symptoms.
I
A
RAAS system inhibitors
Angiotensin-converting enzyme inhibitors are 
recommended in ACS patients with HF symptoms, 
LVEF ≤40%, diabetes, hypertension, and/or CKD.
I
A
Mineralocorticoid receptor antagonists are 
recommended in ACS patients with an LVEF ≤40% 
and HF or diabetes.
I
A
Imaging
In patients with pre-discharge LVEF ≤40%, repeat 
evaluation of the LVEF 6–12 weeks after an ACS (and 
after complete revascularization and the institution 
of optimal medical therapy) is recommended to 
assess the potential need for sudden cardiac death 
primary prevention ICD implantation.
I
C
Vaccination
Influenza vaccination is recommended for all ACS 
patients.
I
A
Recommendations for patient perspectives in acute coronary 
syndrome care
Patient-centred care is recommended by assessing 
and adhering to individual patient preferences, needs 
and beliefs, ensuring that patient values are used to 
inform all clinical decisions.
I
B
It is recommended to include ACS patients in 
decision-making (as much as their condition allows) 
and to inform them about the risk of adverse events, 
radiation exposure, and alternative options. Decision 
aids should be used to facilitate the discussion.
I
B
It is recommended to assess symptoms using 
methods that help patients to describe their 
experience.
I
C
© ESC 2023
ACS, acute coronary syndrome; AV, atrioventricular; CABG, coronary artery bypass 
grafting; CCU, cardiac care unit; CHA2DS2-VASc, Congestive heart failure, 
Hypertension, Age ≥75 years, Diabetes mellitus, Stroke or transient ischaemic attack, 
Vascular disease; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CS, 
cardiogenic shock; DAPT, dual antiplatelet therapy; ECG, electrocardiogram; ESC, 
European Society of Cardiology; HF, heart failure; hs-cTn, high-sensitivity cardiac 
troponin; ICU, intensive care unit; IRA, infarct-related artery; i.v., intravenous; LD, 
loading dose; LDL-C, low-density lipoprotein cholesterol; MD, maintenance dose; 
MINOCA, myocardial infarction with non-obstructive coronary arteries; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; NYHA, 
New York Heart Association; o.d., once daily; OAC, oral anticoagulant; PCI, 
percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 
9; PPCI, primary percutaneous coronary intervention; RAAS, renin–angiotensin– 
aldosterone system; STEMI, ST-elevation myocardial infarction; UFH, unfractionated 
heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 82 -->

### Page 82

### 19 Quality indicators

Quality indicators are tools that can be used to evaluate care quality, 
including structures, processes, and outcomes of care.925 They may 
also serve as a mechanism for enhancing adherence to guideline recom­
mendations, through associated quality improvement initiatives and the 
benchmarking of care providers.926,927 As such, the role of QIs in im­
proving care and outcomes for CVD is increasingly recognized by 
healthcare authorities, professional organizations, payers, and the 
public.925
The ESC understands the need for measuring and reporting quality 
and outcomes of CV care and has established methods for the develop­
ment of the ESC QIs for the quantification of care and outcomes for 
CVDs.925 To date, the ESC has developed QI suites for a number of 
CVDs in parallel with the writing of the ESC Clinical Practice 
Guidelines. Previous QIs for the management of AMI have been tested 
in numerous large registries.928–933 A systematic review of these studies 
has shown that there is room for improvement in terms of levels of at­
tainment of QIs.934
The ESC aims to harmonize its QIs for various CV conditions and in­
tegrate them with ESC registries.935,936 This integrative approach pro­
vides ‘real-world’ data about the patterns and outcomes of care for 
CVD across Europe.
20. Supplementary data
Supplementary data are available at European Heart Journal online.
21. Data availability statement
No new data were generated or analysed in support of this research.
22. Author information
Author/Task Force Member Affiliations: Xavier Rossello, 
Cardiology Department, Hospital Universitari Son Espases, Palma de 
Mallorca, Spain, Clinical Research Department Centro Nacional de 
Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Health 
Research Institute of the Balearic Islands (IdiSBa), Universitat de les 
Illes Balears (UIB), Palma de Mallorca, Spain; J.J. Coughlan, 
Cardiovascular Research Institute, Mater Private Network, Dublin, 
Ireland; Emanuele Barbato, Clinical and Molecular Medicine, 
Sapienza University, Rome, Italy; Colin Berry, British Heart 
Foundation, Glasgow Cardiovascular Research Centre, University of 
Glasgow, Glasgow, United Kingdom, Cardiology, NHS Golden 
Jubilee, Clydebank, United Kingdom, Cardiology, NHS Greater 
Glasgow and Clyde Health Board, Glasgow, United Kingdom; Alaide 
Chieffo, IRCCS San Raffaele Scientific Institute, IRCCS San Raffaele 
Scientific Institute, Milan, Italy, University Vita-Salute San Raffaele, 
Milan, Italy; Marc J. Claeys, Cardiology, Antwerp University 
Hospital, Edegem, Belgium; Gheorghe-Andrei Dan, Colentina 
University Hospital, Cardiology Dpt., “Carol Davila” University of 
Medicine Bucharest, Romania; Marc R. Dweck, British Heart 
Foundation Centre for Cardiovascular Sciences, Chancellors Building, 
Little France Crescent, Little France, Edinburgh, United Kingdom; 
Mary Galbraith (United Kingdom), ESC Patient Forum, Sophia 
Antipolis, France; Martine Gilard, Cardiology, INSERM UMR 1304 
GETBO- Brest University, Brest, France; Lynne Hinterbuchner, 
Department of Cardiology, Clinic of Internal Medicine II, Paracelsus 
Medical 
University 
of 
Salzburg, 
Salzburg, 
Austria; 
Ewa 
A. Jankowska, Institute of Heart Diseases, Wroclaw Medical 
University, Wroclaw, Poland, Institute of Heart Diseases, University 
Hospital in Wroclaw, Wroclaw, Poland; Peter Jüni, Nuffield 
Department of Population Health, University of Oxford, Oxford, 
United Kingdom; Takeshi Kimura, Department of Cardiology, 
Hirakata Kohsai Hospital, Osaka, Japan; Vijay Kunadian, 
Translational and Clinical Research Institute, Faculty of Medical 
Sciences, Newcastle University, Newcastle upon Tyne, United 
Kingdom, Cardiothoracic Centre, Freeman Hospital, Newcastle upon 
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 
United Kingdom; Margret Leosdottir, Department of Cardiology, 
Skane University Hospital, Malmö, Sweden, Department of Clinical 
Sciences, Malmö, Lund University, Malmö, Sweden; Roberto 
Lorusso, Cardio-Thoracic Surgery, Maastricht University Medical 
Centre, Maastricht, Netherlands, Cardiovascular Research Institute 
Maastricht, Maastricht, Netherlands; Roberto F.E. Pedretti, 
Cardiovascular Department, IRCCS MultiMedica, Milan, Italy; 
Angelos G. Rigopoulos, Adult Cardiology, Mitera General 
Hospital-Hygeia Group, Athens, Greece; Maria Rubini Gimenez, 
Department of Internal Medicine and Cardiology, Heart Center 
Leipzig at the University of Leipzig, Leipzig, Germany, Cardiovascular 
Research Institute Basel, University Hospital Basel, Basel, Switzerland; 
Holger Thiele, Internal Medicine/Cardiology; Heart Center Leipzig 
at University of Leipzig, Leipzig, Germany, Leipzig Heart Science, 
Leipzig, Germany; Pascal Vranckx, Cardiology and Critical Care 
Medicine, Jessa Ziekenhuis, Hasselt, Belgium, Faculty of Medicine and 
Life Sciences, University of Hasselt, Hasselt, Belgium; Sven 
Wassmann, Cardiology, Cardiology Pasing, Munich, Germany; 
Faculty of Medicine, University of the Saarland, Homburg/Saar, 
Germany; Nanette Kass Wenger, Department of Medicine 
(Cardiology), Emory University School of Medicine, Atlanta, GA, United 
States of America, Consultant, Emory Heart and Vascular Center 
Emory University, School of Medicine, Atlanta, GA, United States of 
America, Founding Consultant, Emory Women’s Heart Center, Emory 
University School of Medicine, Atlanta, GA, United States of America.
23. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Sigrun Halvorsen (CPG Review 
Co-ordinator) (Norway), Stefan James (CPG Review Co-ordinator) 
(Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Nina 
Ajmone Marsan (Netherlands), Sotiris Antoniou (United Kingdom), 
Riccardo Asteggiano (Italy), Maria Bäck (Sweden), Davide Capodanno 
(Italy), 
Ruben 
Casado-Arroyo 
(Belgium), 
Salvatore 
Cassese 
(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), 
Jean-Philippe Collet (France), Gregory Ducrocq (France), Volkmar 
Falk (Germany), Laurent Fauchier (France), Tobias Geisler 
(Germany), Diana A. Gorog (United Kingdom), Lene Holmvang 
(Denmark), Tiny Jaarsma (Sweden), Hywel Wynne Jones (United 
Kingdom), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), Dipak Kotecha (United Kingdom), Konstantin 
A. Krychtiuk (Austria), Ulf Landmesser (Germany), George Lazaros 
(Greece), Basil S. Lewis (Israel), Bertil Lindahl (Sweden), Ales Linhart 
(Czech Republic), Maja-Lisa Løchen (Norway), Mamas A. Mamas 
ESC Guidelines                                                                                                                                                                                          3801


<!-- PAGE 83 -->

### Page 83

(United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Christian 
Mueller (Switzerland), Lis Neubeck (United Kingdom), Josef Niebauer 
(Austria), Jens Cosedis Nielsen (Denmark), Alexander Niessner 
(Austria), Valeria Paradies (Netherlands), Agnes A. Pasquet (Belgium), 
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), 
Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Giuseppe 
M. C. Rosano (Italy), Leyla Elif Sade (United States of America/ 
Türkiye), François Schiele (France), Jolanta M. Siller-Matula (Austria), 
Christian Sticherling (Switzerland), Robert F. Storey (United 
Kingdom), Matthias Thielmann (Germany), Christiaan Vrints 
(Belgium), Stephan Windecker (Switzerland), Rune Wiseth (Norway), 
and Adam Witkowski (Poland).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of acute cor­
onary syndromes:
Algeria: Algerian Society of Cardiology, Mohammed El Amine 
Bouzid; Armenia: Armenian Cardiologists Association, Hamlet 
Hayrapetyan; Austria: Austrian Society of Cardiology, Bernhard 
Metzler; Belgium: Belgian Society of Cardiology, Patrizio Lancellotti; 
Bosnia and Herzegovina: Association of Cardiologists of Bosnia 
and Herzegovina, Mugdim Bajrić; Bulgaria: Bulgarian Society of 
Cardiology, Kiril Karamfiloff; Cyprus: Cyprus Society of Cardiology, 
Andreas Mitsis; Czechia: Czech Society of Cardiology, Petr Ostadal; 
Denmark: Danish Society of Cardiology, Rikke Sørensen; Egypt: 
Egyptian Society of Cardiology, Tamer Elwasify; Estonia: Estonian 
Society of Cardiology, Toomas Marandi; Finland: Finnish Cardiac 
Society, Essi Ryödi; France: French Society of Cardiology, 
Jean-Philippe Collet; Georgia: Georgian Society of Cardiology, 
Archil Chukhrukidze; Germany: German Cardiac Society, Julinda 
Mehilli; Greece: Hellenic Society of Cardiology, Periklis Davlouros; 
Hungary: Hungarian Society of Cardiology, Dávid Becker; Iceland: 
Icelandic Society of Cardiology, Ingibjörg Jóna Guðmundsdóttir; 
Ireland: Irish Cardiac Society, James Crowley; Israel: Israel Heart 
Society, Yigal Abramowitz; Italy: Italian Federation of Cardiology, 
Ciro Indolfi; Kazakhstan: Association of Cardiologists of 
Kazakhstan, Orazbek Sakhov; Kosovo (Republic of): Kosovo 
Society of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Medet Beishenkulov; Latvia: Latvian Society of 
Cardiology, Andrejs Erglis; Lebanon: Lebanese Society of 
Cardiology, Nicolas Moussallem; Libya: Libyan Cardiac Society, 
Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology, 
Olivija Dobilienė; Luxembourg: Luxembourg Society of Cardiology, 
Philippe Degrell; Malta: Maltese Cardiac Society, Matthew Mercieca 
Balbi; Moldova (Republic of): Moldavian Society of Cardiology, 
Aurel Grosu; Morocco: Moroccan Society of Cardiology, Zouhair 
Lakhal; Netherlands: Netherlands Society of Cardiology, Jurriën 
ten Berg; North Macedonia: The National Society of Cardiology 
of North Macedonia, Hristo Pejkov; Norway: Norwegian Society of 
Cardiology, Kristin Angel; Poland: Polish Cardiac Society, Adam 
Witkowski; Portugal: Portuguese Society of Cardiology, Manuel De 
Sousa Almeida; Romania: Romanian Society of Cardiology, Ovidiu 
Chioncel; San Marino: San Marino Society of Cardiology, Luca 
Bertelli; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic; 
Slovakia: Slovak Society of Cardiology, Martin Studenčan; 
Slovenia: Slovenian Society of Cardiology, Peter Radšel; Spain: 
Spanish Society of Cardiology, Jose Luis Ferreiro; Sweden: Swedish 
Society of Cardiology, Annica Ravn-Fischer; Switzerland: Swiss 
Society of Cardiology, Lorenz Räber; Syrian Arab Republic: 
Syrian Cardiovascular Association, Mohammed Yassin Bani Marjeh; 
Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, 
Majed Hassine; Türkiye: Turkish Society of Cardiology, Aylin 
Yildirir; Ukraine: Ukrainian Association of Cardiology, Alexander 
Parkhomenko; United Kingdom of Great Britain and 
Northern Ireland: British Cardiovascular Society, Adrian Paul 
Banning.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
